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Lay Abstract
Bone in our body constantly undergoes change in a process called bone 
turnover or remodelling. Bone remodelling involves breaking down of bone 
(bone resorption) by bone cells called osteoclasts followed by replacement 
with new bone (bone formation) by bone cells called osteoblasts.  
This process is usually under control but sometimes becomes abnormal and 
results in skeletal disorders like Paget’s disease of bone (PDB). PDB usually 
affects people later in life (age of onset > 55 years of age). In PDB, the 
osteoclasts become overactive and erode the bone too fast which in turn leads 
to accelerated and disorganised bone formation by osteoblasts. The resulting 
bone formed is weak and results in symptoms and complications such as 
bone pain, osteoarthritis, bone deformity, compression of nerves and 
fractures. 
The exact cause of PDB is not fully understood but studies have shown that 
it most likely occurs as a result of genetic changes with an influence from 
several environmental factors. At present, DNA mutations in one of the genes 
called SQSTM1 result in 10% of PDB cases without family history and up to 
40% of cases with family history of PDB. Therefore, more genes remain to be 
explored to determine their contribution to PDB development and improve the 
diagnosis, treatment and prevention of this late-onset chronic metabolic bone 
disease. 
Studies in our laboratory have identified new genes, abnormalities of which 
may result in increased susceptibility to PDB. My doctoral study involves 
investigating one of these genes called PML in relation to bone metabolism 
and PDB. 
I found a few genetic variations in PML which when inherited, may increase 
the risk of getting PDB. Pml was found to be expressed in osteoclasts and 
osteoblasts from mouse and human tissue. PDB patients had lower levels of 
PML compared to healthy controls.  
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Mice with a deletion of Pml in their DNA showed increase in osteoclast 
formation and activity compared to normal control mice. Also, osteoblasts 
from these mice showed increased bone mineralisation compared to controls 
thereby neutralising the bone resorption by osteoclasts. Indeed, I did not find 
any signs of bone lesions and changes in bone microstructure in these mice.  
Further experiments in these mice suggested that changes in Pml expression 
was altering the response of immune cells in maintaining osteoclast 
development and activity but more in-depth studies will be needed to 
understand how genetic variations in PML increase susceptibility to disease.  
Thus, my PhD study has found a novel role of PML in regulating bone 
metabolism by inhibiting osteoclast formation and activity. Alterations in PML 
expression in association with environmental factors could increase risk of 
developing PDB and warrants further investigation. 
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Abstract
Paget’s disease of bone (PDB) is a common bone disorder. The disease is 
characterised by localised abnormalities in bone turnover (Ralston et al. 
2008). Genetic factors are important for PDB. Genome-wide association 
studies (GWAS) identified a susceptibility locus for PDB on chromosome 
15q24.1 in addition to six other loci (Albagha et al. 2010; Albagha et al. 2011). 
The strongest signal for disease association from this locus is located within 
Promyelocytic Leukemia (PML). PML is a tumour suppressor gene involved 
in chromosomal translocation leading to acute promyelocytic leukaemia 
(APL). PML is involved in multiple cellular functions like cell growth, 
senescence, DNA repair, antiviral response and apoptosis but has never been 
implicated directly in bone metabolism. The aim of my PhD was to explore 
role of PML in bone biology. 
Fine mapping of the 15q locus was performed using targeted next generation 
sequencing. In chapter 4, Targeted DNA sequencing of the PDB susceptibility 
locus on chr15 identified variants within PML that are associated with the 
disease. In chapter 5, expression analysis revealed expression of Pml in bone 
cells from murine and human tissue and its expression varies during the 
development and differentiation of these cells. PML expression was found to 
be downregulated in patients with PDB. In chapters 6 and 7, experiments with 
RAW 264.7 cell line and Pml knock out mice point to a negative regulatory 
role of PML in osteoclast differentiation. Osteoclasts from Pml knockout mice 
show increased formation, fusion and activity in response to RANKL 
compared to wt mice. The expression levels of osteoclast related genes such 
as Ctsk (Cathepsin K), Dcstamp and Nfatc1 were also higher in Pml knockout 
mice. Osteoblasts differentiated from these mice show increased mineralised 
nodule formation in vitro compared to wt mice. Skeletal phenotyping by micro 
CT revealed no significant differences in structure and bone density between 
Pml knockout and wt mice irrespective of age. 
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Interferon gamma (IFN-γ) is a cytokine which is known to induce Interferon 
Regulatory Factor 8 (IRF-8) and PML in mouse peritoneal macrophages (Dror 
et al. 2007). IRF-8 is a transcription factor downregulated during RANKL 
mediated osteoclastogenesis (Zhao et al. 2009) and an essential regulator of 
PML gene in activated macrophages (Dror et al. 2007). In chapter 8, it was 
found that IFN-γ inhibited osteoclastogenesis in wt mice but failed to have a 
pronounced effect on osteoclasts in mice lacking Pml. Thus, lack of PML 
possibly renders IFN-γ and IRF-8, ineffective in suppressing 
osteoclastogenesis.  
Thus, PML controls osteoclast development probably by modulating response 
of IRF-8 and IFN-γ in association with direct or indirect regulation of osteoclast 
related genes such as Ctsk (encoding Cathepsin K), Dcstamp and Nfatc1. 
Osteoclasts are already primed for increased formation, differentiation, fusion 
and activity due to upregulation of these factors in absence of PML. 
My doctoral study therefore identifies PML as a novel regulator of bone 
metabolism. Functional genetic variants within PML gene possibly contribute 
to reduced PML expression thereby predisposing to PDB by increasing 
osteoclast differentiation and activity with an increase in osteoblast 















































Bone is a dynamic organ that supports and protects various tissues of the 
body. It forms an integral part of the skeletal system along with network of 
ligaments, tendons and joint tissue (cartilage and synovium). It enables body 
movements and is also a specialised connective tissue involved in 
haematopoietic cell production, mineral and fat storage as well as other 
metabolic and endocrine functions (Burr & Akkus 2013; Kini and Nandeesh 
2012). 
Formation of new bone is termed ossification. Bone development occurs by 
two important processes during embryonic development as well as 
postnatally: Intramembranous ossification is characterised by formation of 
bone from mesenchymal connective tissue giving rise to flat bones of the skull 
as well as scapula, mandible and clavicle whereas endochondral ossification 
involves development of bone from cartilage. This results in long bone 
formation of tibia, femur, radius and humerus (Kini and Nandeesh 2012; Allen 
& Burr 2013). 
Bone can be divided into several types based on anatomy and structure. 
Structurally, bone is divided into cortical (compact) bone and trabecular 
(cancellous or spongy) bone and microscopically/histologically into lamellar 
and woven bone. Anatomically, based on shape, the bone is divided into long, 
short, flat, irregular and sesamoid bones (Clarke 2008). 
Cortical bone surrounding the marrow space, is solid, dense whereas 
trabecular bone appears spongy and consists of a network of interconnected 
trabeculae within the bone marrow. Cortical bone constitutes 80% of the 
skeleton and has a low surface area and lower remodelling rate and is found 
in outer layer of flat bones and diaphysis of long bones. Cortical bone has an 
outer periosteum and inner endosteum. The basic units of cortex are called 
osteons or haversian systems which are cylindrical structures composed of a 
series of concentric lamellae of collagen fibres surrounding a central 
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haversian canal containing nerves, blood vessels and lymphatics. In contrast, 
trabecular bone is less dense, has a much larger surface area and higher 
remodelling rate though it constitutes only 20% of the skeleton. Lamellae 
within trabecular bone run parallel to each other. Trabecular bone is found in 
flat bones, metaphyseal ends of long bones and vertebrae (Burr & Akkus 
2013; Ralston 2017). 
Figure 1.1 Microscopic sub-structure of cortical bone. 
Image obtained from (Ritchie et al. 2009). 
Lamellar bone is characterised by regular parallel arrangement of collagen 
into sheets/lamellae. This is absent in woven bone wherein the collagen fibrils 
are arranged in a random manner. This results in lamellar bone being much 
stronger but less metabolically active compared to woven bone (Kini and 
Nandeesh 2012). Woven bone is normally produced during primary bone 
formation but is also seen in abnormal high bone turnover conditions like 
Paget’s disease of bone and hyperparathyroidism (Clarke 2008). 
The different parts of long bone (femur) are shown in Figure 1.2. The main 
cylindrical part of the long bone surrounding the medullary cavity is called 
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diaphysis. The cavity contains yellow bone marrow and the diaphyseal walls 
are composed of hard, dense compact bone. The ends of long bones are 
called epiphyses which are covered by articular cartilage and filled with 
spongy/cancellous bone and red marrow.  Metaphysis is the zone between 
diaphysis and epiphysis. During bone growth, a layer of hyaline cartilage 
called growth plate separates epiphysis from metaphysis which eventually 
forms the epiphyseal line at the end of growth period. Medullary cavity is lined 
by endosteum, a thin layer of connective tissue where bone growth, repair 
and remodelling occur. Periosteum, a fibrous connective tissue layer covering 
outer surface of bone, contains blood vessels, nerves, lymphatics as well as 
progenitor cells and protects and nourishes the bone (OpenStax Anatomy & 
Physiology 2016). Flat bones are composed of spongy bone enclosed within 
two thin layers of compact bone and have marrow. 
Figure 1.2 Structure of a long bone. 
(OpenStax Anatomy & Physiology 2016) 
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Bone is therefore composed of cortical bone, cancellous bone, bone marrow, 
extracellular matrix, blood vessels, nerves, lymphatics and bone cells. Bone 
matrix consists of organic and inorganic components. Organic component is 
termed osteoid with Type 1 collagen constituting 90% and remainder 10% 
formed by proteoglycans and non-collagenous proteins including bone 
sialoprotein, osteopontin, osteonectin and osteocalcin. The inorganic 
component is mainly composed of minerals calcium and phosphorus that link 
together to form crystals of hydroxyapatite deposited within the organic matrix. 
Bone cells include osteoblasts, osteoclasts, osteocytes and osteoprogenitor 
stem cells within the bone marrow (Burr & Akkus 2013). 
1.2 Bone cells 
Osteoclasts 
Osteoclasts are the primary bone resorbing cells of haematopoietic origin 
derived from monocyte-macrophage lineage precursor cells. They are 
involved in bone modelling as well as remodelling. Decreased osteoclast 
activity results in increased bone mass and vice versa. During bone modelling, 
recruitment of osteoclast precursors to bone occurs where they undergo 
proliferation and differentiation followed by fusion into multinucleated mature 
cells. Osteoclasts are polarised with attainment of functional domains at the 
bone surface, followed by acidification and degradation of mineralised bone 
matrix. The average lifespan of an osteoclast is about 12 days (Rosenberg et 
al. 2012). Post bone resorption, osteoclasts undergo apoptosis (Bellido et al 
2013). Osteoclastogenesis is regulated by several signalling pathways 
involving multiple components, abnormalities of which results in various bone 
diseases. 
Macrophage colony stimulating factor (M-CSF) and Receptor activator of the 
nuclear factor NF-kB ligand (RANKL) are the two most important cytokines 
involved in differentiation of haematopoietic precursors to functional 
osteoclasts. M-CSF which is secreted by the bone marrow stromal cells 
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(BMSCs), osteoblasts as well as osteocytes, contributes to osteoclast 
differentiation, migration and survival (Tanaka et al. 1993; Insogna et al 1997). 
M-CSF binds to its receptor colony stimulating factor 1 receptor (c-fms) which 
is present on osteoclast precursors. It also controls the spreading, motility, 
cytoskeletal organisation and apoptosis of the mature resorbing cell via 
association with c-Src and PI3-Akt axis stimulation (Fig.3) (Insogna et al 1997; 
Teitelbaum & Ross 2003). 
Haematopoietic stem cells differentiate into early osteoclast precursors in 
presence of transcription factor PU.1 especially their commitment to myeloid 
lineage. PU.1 also induces c-fms expression in osteoclast precursors. M-CSF 
binding to c-fms induces expression of RANK on osteoclast precursors 
thereby inducing them to differentiate into osteoclasts in response to RANKL 
stimulation. Csf1 knockout mice show osteopetrosis (Yoshida et al. 1990) but 
recover with age from decrease in osteoclast activity and number (S. Niida et 
al 1999; Myint et al. 1999; Teitelbaum & Ross 2003). However, Tnfsf11 
(RANKL) knockout mice have osteopetrosis that does not improve with age 
indicating that M-CSF alone is not enough to drive osteoclast precursors to 
osteoclasts in vivo and RANKL is the more dominant cytokine (Begg et al. 
1993; Kong et al. 1999; Kearns et al. 2008). RANKL is expressed on surface 
of osteoblasts as well as osteocytes and dendritic cells but is also secreted in 
soluble form (Kearns et al. 2008). It binds to its receptor RANK on osteoclast 
precursors leading to their activation and differentiation into multinucleated 
osteoclasts (Lacey et al. 1998; Wada et al. 2006; Kohli & Kohli 2011). 
RANK (which is a member of TNF receptor superfamily like RANKL) is 
expressed on osteoclast precursors as well as mature osteoclasts (Li et al. 
2000). RANK as well as RANKL knockout mice show osteopetrosis (Dougall 
et al. 1999; Kong et al. 1999) due to lack of osteoclast formation and loss of 
function mutations in humans’ results in a similar phenotype (Sobacchi et al. 
2007; Guerrini et al. 2008). 
RANK-RANKL interaction results in activation of several signalling pathways 
which play an important role in osteoclast formation, activation and survival.  
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Figure 1.3 Signal transduction pathways involved in osteoclastogenesis.       
Curved green arrow indicates NFATc1 autoamplification and red marker with cross indicates deubiquitination of 
TRAF6 leading to inhibition of RANK signalling. See text for further description.
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One of the most important signalling pathways for osteoclast formation is 
nuclear factor Kappa B (NF-κB) which resides in an inactive state in the 
cytoplasm complexed to IKBα. RANKL binds to its receptor RANK resulting 
in recruitment of TNF-receptor associated factor 6 (TRAF6) to RANK’s 
cytoplasmic domain. TRAF6 polyubiquitination and p62 create a platform for 
assembly of TAK1-TAB2 complex. The deubiquitinating enzyme CYLD 
inhibits RANK signalling by binding to complex of TRAF6 and p62 (via its 
ubiquitin domain) (Jin et al 2008). Optineurin (OPTN) is involved in inhibition 
of NF-κB in immune cells mediated via its interaction with CYLD 
(Nagabhushana et al 2011) and negative regulation of osteoclast 
differentiation in mice (Obaid et al. 2015). Phosphorylation of TAK1 results in 
K63 mediated polyubiquitination of NEMO and phosphorylation of IKKα. This 
in turn leads to phosphorylation and proteasomal degradation of IKBα 
liberating NF-κB which enters the nucleus to activate expression of target 
genes. NF-κB has two signalling pathways induced by RANKL: Canonical 
RelA/p50 pathway and non-canonical RelB/p52 pathway. Lack of these NF-
κB subunits renders the mice unable to form osteoclasts. (Franzoso et al. 
1997) 
Along with NF-κB, RANK/TRAF mediated signalling also activates: 
1. c-Fos / c-Jun N-terminal kinase (JNK): the activator protein-1 (AP-1)
complex and calcineurin / PLCγ / NFATc1 pathways which play an
important role in osteoclast formation;
2. Mitogen-activated protein kinase kinase 6 (MKK6) / p38 mitogen-
activated protein kinase (MAPK) / microphthalmia-associated
transcription factor (MITF) along with Src involved in osteoclast
activation and
3. Extracellular signal-regulated kinase (ERK) as well as Src which are
involved in osteoclast survival. (Boyce et al 2013).
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Thus, activated NF--κB, AP-1 complex and MITF transcription factors in 
conjunction with NFATc1 upon entering the nucleus, promote expression of 
genes responsible for osteoclast differentiation, resorption and survival 
including, tartrate resistant acid phosphatase (TRAcP), calcitonin receptor, 
matrix metalloproteinase 9 (MMP9), Cathepsin K, dendritic cell-specific 
transmembrane protein (DC-STAMP), chloride channel 7 (CLC-7), osteoclast-
associated receptor (OSCAR) and β3 integrins. NFATc1 is the master 
transcription factor for osteoclastogenesis which is upregulated in response 
to NF-κB, c-Fos and increased intracellular calcium/calcineurin and leads to 
its own autoamplification as well (Mellis et al. 2011; Boyce et al 2013). 
Hormones such as vitamin D (1,25-(OH)2 vitamin D3) and parathyroid 
hormone (PTH) as well as cytokines such as Interleukins (IL-6, IL-1 and IL-
11) enhance osteoclastogenesis by upregulating expression of RANKL
(Bellido et al 2013).
Osteoclastogenesis is also inhibited by inflammatory factors, cytokines and 
transcriptional repressors which play a crucial role in bone homeostasis by 
fine tuning remodelling of bone and preventing excessive bone resorption. 
RANKL signalling induces downregulation of osteoclast inhibitory factors. 
These include v-maf musculoaponeurotic fibrosarcoma oncogene family 
protein B (MafB), Eos (IKAROS Family Zinc Finger 4), inhibitors of 
differentiation/DNA binding (ids), B-cell lymphoma 6 (Bcl6), and interferon 
regulatory factor-8 (IRF-8) (Boyce et al 2013). Bcl6, Inhibitor of DNA binding 
1 (Id1) and IRF8 deficient mice therefore exhibit decreased bone mass and 
increased osteoclastogenesis. Also, NFATc1 induces B-lymphocyte induced 
maturation protein 1 (Blimp1) in response to RANKL stimulation, which in turn 
suppresses MafB, IRF8 and Bcl6 expression. Loss of Blimp1 in murine 
osteoclasts leads to Bcl6 up-regulation and they exhibit osteopetrosis 
resulting from impaired osteoclastogenesis (Miyauchi et al. 2010; Zhao & 
Ivashkiv 2011). 
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Thus, RANKL/RANK mediated upregulation of NFATc1 leads to promotion of 
osteoclastogenesis directly, as well as indirectly by suppression of negative 
regulators (Boyce et al 2013). 
Osteoblasts and osteocytes also secrete osteoprotegerin (OPG). OPG acts 
as a decoy receptor of RANKL preventing its binding to RANK receptor on 
osteoclasts leading to inhibition of osteoclastogenesis and bone resorption 
(Yasuda et al 1998, Lacey et al 1998). Therefore, ratio of RANKL to OPG 
determines the rate of osteoclast differentiation (Boyce et al 2013). 
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Figure 1.4 Regulation of osteoclastogenesis. 
Myeloid precursors differentiate into osteoclast precursors in presence of M-CSF. RANKL stimulation promotes formation of 
mononuclear osteoclasts which fuse to form multinucleated osteoclasts. These secrete various factors and function as active 
polarised bone resorbing cells. This process is regulated at various stages by multiple genes encoding transcription factors, 
receptors and cytokines as shown above. Inhibitors of osteoclastogenesis (red markers) are shown in purple.
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A characteristic feature of mature osteoclasts is multinucleation that results 
from fusion of mononuclear precursors. Various proteins such as DC-STAMP, 
OC-STAMP, ATP6v0d2 (a subunit of ATPase) and CD9 are known to be 
involved in this process. Activation involves cytoskeletal and membrane 
reorganisation resulting in osteoclast polarisation. An apical membrane is 
formed in close contact with the bone surface and a basolateral domain 
pointing away from the bone. Osteoclasts form tight circular ring-like sealing 
zones (SZ) using actin filament rich podosomes that secures them to the bone 
surface forming a cavity or resorption pit underneath (also known as 
Howship’s lacunae). Within the sealing zone, cytoplasmic membrane of 
osteoclast is thrown into finger-like processes called the ruffled border (RB) 
which increases the cell surface area thereby facilitating secretion and uptake 
of components required for dissolution of bone matrix and minerals. The 
cytoplasm is filled with vesicles and vacuoles including lysosomes which 
contain the acid phosphatase TRAcP, a cellular and histologic marker of 
actively resorbing osteoclasts. Attachment to bone matrix is facilitated by the 
vitronectin receptor αVβ3 Integrin via a special motif present in bone matrix 
proteins bone sialoprotein (BSP) and osteopontin (OP). Extracellular 
compartment is acidified by secretion of chloride ions and protons across 
ruffled border. Protons generated by action of cytosolic carbonic anhydrase II 
(CA), are transported by V-ATPase at the ruffled border membrane and 
chloride ions are transported via the CLC-7 ion transporter. Mitochondria 
provide the energy in the form of ATP. Hydroxyapatite (mineralised) portion 
of the bone matrix is dissolved by HCl formed in the resorption lacuna. The 
remaining organic portion of matrix (composed mainly of Type I collagen) is 
digested enzymatically by the secreted matrix metalloproteinases (MMP) 
such as MMP9, MMP14, Cathepsin K and TRAcP (tartrate resistant acid 
phosphatase). Though unclear, TRAcP is thought to be involved in 
dephosphorylating bone matrix proteins thereby facilitating integrin binding 
and at the same time, generate reactive oxygen species for matrix 
degradation. The degraded products in the resorption zone are internalised 
into the cell and then either undergo lysosomal degradation or get 
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transcytosed via the basolateral membrane (Fig.1.5) (Mellis et al. 2011, 
Bellido et al 2013; Boyce et al 2013). 
Figure 1.5 Schematic representation of an active resorbing osteoclast 
describing its morphology and function.  
TZ is the transition zone. Figure obtained from Bellido et al. 2013. See text for 
description. 
Osteoblasts 
Osteoblasts are mononuclear cells involved in bone formation. They secrete 
bone matrix proteins and subsequently mineralise the bone matrix. They 
originate from the mesenchymal stem cells (MSCs) of bone marrow which can 
differentiate into several cell types such as osteoblast, adipocyte, 
chondrocyte, fibroblast and myocyte. MSCs commitment to osteoblast 
lineage, differentiation of osteoblasts from osteoprogenitor cells  
/preosteoblasts and osteoblast differentiation are regulated by various factors 
including Runx2, Osterix, BMPs, Wnt/B-catenin pathway, Notch signalling, 
growth factors (IGF1, TGF-β and FGFs) and hormones (estrogen, PTH, 
glucocorticoids). Mutations in the above mentioned factors have been 
reported in human diseases with skeletal deformities such as craniofacial 
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dysplasia, low/high bone mass as well as joint and limb deformities (Kini and 
Nandeesh 2012; Boyce et al 2013). 
Runx2 belongs to Runt family of transcription factors (TFs). It is the earliest 
TF responsible for commitment of MSCs to osteoblast lineage and binds to 
osteocalcin promoter thereby regulating bone formation. Runx2 knockout 
mice are devoid of osteoblasts resulting in no bone formation in the ribs at 
birth leading to death from respiratory failure (Otto et al. 1997; Komori et al. 
1997). Osterix (Osx) is a zinc finger transcription factor that acts downstream 
of Runx2 and regulates differentiation of osteoblast progenitors to 
osteoblasts. Mice with  a conditional deletion of Osx showed abnormal 
postnatal bone growth and bone homeostasis including osteoblast 
differentiation (Nakashima et al. 2002; Zhou et al 2010). 
Bone morphogenetic proteins (BMPs) such as BMP2 and BMP7 augment 
expression of Runx2 and Osx in MSCs to promote osteoblast differentiation. 
(Datta et al. 2008) 
Wnt (Wingless) is another major signalling pathway that promotes osteoblast 
differentiation. Wnt ligands act by canonical (through B catenin mediated gene 
transcription) or noncanonical pathways (B catenin independent gene 
transcription) to inhibit osteoblast apoptosis. Wnts stimulate differentiation of 
MSCs to osteoblast lineage and those of preosteoblasts. They prevent 
apoptosis of mature osteoblasts as well as osteocytes and increase 
expression of OPG from osteoblasts thereby inhibiting osteoclast mediated 
bone resorption. Low-density lipoprotein receptor-related protein 5 (LRP5) 
and frizzled proteins act as Wnt ligand receptors. Mutations with a gain of 
function in LRP5  in patients results in high bone mass associated with strong 
bones resistant to fracture whereas children affected by osteoporosis-
pseudoglioma syndrome due to loss of function mutations in LRP5 have low 
bone mass associated with decreased Wnt signalling in osteoblasts (Gong et 
al 2001; Boyden et al 2002). 
Indian hedgehog (Ihh) regulates osteoblast function by increasing expression 
of Runx2 (Shimoyama et al. 2007). Fibroblast growth factor (FGF) and 
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connexion 43 also regulate osteoblast differentiation. FGF-2 knockout mice 
show lower bone mass and FGF18 upregulates osteoblast differentiation in 
an autocrine manner. Connexin 43 is the bone specific connexin and 
mutations of gene encoding it impair osteoblast differentiation and lead to 
skeletal malformation in mice (Florencio-Silva et al. 2015). 
Notch family of transmembrane receptor signalling inhibit osteoblast 
differentiation by maintaining mesenchymal cells in progenitor stage. 
Depletion of Notch in osteoblast progenitors led to high bone mass in younger 
mice that progressed to severe osteopenia with ageing. Also, Notch depletion 
in osteoblast increased osteoclastogenesis due to reduced OPG production. 
Several other osteoblast negative regulatory factors act by inhibiting the BMP, 
Wnt or Smad signalling pathways. These include inhibitors of BMP such as 
gremlin, noggin and chordin and Wnt inhibitors sclerostin and dickkopf 1 
(DKK1) (Boyce et al 2013). 
Insulin like growth factor 1 (IGF1) also regulates Osx expression in 
osteoblastic cells (Celil & Campbell 2005) whereas Transforming growth 
factor β (TGF-β) has a dual effect on Runx2 activity as well as on osteoclast- 
osteoblast function. TGF-β supports osteoprogenitor cell proliferation and 
early differentiation but also inhibits later stages of osteoblast maturation, 
osteoblast mineralization, and its transition into osteocyte. TGF-β binds 
directly with its receptors on osteoclast to promote osteoclastogenesis but 
also inhibits their differentiation by decreasing RANKL/OPG secretion ratio 
(Wu et al. 2016). MicroRNAs regulate gene expression in osteoblasts leading 
to stimulation or inhibition of osteoblast differentiation (Florencio-Silva et al. 
2015). For example, miR-218 stimulates Wnt signalling pathway to promote 
osteoblast differentiation (Hassan et al. 2012) whereas miR-335 represses 
Runx2 to inhibit osteogenic differentiation from hMSCs. (Tomé et al. 2011).  
PTH enhances osteoblast number and activity by phosphorylating and 
activating Runx2, inducing IGF1 synthesis, stimulating Wnt/B-catenin 
pathway by inhibiting sclerostin and reducing the negative effects of 
peroxisome proliferator activated receptor gamma (PPARγ) on osteoblast 
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differentiation whereas continued excess secretion leads to enhanced bone 
resorption (Franceschi et al. 2003; Lombardi et al. 2011). Vitamin D is the 
main regulator of calcium homeostasis and skeletal health which indirectly 
enhances bone formation by increasing calcium absorption from the intestine 
and directly inhibits bone formation by regulating osteoblast differentiation and 
function via downregulation of Runx2 (Kim et al. 2016). Oestrogen stimulates 
Runx2 activity and synergises with Wnt/B-catenin pathway to promote 
osteoblast differentiation of MSC-progenitor cells (McCarthy et al. 2003; Gao 
et al. 2013). Glucocorticoids have a dual role in bone turnover. They induce 
rapid bone loss transiently by delaying osteoclast apoptosis but ultimately 
lead to suppression of bone formation due to decreased osteoblastogenesis 
and osteoclastogenesis as well as increased osteoblast-osteocyte apoptosis 
(Bellido et al 2013). 
Osteoblasts secrete bone matrix proteins Type1 collagen, osteocalcin (OCN), 
osteonectin, osteopontin and bone sialoprotein. They also secrete alkaline 
phosphatase (ALP), an enzyme involved in bone mineralisation. OCN 
regulates bone formation whereas circulating levels of OCN and ALP are used 
as biomarkers of bone formation (Kuo & Chen 2017).  
Mature osteoblasts are cuboidal in shape with large round nuclei, enlarged 
Golgi and extensive ER. Upon completion of bone matrix formation, they 
either become quiescent flat-shaped lining cells of the bone surface or die 
from apoptosis whilst the remainder get embedded in the bone matrix to form 
osteocytes which are the most abundant cells of the bone tissue (Bellido et al 
2013; Florencio-Silva et al. 2015). Lifespan of an osteoblast ranges from a 
few to about 100 days (Rosenberg et al. 2012). 
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Figure 1.6 Regulation of osteoblast differentiation.  
See text for further description. (PGE2, Prostaglandin E2; DKK1, Dickkopf 1).
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Bone formation is also regulated by osteoclast-osteoblast communication 
factors. Osteoclast mediated bone resorption releases coupling factors from 
bone matrix such as IGF1 and TGF-β which induce migration of osteoblasts 
to resorbing surfaces along with sphingosine-1-phosphate (S1P) and BMP6 
expressed by osteoclasts. Ephrins and semaphorins are another class of 
osteoblast-osteoclast communication factors that regulate bone formation 
(Boyce et al 2013). Ephrin B2 which is expressed by osteoclasts acts on its 
receptor Ephrin B4 on osteoblasts to promote bone formation while 
simultaneously inhibiting bone resorption whereas semaphorin 4D (Sema 4D) 
released by osteoclast inhibits bone formation by binding to Plexin B1 on 
osteoblasts (Negishi-Koga et al. 2011; Ralston 2017). Osteoblasts also 
regulate osteoclast function by secreting many factors such as RANKL, M-
CSF and OPG (Bellido et al 2013; Florencio-Silva et al. 2015). 
Figure 1.7 Schematic representation of different factors involved in osteoclast, 
osteoblast and osteocyte interaction.  
See text for description. (PDGF, platelet derived growth factor) 
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Osteocytes 
Osteocytes are mature osteoblasts which become embedded in the newly 
formed bone matrix during bone formation. These are the most long-lived and 
abundant cells of the bone which act as mechanosensors and coordinate 
osteoblast and osteoclast function in response to mechanical signals (strain 
and fluid flow) and circulating factors (ions and hormones).  
Figure 1.8 Haematoxylin & eosin stained histology section of a human bone. 
Shows various cell types: Osteoclasts resorbing bone, osteoblasts lining the 
bone and osteocytes embedded in the bone matrix (Courtesy of Prof. Donald 
Salter). 
Osteocytes respond to microdamage by activating osteoclasts by producing 
RANKL to remove damaged bone as part of bone remodelling. In addition, 
they produce M-CSF and OPG to regulate bone resorption. They also 
regulate osteoblast mediated bone formation by secreting sclerostin and 
DKK1 as well as express genes that regulate phosphate and mineral 
metabolism such as phosphate regulating endopeptidase homolog X-linked 
(PHEX), dentin matrix acidic phosphoprotein 1 (DMP1) and fibroblast growth 
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factor 23 (FGF23). Osteocytes eventually undergo apoptosis and their 
reduced viability results in decreased remodelling and fragile bone conditions 
associated with glucocorticoid excess, mechanical disuse and oestrogen 
withdrawal (Bellido et al 2013). 
1.3 Bone modelling and remodelling 
Bone undergoes change in shape and mass known as modelling to enable it 
to grow and withstand biomechanical forces. This process is in action during 
childhood and adolescence but slows down in adult life except in conditions 
such as hypoparathyroidism, renal osteodystrophy and anabolic therapy. 
Also, bones undergo constant turnover called remodelling. This lifelong 
process involves replacing any old, damaged bone with new bone to maintain 
structural integrity of the skeleton and mineral homeostasis. Remodelling 
process is tightly regulated with osteoclast bone resorption coupled to 
osteoblastic bone formation. A normal remodelling cycle last 4-6 months with 
osteoclast resorption occurring between 3-6 weeks and the remainder taken 
up by bone formation. Abnormalities in this bone turnover cycle results in a 
variety of bone disorders like Paget’s disease of bone and Osteoporosis. 
Remodelling cycle is divided into the following sequential phases (Allen & Burr 
2013): 
Activation: This is initiated by microdamage or mechanical stress or osteocyte 
apoptosis or random non-signalling event. All of these events result in 
osteoclast precursors’ migration to the bone surface where they proliferate, 
differentiate and fuse to become fully functional osteoclasts. 
Resorption: Once mature osteoclasts form, bone lining cells retract and allow 
osteoclast attachment to the bone surface, seal the remodelling site and 
dissolve the mineralised bone to release collagen fragments. Measuring these 
fragments in urine and blood can serve as useful biomarkers for assessment 
of bone remodelling. This phase is regulated by release of cytokines M-CSF, 
RANKL and OPG from osteoblast lineage cells including osteocytes. 
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Reversal: Osteoclasts complete their resorption, undergo apoptosis and bone 
formation is initiated by osteoblasts. The bone lining cells clean the residual 
bone matrix from the resorption lacuna and lay down a new thin layer of bone 
matrix called the cement line which delineates the older matrix from 
surrounding new bone. 
Formation: Bone formation by osteoblasts begins with deposition of organic 
unmineralised matrix composed mainly of Type I collagen fibres (osteoid) 
followed by inorganic hydroxyapatite crystal deposition. Mineralization of 
osteoid occurs in two phases:  
Primary mineralization lasts for 2-3 weeks and starts when calcium and 
phosphate ions incorporate into the collagen matrix and accounts for 70% of 
the final mineral content. Osteoid turns into mature mineralised matrix during 
secondary mineralization thereby giving bone its rigidity, stiffness and 
durability (up to a year or more).  
Bone forming osteoblasts meet one of three fates: Majority (90%) become 
apoptotic and die to be replaced by new osteoblasts as long as bone formation 
proceeds at the local remodelling site. Of the remaining ones, some get 
embedded in the bone matrix to form osteocytes and the remainder form 
inactive bone lining cells (that retain the capacity to become activated and 
capability to produce bone matrix). 
Quiescence: The last stage of the remodelling cycle results in bone lining cells 
or surface osteocytes covering the remodelled bone surface. Over time, the 
matrix within the remodelling unit will mineralize. Majority of bone surfaces 
within the body are in a quiescent state at any given time, though capable of 
activating in the next bone remodelling cycle. 
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Figure 1.9 The bone remodelling cycle. 
This is initiated by various signals that recruit osteoclast precursors to affected 
bone surface where they develop into mature osteoclasts and bone resorption 
takes place. This is followed by recruitment of osteoblast precursors to the 
resorbed site where they proliferate and differentiate into mature osteoblasts. 
Osteoblasts   secrete osteoid following by mineralisation of bone matrix giving 
rise to new bone.  Finally, bone enters the resting phase wherein the 
remodelled bone is covered by bone lining cells thereby completing the 
remodelling cycle (Ralston 2017). 
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1.4 Paget’s disease of Bone (PDB) 
Introduction 
PDB was initially described by Sir James Paget in late 19th century as “osteitis 
deformans”, a chronic inflammation of the bone leading to deformities (Paget 
1877). It is a common metabolic bone disorder second only to osteoporosis 
and is characterised by focal abnormalities of increased bone turnover and 
abnormal bone remodelling (Ralston et al. 2008; Alonso et al. 2017). 
Epidemiology 
PDB affects 1-2% of Caucasians aged 55 years and above. The risk of 
developing PDB increases with age. It affects men more than women 
especially in UK (van Staa et al. 2002). The disease occurs worldwide but 
distribution varies widely between geographic regions. UK has the highest 
prevalence of PDB in the world. However, the disease is also observed 
frequently in western and southern Europe (Detheridge et al. 1982) and in 
British migrant colonies of Australia, South Africa and New Zealand (Barker 
1984). However, it is rare in Asia, Scandinavia and Africa (Dahniya 1987; 
Takata et al. 2006). Several studies have recently observed a decline in PDB 
prevalence and clinical severity in several places such as New Zealand, UK 
and some other European countries over the past two and a half decades 
(Poór et al. 2006; Corral-Gudino et al. 2013) as well as delayed onset of 
disease in individuals with a family history of PDB (Bolland et al. 2007), while 
in other places such as Italy and US (Tiegs et al. 2000; Gennari et al. 2005), 
there are no major changes in the incidence. The exact mechanisms behind 
these changes are not understood, but environmental factors such as 
changes in ethnic make-up of the population resulting from migration, less 
exposure to viral infections / zoonoses, more sedentary lifestyle and improved 
nutrition are suggested to play a role (Ralston & Layfield 2012; Corral-Gudino 
et al. 2013; Alonso et al. 2017). 
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 Clinical features 
PDB has a late-onset and many patients (80%) are asymptomatic. Bone pain 
is the commonest presentation possibly due to increased bone turnover 
(primary pain) or secondary to complications such as osteoarthritis, spinal 
stenosis, pseudofractures or co-existing musculoskeletal condition. Clinical 
signs include bone deformity and the skin overlying an affected bone feels 
warm (Ralston 2013). 
Pagetic lesions are focal in nature. The disease mainly affects the axial 
skeleton and the most commonly affected sites include pelvis (70% of cases), 
femur (55% of cases), lumbar spine (53% of cases), skull (42% of cases) and 
tibia (32% of cases) (Kanis 1992). The disease either affects a single skeletal 
site (monoostotic) or most often multiple noncontiguous sites (polyostotic) 
(Bolland & Cundy 2013). 
Complications commonly resulting from PDB include bone fracture, bone 
deformity, deafness due to skull involvement, nerve compression and 
secondary osteoarthritis. These complications can be extremely disabling due 
to loss of mobility and can result in a substantial reduction in quality of life. Its 
late-onset and asymptomatic nature means long term permanent skeletal 
damage may have already occurred by the time it is diagnosed. Rare 
complications include osteosarcoma (less than 1% of cases), high-output 
cardiac failure, obstructive hydrocephalus and hypercalcemia in immobilized 
patients (Ralston et al. 2008). 
 
 Pathology  
Pagetic lesion is initiated by an increased bone resorption at affected site(s). 
The primary abnormality lies in osteoclasts, the cells responsible for bone 
resorption which are enlarged and numerous, hypernucleated and 
hyperactive. This is accompanied by rapid new bone formation by osteoblasts 
which seem to be normal (Roodman & Windle 2005; Ralston & Layfield 2012). 
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Many osteoclasts also contain nuclear inclusion bodies that have been 
compared to viral nucleocapsids. These have been proposed to result from a 
persistent viral infection. The exact nature of these inclusion bodies is not 
established since they are not specific to PDB and also found in other 
conditions such as hereditary oxalosis (Bianco et al. 1992), osteopetrosis 
(Mills et al. 1988) and neurodegenerative diseases (Sieradzan et al. 1999). 
Recently, they have also been suggested to be non-degraded protein by-
products of dysregulated autophagy, a novel pathway associated with PDB 
pathogenesis. There is also evidence of marrow fibrosis and bone 
hypervascularity (Ralston & Layfield 2012).  
Figure 1.10 Microscopic images of a Pagetic bone. 
A) 20X magnified H&E image of a Pagetic bone biopsy showing
hypernucleated osteoclasts (arrows), Osteoblasts (Ob) lining trabecular bone
(TB) and fibrovascular marrow (FM). Image reproduced from (Singer 2015).
(B) Typical nuclear inclusions seen in osteoclasts from patient with PDB using
electron microscopy.
(C) Magnified high power image of the inclusion seen in (B). Images
reproduced from (Ralston 2008).
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Increase in bone turnover results in 3 phases of PDB all of which can be 
observed at the same time but at different sites in an affected individual:  
• Osteolytic phase: increased bone resorption leading to lytic changes
seen in radiographs.
• Mixed phase: consisting of sclerotic bone resulting from new bone
formation accompanying the osteolysis.
• Sclerotic phase: is observed due to a reduction in bone turnover and
cells (Ooi & Fraser 1997).
Newly formed collagen fibres are arranged in a chaotic fashion rather than 
linear to form more primitive woven bone. The resulting bone has a 
characteristic mosaic appearance consisting of abnormal woven bone and 
few areas of lamellar bone linked in a disorderly fashion by numerous cement 
lines from previous osteolysis (Misra et al. 2013). There is increased osteoid 
in the bone matrix without much alterations in mineralisation. The disrupted 
architecture of pagetic bone leads to loss of structural integrity (Zimmermann 
et al. 2015; Alonso et al. 2017). 
Diagnosis 
PDB diagnosis is incidental in most cases, the first indication often being an 
elevated serum alkaline phosphatase (ALP) or an abnormal X-ray/radiograph 
in an individual who is being investigated for other reasons (Guma et al. 2002; 
Ralston et al. 2008). 
Plain radiograph (X-ray) typically shows areas of focal osteolysis mixed with 
sclerotic areas along with bone expansion, coarsened trabeculae and 
thickened cortices (Ralston 2013). Technetium 99m bone scanning (Tc99m) 
identifies areas of increased uptake of radiolabelled bisphosphonate and is 
associated with areas of high bone remodelling. Tc99m along with targeted X-
rays (of abdomen, facial bones, skull and tibiae) is recommended to fully and 
accurately determine the extent of metabolically active disease (Ralston et al. 
2019). It is highly sensitive and non-specific but has the advantage of 
detecting lesions even in early stages of PDB (Selby et al. 2002). 
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Figure 1.11 Diagnostic features of PDB 
A) Radiograph of tibial bone affected by PDB which shows bone expansion,
deformity and areas of osteolysis as well as osteosclerosis.
(B) Increased tracer uptake in PDB affected femur using radionuclide scan.
(C) Pathological fracture in PDB affected femur bone.
(D) Severe bone deformity of PDB affected tibia. Pictures obtained from
(Ralston et al. 2008).
Serum total ALP is recommended as the first line biochemical test for 
screening metabolically active PDB in combination with Liver function tests 
(LFTs). Elevated serum ALP in isolation in absence of liver disease and 
otherwise normal biochemical results is typical of PDB. MRI and CT are rarely 
required except for assessing complications like spinal stenosis and 
osteosarcoma. Other biochemical laboratory tests for calcium, albumin and 
1,25-(OH)2 Vitamin D3 are often normal though vitamin D deficiency is 
common in older patients with PDB. Elevation of specialised biomarkers such 
as bone specific alkaline phosphatase, PINP and CTX are not recommended 
for diagnosis or treatment response except for assessing PDB activity in 
untreated patients or when ALP is normal and in presence of concomitant liver 
disease. A bone biopsy of affected site is seldom required for diagnosis 
(Ralston 2013; Ralston et al. 2019). 
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Aetiology 
In spite of significant developments in last few decades, causes of PDB are 
still incompletely understood. It is regarded as a complex disease resulting 
from an interplay between genetic and environmental factors. 
1.4.6.1 Environmental triggers 
A reduction in prevalence of disease in some countries in recent years as well 
as absence or delayed appearance of symptoms in offspring of patients with 
SQSTM1 mutation mediated familial PDB point to environmental triggers 
regulating disease occurrence and severity (Ralston & Albagha 2011).  
Several environmental factors such as viral infection, dietary intake of calcium 
in childhood, Vitamin D deficiency, mechanical loading of the skeleton, 
exposure to environmental toxins, a rural lifestyle, exposure to farm animals 
and chronic infection with measles, respiratory syncytial or distemper virus 
have been suggested to play a role as well but evidence is inconclusive. Most 
extensively studied environmental factor is paramyxovirus (chronic measles) 
infection but evidence in favour of viral aetiology remains conflicting (Ralston 
& Layfield 2012). 
Measles virus nucleocapsid gene (MVNP) expression in murine osteoclasts 
leads to Pagetic-like phenotype in these osteoclasts and induces bone lesions 
(Kurihara et al. 2011). More recently, MVNP has been associated with IGF1 
and IL6 upregulation in osteoclasts in mouse models as well as PDB patients 
and also induces osteoblast differentiation in parallel thereby strongly 
supporting the role of MVNP in PDB pathogenesis (Teramachi et al. 2016). 
1.4.6.2 Genetics and PDB 
PDB has a strong genetic component. Evidence in support of this includes 
- Familial clustering in classical PDB; 5-40% of cases have a positive
family history. The disease, in many cases, is inherited in an autosomal
dominant fashion and shows high penetrance as one approaches
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seventh decade  (Sofaer et al. 1983; Hocking et al. 2001; Laurin et al. 
2001; Albagha & Ralston 2016). 
- Ethnic differences in PDB prevalence persist after emigration (Barker
1984).
- Several candidate loci identified by genome linkage scans (Laurin et al.
2001; Hocking et al. 2001).
- Mutations in four genes identified as cause of PDB and associated
syndromes (Lucas et al. 2006).
Several genes have been identified that cause classical PDB as well as rare 
PDB-like syndromes. 
Genes that cause rare PDB-like syndromes 
Several rare disorders which share some of the clinical features of PDB, have 
been described. They show Mendelian inheritance and early age of onset.  
Mutations in TNFRSF11B gene which encodes OPG are responsible for 
Juvenile Paget’s disease (JPD) (Whyte et al. 2002). JPD is inherited in an 
autosomal recessive manner. Clinical features include bone pain, deformity 
and fracture during childhood with a grossly abnormal bone turnover resulting 
in a mix of lytic and sclerotic enlarged bone lesions similar to PDB. OPG 
mutations include full deletion as well as missense change which result in 
complete lack of OPG or defective OPG protein not capable of binding RANKL 
and inhibiting osteoclastogenesis / bone resorption. These mutations are 
absent in classical PDB but there is some evidence which suggests that 
variants at this locus predispose to PDB at least in females (Ralston & 
Albagha 2012). 
Mutations in TNFRSF11A gene encoding RANK result in familial expansile 
osteolysis (FEO) (Osterberg et al. 1988), Expansile skeletal 
hyperphosphatasia (ESH) (Whyte et al. 2000) and Early onset familial PDB 
(EoPDB) (Nakatsuka et al. 2003) all of which show autosomal dominant 
inheritance and overlapping clinical features such as early deafness, tooth 
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loss and focal osteolytic expansile bone lesions that manifest in childhood or 
early adulthood. The causative mutations are duplications of 15-27 
nucleotides in Exon1 leading to elongation of RANK signal peptide that result 
in its abnormal cleavage and accumulation in the golgi apparatus. This 
probably results in aberrant NF-kB signalling but evidence is conflicting. 
Although similar mutations in RANK have been excluded to cause classical 
PDB, common variants at this locus are strongly associated with PDB 
susceptibility (Albagha et al. 2010, 2011).  
Inclusion body myopathy, PDB and Frontotemporal dementia (IBMPFD) is 
another autosomal dominant disease syndrome resulting from missense 
mutations in the gene Valosin-containing protein (VCP) (Watts et al. 2004). 
The clinical features mainly include myopathy (age of onset after 40yrs 
affecting 90% of the patients), PDB in 40% of cases which manifests at an 
earlier age (between 40 and 50 years) and dementia in 40% of cases with an 
average age of onset between 50 and 60 years. VCP encodes p97 which is 
involved in membrane fusion, ubiquitin mediated protein degradation and 
autophagy. The mechanism by which mutant VCP leads to IBMPFD 
phenotype is not fully understood but possibilities include an impairment of 
autophagy in presence of VCP mutations or  abnormal activation of the NF-
kB signalling along with dysregulation in IKBα protein degradation, which 
could contribute to the mechanism of pathogenesis in multiple tissues affected 
by IBMPFD especially bone (Ralston & Albagha 2011; Ralston & Albagha 
2012). Mutations of VCP have been ruled out as a cause of classical PDB but 
we have recently found a novel heterozygous missense mutation in a single 
elderly patient with classical PDB lacking myopathy or neurological 
complications (Wani, Albagha and Ralston, unpublished data). 
Various loss of function missense mutations have been found in 
heterogeneous nuclear ribonucleoproteins (hnRNPs) A2B1 and A1 genes in 
families affected by IBMPFD/ALS (amyotrophic lateral sclerosis) in absence 
of VCP mutations. The resulting dominantly inherited multisystem 
proteinopathy involves degeneration of muscle, bone, brain and motor 
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neurons arising due to altered RNA metabolism as a result of defective 
ribonucleoprotein granule assembly (Nalbandian et al. 2011; Kim et al. 2013). 
Patients with PDB have increased risk of developing giant cell tumour of bone 
(GCT). Though PDB is associated with GCT in less than 1% of cases, these 
patients have increased severity of PDB and reduced life expectancy 
(Rendina et al. 2015). Mutations (c.2810C>G and c.725G>T) in ZNF687 gene 
are not only associated with severe, early onset classical form of PDB but the 
mutation c.2810C>G in addition increases the likelihood of developing GCT 
(Divisato et al. 2016). ZNF687, a downstream target of NF-kB, encodes C2H2 
zinc finger protein that acts as a transcriptional co-regulator of bone cell 
proliferation and differentiation.  It is highly expressed during osteoclast and 
osteoblast development and significantly upregulated in  tumour tissue of 
patients with PDB/GCT as well as peripheral blood of PDB cases irrespective 
of SQSTM1 status (Divisato et al. 2016). 
Based on current evidence, classical PDB appears to result more likely from 
a combination of rare variants (in genes such as SQSTM1) and more common 
alleles, which, in spite of their smaller effect size, when inherited together with 
rare high penetrance variants, are likely to increase PDB risk considerably 
(Ralston & Albagha 2011; Albagha et al. 2013). 
Genes that cause classical PDB include: 
SQSTM1:        
The most important gene in relation to PDB is the sequestosome 1 (SQSTM1) 
gene encoding p62 protein. p62 has three functional domains: an N-terminal 
region which is involved in kinase interactions, a hinge region and a C-terminal 
region containing the Ubiquitin-binding domain (UBA) (Geetha & Wooten 
2002). Linkage analysis first identified the chr 5q35 locus to be associated 
with PDB in two independent populations (Laurin et al. 2001; Hocking et al. 
2001). Mutation screening of the critical region identified a proline to leucine 
change at codon 392 (P392L) in the UBA of SQSTM1 as the cause of PDB in 
a French-canadian population cohort (Laurin et al. 2002). Subsequent studies 
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identified P392L in British and several other populations including Chinese 
people where PDB appearance is rare (Hocking 2002; Beyens et al. 2004; 
Falchetti et al. 2004; Johnson-Pais et al. 2003; Gu et al. 2012). Several more 
mutations clustered in the UBA domain as well as few others outside the UBA 
of SQSTM1 have been found to be associated with PDB in populations 
worldwide, P392L being the most common (Rea et al. 2013). 
p62 is an adaptor protein that binds ubiquitin. It plays an important role in NF-
kB signalling and osteoclast activation downstream of RANK. RANK-RANKL 
interaction results in polyubiquitylation of TRAF6 leading to activation of 
several downstream signalling pathways (Layfield & Hocking 2004) and 
nuclear translocation of NF-kB, AP-1 and NFATc1 ultimately leading to 
transcriptional activation of osteoclast specific genes such as ACP5 (TRAcP) 
and CTSK (Cathepsin K).  Recruitment of CYLD to the RANK-TRAF6 protein 
complex requires ubiquitin binding domain of p62. Deletion of this domain 
and/or the mutations within it result in impaired p62-CYLD binding thereby 
leading to increased TRAF6 ubiquitination, enhanced RANK and NF-kB 
signalling leading to increased osteoclast activity and bone resorption (Jin et 
al. 2008; Ralston & Layfield 2012). 
p62 is also involved in the process of autophagy, a novel pathway which has 
recently being found to be dysregulated or defective in PDB (Usategui-Martín 
et al. 2015). 
Approximately 10% of sporadic cases and 40% of familial cases of PDB show 
germline SQSTM1 mutations (Laurin et al. 2002; Hocking 2002). Although 
presence of SQSTM1 mutations hastens the onset of PDB and increases its 
severity, few patients with these mutations have a phenotype not suggestive 
of PDB, meaning additional mutations or exposure to environmental trigger(s) 
is needed for the disease to manifest and SQSTM1 mutations are 
predisposing rather than causing the disease by itself. Thus, additional causal 





Genes associated with increased susceptibility to PDB: 
With the aim of identifying additional causal genes, Genome wide association 
studies (GWAS) were performed by our group and have identified single 
nucleotide polymorphisms at the seven loci on chr 1, 7, 8, 10, 14, 15 and 18 
(containing CSF1, NUP205, DCSTAMP, OPTN, RIN3, PML and TNFRSF11A 
respectively) as significant risk factors for PDB development (Albagha et al. 
2010; Albagha et al. 2011). Three of these (CSF1, TNFRSF11A and 
DCSTAMP) have known roles in bone metabolism whereas the remaining 
four had not been implicated in bone metabolism at the time GWAS were 
conducted. Two of these regions have now been studied in detail and found 
to have a functional role in bone metabolism: RIN3 encoded by the 14q locus 
and OPTN encoded by the 10q locus (Vallet et al. 2014; Obaid et al. 2015). 
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CSF1: is located on chr 1p13 and encodes cytokine M-CSF which is involved 
in macrophage and osteoclast differentiation as well as osteoclast survival. 
The strongest association at this locus was with SNP rs484959 located 87kb 
upstream of CSF1 (Albagha et al. 2010). Untreated PDB patients have raised 
serum CSF1 level (Neale et al. 2002) whereas loss of function mutations in 
Csf1 in mice and rats cause osteopetrosis (Yoshida et al. 1990). Causal 
variants from CSF1 have yet to be identified but most likely induce PDB by 
regulating CSF1 expression levels and activity (Ralston & Albagha 2012; 
Albagha & Ralston 2016). 
NUP205: The strongest GWAS signal at chr7q33 was rs4294134 within 
intronic region of NUP 205 which encodes the nucleoporin 205KDa, a 
component of the nuclear pore complex that regulates transport processes 
between nucleus and cytoplasm but has unknown role in bone metabolism 
(Albagha et al. 2011; Albagha & Ralston 2016). 
DCSTAMP: is located on chr8q22 and encodes DC-STAMP which is essential 
for fusion of osteoclast precursors to form mature multinucleated osteoclasts 
(Yagi et al. 2005). RANKL upregulates DC-STAMP expression in osteoclast 
precursors. DC-STAMP is essential for RANKL-induced osteoclastogenesis. 
PDB patients show hypernuclear and larger osteoclasts compared to healthy 
controls. Genetic variants at this locus could therefore result in predisposition 
to PDB by enhancing DCSTAMP expression leading to increased fusion of 
osteoclasts (Ralston & Albagha 2012). 
OPTN: located on chr 10p13 locus which encodes for Optineurin, is involved 
in the regulation of NF-kB signalling and autophagy (Zhu et al. 2007; Shen et 
al. 2011) which could explain its involvement in PDB. The strongest GWAS 
SNP rs1561570 was found to be an eQTL with reduced OPTN mRNA 
expression in PDB-predisposing high risk T-allele carriers. Optn knock-in 
(D477N) mutant mice (with a polyubiquitin binding defect) show increased 
osteoclast activation and bone turnover with low penetrance PDB-like lesions. 
OPTN was found to negatively regulate osteoclast differentiation by 
controlling IFN- β signalling and NF-kB in these mice. Thus, genetic variants 
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at the OPTN locus could be leading to reduced OPTN expression thereby 
predisposing to PDB by increasing osteoclast differentiation and activity. 
(Obaid et al. 2015). Another study, however, has shown that SNP rs1561570 
leads to increased OPTN expression via loss of methylation site leading to a 
phenotype of increased osteoclast activity (Silva et al. 2018) though the 
sample size in this study was much smaller. A more recent study has now 
confirmed that complete deletion of Optn (using Optn knockout mice) results 
in hyperactive osteoclasts and abnormal bone remodelling leading to 
osteolytic lesions characteristic of PDB via altered Type 1 IFN signalling. The 
lesions were observed mainly in aged mice (22 months) (Wong et al. 2019). 
RIN3: encoding Ras and Rab interactor 3 protein located on chr 14 was the 
most likely candidate gene from this locus. RIN3 interacts with Ras and Rab 
GTPases which play an important role in vesicular trafficking (Kajiho 2003) 
and osteoclast function. 14q32 locus was investigated in PDB patients and 
controls by deep sequencing and identified p.R279C as the most probable 
causal variant from this locus. p.R279C was in strong LD with the GWAS 
signal rs10498635. 13 rare missense variants affecting important RIN3 
domains were found which when combined increased the risk of disease 
presentation. RIN3 expression was tenfold higher in osteoclasts compared to 
osteoblasts. Thus, RIN3 could be contributing to PDB pathogenesis by 
positively regulating osteoclast function (Vallet et al. 2014; Alonso et al. 2017) 
TNFRSF11A: located on Chr 18q21 encodes RANK involved in osteoclast 
differentiation and bone resorption (Li et al. 2000). This region corresponds to 
PDB7 locus previously identified in families by linkage analysis (Good et al. 
2002). Disruption of RANK leads to osteopetrosis in mice and genetic 
variability in TNFRSF11A could increase PDB severity in those with SQSTM1 
mutations (Li et al. 2000; Gianfrancesco et al. 2012). Mechanisms involved in 
association of common genetic variants at this locus with PDB predisposition 
currently remain unclear (Alonso et al. 2017). 
PML/GOLGA6A: located on the chr 15q were the most likely candidate genes 
from this locus though both of them have never been implicated in bone 
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metabolism. The strongest association was with SNP rs5742915, which 
results in an amino acid change at codon 645 within PML gene (phenylalanine 
to leucine: p.Phe645Leu) (Albagha et al. 2011). PML gene has been 
described in detail later in section 1.5.  
Somatic mutations in PDB  
PDB is a focal disease and shows asymmetric distribution. What causes this 
is not clear yet. It could be explained by presence of somatic mutations in 
SQSTM1 and other PDB associated genes. Studies have found P392L as a 
somatic mutation in affected PDB bones from some patients and few Pagetic 
osteosarcomas whereas in others, the results were negative. The signal for 
mutant allele was weak and lower compared to those of P392L germline 
heterozygotes indicating only a minor proportion of cells affected by somatic 
mutations (Matthews et al. 2009; Merchant et al. 2009; Ralston & Layfield 
2012). Another study (Sparks et al. 2001) found no somatic mutations in the 
gene TNFRSF11A (RANK) from affected PDB tissue and osteosarcoma cell 
lines. We are exploring the role of somatic mutations in focal nature of PDB 
using exome sequencing of DNA extracted from affected human bones and 
comparing it to DNA sequences obtained from peripheral blood. 
Autophagy associated genes and other candidate genes for PDB  
Autophagy is the process involved in degradation of cytoplasmic proteins, 
damaged organelles and protein aggregates. It has recently been found to be 
dysregulated or defective in PDB. Several PDB associated genes such as 
SQSTM1, OPTN and VCP are involved in the process of autophagy. SQSTM1 
directs ubiquitinated proteins for degradation in autophagolysosomes. Mice 
with the P394L Sqstm1 mutation show enhanced autophagosome formation 
(consistent with increased Sqstm1, light chain 3 gene (Lc3) and autophagy-
related gene 5 (Atg5) mRNA expression in osteoclast precursors from these 
mice as well as increased LC3-II protein levels) (Daroszewska et al. 2011; 
Ralston & Layfield 2012). Autophagy genes (ATG5, ATG4B and ATG7) have 
been shown to affect osteoclastic bone resorption and polymorphisms in ATG 
genes have been shown to increase risk of PDB (ATG5 and ATG16L1) and 
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vice versa (ATG10) in a Spanish cohort of PDB cases (DeSelm et al. 2011; 
Usategui-Martín et al. 2015). 
Nominally significant associations have been identified in some studies 
between PDB and polymorphisms in genes CASR, ESR1 and TNFRSF11B 
whereas no association was found in genes IL1RA, IL6, IL1B, IL8, TNFA, 
TNFFS11 and VDR (Donáth et al. 2004; Corral-Gudino et al. 2006; Beyens et 
al. 2007; Corral-Gudino et al. 2010). Though TNFRSF11B encoding OPG did 
not appear as a candidate locus in GWAS, current evidence suggest that 
variants in this gene predispose to PDB only in women and further studies are 
warranted (Beyens et al. 2007; Ralston & Albagha 2011). 
 Treatment 
Bone pain is the main indication for treatment in PDB. The first choice of drugs 
are nitrogen-containing bisphosphonates with zoledronic acid most preferred 
of the lot in achieving a favourable pain response. These are potent anti-
resorptives which preferentially target the affected skeletal sites and are 
highly effective in suppressing the increased bone turnover at these active 
PDB skeletal sites (Reid et al. 2011; Ralston 2013; Ralston et al. 2019). A 
research project “Pain in Paget’s disease (PiP)” under Prof. Stuart Ralston is 
in progress to look in detail at causes and understand mechanisms of pain to 
try and improve pain management in PDB patients.  
Calcitonin is also effective in reducing bone pain and suppressing bone 
turnover but is less potent than bisphosphonates and has more adverse 
effects and is therefore used only in exceptional cases for short term treatment 
of PDB when bisphosphonates are contraindicated such as those with renal 
impairment. Other drugs such as anti-inflammatory, analgesics and 
antineuropathic agents are often used or required to manage pain. Osteoclast 
inhibitor Denosumab which is a monoclonal antibody inhibiting RANKL has 
shown promise but there is insufficient evidence to warrant its clinical use in 
PDB and it has therefore not yet been licensed for treating PDB (Ralston 
2013; Ralston et al. 2019). 
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Non pharmacological agents such as acupuncture, physiotherapy and 
hydrotherapy have been tried for relieving pain and increase muscle strength 
as well as mobility but clinical evidence is lacking. Orthopaedic surgery is 
recommended for fracture fixation through the pagetic bone; total knee or hip 
replacements recommended for patients with complications such as 
osteoarthritis (where medical treatment is unsatisfactory) and spinal surgery 
may be considered for spinal stenosis/compression due to PDB (Ralston et 
al. 2019). Surgery may be required for those with osteosarcoma but the 
prognosis is often poor in these cases (Sharma et al. 2005). 
PRISM (Paget’s disease of bone: Randomized trial of intensive 
bisphosphonate treatment versus symptomatic management) study and its 
extension did not find any evidence of clinical benefit in treating PDB patients 
with intensive bisphosphonate therapy versus symptomatic management 
(Langston et al. 2010, Tan et al. 2017). Thus, guidelines recently published 
recommend treating patients with the aim of improving symptoms rather than 
pursue a treat-to-target treatment strategy aimed at normalising total ALP in 
PDB (Ralston et al. 2019). Treatment of PDB patients with altered biochemical 
activity and/or family history in absence of symptoms is still under debate. An 
international randomized clinical trial Zoledronate in the prevention of Paget’s 
(ZiPP study, ISRCTN11616770) led by Prof. Stuart Ralston at the University 
of Edinburgh, UK is currently in progress to determine if Zoledronate can 
prevent PDB in asymptomatic individuals with family history and SQSTM1 
mutations (Alonso et al. 2017). Another study led by Prof. Ralston is also 
investigating contribution of genetic and microbiome markers to PDB 
development in asymptomatic offspring of PDB patients.  
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1.5 Promyelocytic Leukaemia (PML) 
One of the GWAS loci was located on 15q24.1 and it contains two likely 
candidate genes PML and GOLGA6A both of which have unknown role(s) in 
bone metabolism. The association at this locus was replicated in several 
independent populations from UK, Australia, Spain, Italy, Belgium and the 
Netherlands. The strongest association was with SNP rs5742915, which 
results in an amino acid change at codon 645 within PML gene (phenylalanine 
to leucine: p.Phe645Leu) (Fig. 13) (Albagha et al. 2010; Albagha et al. 2011). 
 
 
PML is a tumour suppressor gene that is disrupted in acute promyelocytic 
leukemia (APL) resulting in its fusion to retinoic acid receptor alpha (RARA) 
gene as a result of the chromosomal translocation t(15;17) (Nisole et al. 
2013). 
The PML gene is located on long arm of chromosome 15. The gene consists 
of nine exons. Alternative splicing of exons 5-9 yields a large number of 
isoforms. The seven main ones are experimentally validated and designated 
PML I-VII. PML I is the longest isoform with 882 amino acids (aa) whereas 
PML VII is the shortest with 435 aa. They share the N-terminal region (exon 
Figure 1.12                  
Regional association plot of 
15q24.1 locus.                                            
Shows chromosomal position of SNPs in 
15q region plotted against −log10 P 
values based on NCBI hg build 36. 
Genotyped (squares) and imputed 
(circles) SNPs are colour coded 
according to the extent of LD with 
highest association SNP rs5742915. The 
estimated recombination rates (cM/Mb) 
from HapMap CEU release 22 are shown 
as light blue lines. The blue arrows 
represent known genes. (Albagha et al. 
2011) 
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1-3) and differ in their C-terminal regions (El Bougrini et al. 2011; Nisole et al.
2013; Guan & Kao 2015).
The GWAS hit rs5742915 lies at the start of Exon 9 in the C terminal region 
of PML and therefore exists only in isoform 1. The amino acid change 
associated with this SNP is predicted to be tolerated by SIFT and benign by 
Polyphen and is not conserved through evolution. This means there are likely 
to be other variants driving the association with PDB risk. The gene as a 
whole, is not evolutionally conserved across eukaryotes. PML protein appears 
to be show conservation in mammals but seems to be absent from plants and 
from lower eukaryotes. Thus, PML function seems to be restricted to higher 
eukaryotes (Borden 2002; Borden 2008).   
Figure 1.13. Chromosomal location and Structure of PML gene with seven 
main isoforms.  
Adapted from (Nisole et al. 2013). 
PML protein is ubiquitously expressed and is a member of the tripartite motif 
family and therefore also known as TRIM19. The N-terminal 418 aa, common 
to all isoforms, contains a number of well characterized zinc-binding domains. 
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These include a RING (really interesting new gene) finger domain, adjacent 
to two cysteine/histidine-rich motifs known as B-boxes (B1 and B2). The 
RING, B-boxes and α-helical coiled-coil domain, form a conserved motif 
known as TRI-partite motif (TRIM) or RBCC (El Bougrini et al. 2011; Nisole et 
al. 2013).  
The difference in the COOH-terminal parts of the isoforms not only determines 
their localisation in the cell but also determines their partners, and in turn, the 
specific function(s) for each isoform. PML is localised to subnuclear matrix-
associated structures, known as PML nuclear bodies (NBs). The RBCC 
domain plays an integral role in this as well as PML homodimerisation via the 
coiled-coil domain. Exon 6 encodes a nuclear localization sequence (NLS) 
which is responsible for PML nuclear localization. The nuclear export signal 
(NES) located on exon 9 is found only in PML I isoform, consistent with the 
cytoplasmic and nuclear distribution of this isoform. The SUMO interacting 
motif (SIM) is located on exon 7 with its hydrophobic core adjacent to specific 
serines that act as sites for Casein Kinase 2 (CK2) phosphorylation (El 
Bougrini et al. 2011; Nisole et al. 2013).  
Figure 1.14. Domain organisation, motifs and Amino acid (aa) positions in the 
longest PML protein.  
Adapted from (Nisole et al. 2013) 
PML nuclear bodies range from 0.2 to 1um in size. PML is essential for the 
formation of these important structures since they interact with a number of 
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proteins, either transiently or stably and comprise chromosomal regions of 
high transcriptional activity. They regulate important cellular processes such 
as cell cycle, apoptosis and transcription, in association with their interacting 
partners. Modifier proteins such as deubiquitinases, phosphatases, kinases, 
acetyltransferases and ubiquitin/SUMO E3 ligases, as well as their substrates 
co-localise and interact to bring about protein modification at PML nuclear 
bodies  (Salomoni & Pandolfi 2002; Bernardi & Pandolfi 2007; Guan & Kao 
2015; Ahmed et al. 2017). 
Role of PML in multiple biological processes 
PML has been shown experimentally to physically interact with 120 proteins 
either transiently or constitutively leading to mutual regulation 
(http://thebiogrid.org). PML is therefore involved in multiple cellular pathways 
and activities such as regulation of cell growth, senescence, apoptosis, DNA 
repair, stem cell maintenance, protein degradation, autophagy and antiviral 
responses (Guan & Kao 2015). 
PML senses DNA damage and organises multiple DNA repair complexes 
(such as Rad50/NBS1/hMre11 and BLM/Rad51/RPA) thereby maintaining 
genome integrity and stability and plays a crucial role in promoting alternative 
lengthening of telomeres (Dellaire and Bazett-Jones 2004; Chung et al. 2012). 
PML is also involved in transcriptional regulation and functions mainly through 
nuclear bodies by interacting with cofactors to repress or activate 
transcription. PML disrupts DNA binding activity of Sp1 and its transactivation 
of epidermal growth factor promoter (Vallian et al. 1998) and interferes with 
Nur77 binding to its target promoter (Wu et al. 2002) as well as STAT3 DNA 
binding and activity (Kawasaki et al. 2003). PML represses NF-kB induced 
transcription of A20 (a NF-kB target gene) by competitively binding to A20 
promoter (Wu et al. 2003). PML is required for transcriptional repression by 
tumour suppressor Mad and it achieves this by forming complexes with 
multiple corepressors (c-ski, N-Cor and mSin3A) (Khan et al. 2001) as well as 
histone deacetylase 1 (HDAC1) thereby exerting control at the epigenetic 
level (Wu et al. 2001). 
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PML also exhibits positive effects on transcription of many genes. PML 
stimulates AP-1 transcriptional activity (Vallian et al. 1998) and is essential for 
c-Jun DNA binding and activity in response to UV irradiation (Salomoni et al.
2005). PML is required for all-trans retinoic acid (ATRA)-dependant
transactivation of p21 (Wang et al. 1998) and physically associates with and
facilitates activity of important haematopoietic stem cell differentiation TF’s
GATA 1 (Wu et al. 2014) and GATA 2 (Tsuzuki et al. 2000). PML activates a
subset of B-catenin responsive genes such as ARF and Siamois (Shtutman
et al. 2002) and at the same time, sequesters transcriptional corepressor Daxx
in PML NBs to cause transcriptional derepression of Pax3 (Lehembre et al.
2001). PML also forms transcriptional complex with NF-kB, STAT1 and CBP
to activate Type I interferon (IFN-β) response  (Guan & Kao 2015).
PML mediates apoptosis in response to various stimuli such γ-irradiation, Fas, 
IFNs (Type I and II) and TNF-α. The process requires caspase-3 activation by 
PML but PML can also mediate non-caspase mediated apoptosis by recruiting 
BAX and p27KIP1 (Wang et al. 1998; Huang et al. 2011). PML is a critical 
regulator of p53 tumour suppressor activity and p53 mediated cellular 
processes such as apoptosis, cell cycle arrest, DNA repair and senescence. 
PML activates p53 by sequestering Mdm2 thereby inhibiting p53 degradation 
and by promoting phosphorylation as well as acetylation of p53 (Bernardi et 
al. 2004). PML also promotes apoptosis by inhibition and sequestration of 
AKt/protein kinase B, inhibition of NF-kB survival pathway whereas 
cytoplasmic PML positively regulates TGF-β-induced apoptosis and promote 
its tumour suppressive activity (Guan & Kao 2015). 
PML protein is upregulated in response to Ras oncogene resulting in 
potentiation of retinoblastoma protein (Rb) and p53 leading to premature cell 
senescence (Pearson et al. 2001).  
Regulation of PML 
PML expression is regulated by multiple factors and at multiple levels. Various 
cytokines such as Interferons, TNF-α and IL-6 enhance PML transcription via 
JAK-STAT pathway activation, STAT-1 activation and via stimulation of NF-
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kB/JAK-STAT pathway respectively. Furthermore, B-catenin and plakoglobin 
act on PML promoter to activate its transcription. PML mRNA translation has 
been found to be enhanced in rodent cells by oncogenic Ras and TNF-α has 
been shown to stimulate the IRES site in the 5’-UTR of human PML mRNA 
(Guan & Kao 2015). 
Post-translational modifications of PML are also known to regulate its protein 
levels within the cell and thereby control its functions. Arsenic trioxide, an 
inorganic cytotoxic compound which is used in chemotherapy of APL patients, 
directly binds to PML resulting in SUMOylation-dependent, ubiquitin-mediated 
proteasomal degradation of PML via RNF4 (Lallemand-Breitenbach et al. 
2008). CK2 phosphorylation promotes PIAS-1 mediated degradation of PML 
(Scaglioni et al. 2006). Similarly, PML phosphorylation by ERK2, IGF1 and 
CDK1/2 results in PML-Pin1 interaction, protein isomerization followed by 
ubiquitin-mediated PML degradation (Lim et al. 2011). Protein 
acetyltransferase p300 acetylates PML leading to its degradation (Hayakawa 
et al. 2008) whereas deacetylase SIRT1 induces PML SUMOylation leading 
to accumulation of PML as well as increase in PML NB abundance (Guan et 
al. 2014).   
Specific function of PML isoforms 
Alternative splicing of PML gene generates several isoforms.  Many studies 
have performed to try and understand specific function of different isoforms. 
PML I plays an important role in haematopoietic cell (myeloid lineage) 
differentiation by interacting with acute myeloid leukaemia 1. PML I interaction 
with HSV-1 ICP0 results in self-degradation by a SUMO-independent 
mechanism. PML IV, the most studied PML isoform, is involved in antiviral 
defence against many viruses such as Varicella-zoster virus, rabies virus and 
Encephalomyocarditis virus mainly via sequestration in PML NB’s and also 
interacts with p53, PU.1, TRF1 and TIP60 to mediate their activity. In contrast, 
PML II interacts with Ad5-E1A-13Svirus to activate its transcription. PML III is 
involved in inhibition of centrosome duplication via suppression of Aurora A 
activation. PML V acta as a scaffold for PML NB formation and recruitment of 
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Daxx and Sp100 in PML NB’s. PML VI lacks the SIM and thereby confers 
resistance to arsenic-induced PML degradation (Nisole et al. 2013).  
In addition to 6 PML nuclear isoforms, a fraction of PML is also localised in 
the cytoplasm. The cytoplasmic isoform PML VIIb is involved in activation of 
TGF-β signalling and induction of target genes via interaction with SMAD 2/3 
and SARA (Lin et al. 2004). 
PML has, however, never been implicated directly in bone metabolism. My 
PhD study deals with exploring the role of chr 15q24 locus containing PML in 
bone metabolism and disorders of bone turnover such as PDB.  
GOLGA6A 
The GOLGA6A gene encodes a member of the golgin family of coiled-coil 
proteins. They are associated with the Golgi apparatus, and probably act as 
structural supports for the Golgi cisternae as well as play a role in membrane 
fusion (Albagha et al. 2011). The gene contains 18 exons spanning 10kb 
(www.omim.org/entry/610288). 
The protein has a predicted molecular mass of 75KDa with a restricted pattern 
of expression confined mainly to testis. The role of the GOLGA6A gene in 
bone metabolism is currently unknown. However, skeletal dysplasia which is 
lethal (Smits et al. 2010) and a severe form of osteoporosis (Hennies et al. 

































2 Project Aims and likely impact of findings
To examine the role of chromosome 15 locus in bone metabolism and 
development of Paget’s disease of bone by: 
- Fine mapping of 15q24 locus to identify functional genetic variants and
susceptibility genes in relation to PDB using targeted next generation
sequencing and functional analysis of any relevant variants.
- Investigate how abnormalities in PML regulate bone cell function
thereby contributing to PDB using:
• Expression analysis of PML in bone cells of murine as well as
of human origin and in patients with PDB.
• In vitro knockdown and overexpression assays in mouse
monocyte-macrophage-like cell line – RAW 264.7 to assess and
understand PML gene function in bone and
• Examine phenotype of young as well as older Pml knockout
mice and analyse relevant mechanisms and bone signalling
pathways.
2.1 Impact 
• Genetic factors identified at this locus could be used in conjunction with
other genetic markers to assess individuals with family history as well
as higher risk of developing PDB so that treatment or disease
modifying strategies can be implemented early in life before permanent
damage occurs.
• Better understanding of PDB pathophysiology as well as identify new
molecular and bone signalling pathways and potential therapeutic
targets.
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3 Material and Methods 
3.1 Reagents/Materials 
Media: Minimal Essential Medium Eagle - αMEM (Sigma), Dulbecco's 
Modified Eagle's medium- DMEM (Sigma), Fetal Calf Serum (Hyclone) and L-
Glutamine (Invitrogen).  
Antibodies: PML (sc-5621 1:500 SantaCruz Biotechnology), Rabbit Anti-Actin 
1:1000 (AA20-33) IgG (Sigma), Rabbit alpha-tubulin mAb 1:1000 (2125 Cell 
Signalling)  
Cytokines: Murine M-CSF (Prospec Tech.) and human recombinant RANK-L 
(gift from Dr. Patrick Mollat-Proskelia SASU and R&D Systems), IFN-γ 
(Lifetech, gift from Elaine Nimmo, IGMM).   
Buffers, chemicals and other reagents: Cell dissociation buffer (Gibco), 
RNAlater solution (Sigma-Thermoscientific), Penicillin (Invitrogen), 
Streptomycin (Invitrogen), Genticin (Neomycin analogue-G418 LifeTech), 
jetPEI-Macrophage (Polyplus) and Alamar Blue reagent (Invitrogen). Please 
see appendices 1, 5 and 6 for further details. 
Kits: GenElute Mammalian Total RNA kit (Sigma), RNeasy kit and DNeasy 
blood and tissue kit (Qiagen), qScript cDNA SuperMix kit (QuantaBioscience), 
SensiFAST Probe No-ROX kit (Bioline), Ambion Ribopure Blood RNA 
isolation kit;  







3.2 Targeted Next generation DNA sequencing 
 Study population 
138 cases (negative for SQSTM1 mutations and age at diagnosis of PDB <65 
years) and 50 controls (unaffected individuals) were selected, DNA prepared 
and samples sent to Oxford Genomics for Targeted capture and sequencing.  
 Sequencing 
15q24 locus was investigated by target capture of a 200 kb region surrounding 
the GWAS SNP rs5742915 using Haloplex target enrichment kit from Agilent. 
This region included six genes (LOXL1, PML, STOML1, GOLGA6A, ISLR, 
ISLR2).  
Libraries were prepared, labelled with barcodes and sequenced on the 
Illumina HiSeq2000 platform. Sequencing analysis was performed by my 
supervisor Dr. Albagha and data was provided after QC, variant calling and 
annotation for further analysis. Burrows-Wheeler Alignment tool (BWA) 
package was used to map the sequenced reads (Fastq) to the reference 
human genome (hg19/b37). Picard version 1.89 was used to remove 
duplicate reads. Local re-alignment of the mapped reads around potential 
indel sites was done using Genome Analysis Toolkit ver 1.6 (GATK; 
http://www.broadinstitute.org/gsa/wiki/index.php/Home_Page). GATK was 
also used to recalibrate base quality (Phred Scale) scores and GATK unified 
genotyper used to call SNPs and indel variants.  
 Data analysis 
PLINKSeq was used to analyse the genetic variation data. Publicly available 
databases such as ENSEMBL, 1000 genomes, NHLBI and ENCODE were 
used for annotation and/or filtering the variants. Variants passing quality 
control measures were filtered to include missense variants, 3’ or 5’ UTR 
variants and functional variants as predicted by ENCODE. 
 
Publicly available bioinformatics tools such as SIFT and PolyPhen-2 were 
used to predict the functional effect of identified SNPs. Other tools such as 
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Mutation taster, I-mutant 2.0, SNIPA browser (Germany) and Regulation 
spotter were also used to assess SNP effects. Association testing of common 
variants was done by chi-square allelic test and rare variants were subjected 
to Fisher’s exact test. 
3.3 Mice 
PML knockout (KO) mice (Pml-/-) on a C57/B16 background were obtained 
from National Cancer Institute, USA. PML was disrupted in the mouse germ 
line and knockout generated by deleting part of exon 2 (94 bp) which encodes 
the RING finger domain (Wang et al. 1998). Wild type (WT) C57/B16 mice 
were used as controls. 
Ethics Committee at the University of Edinburgh approved all animal protocols 
and procedures and they were conducted in accordance with the UK Home 
Office regulations (Personal licence number IBF9C1299, Project licence 
number 70/7964) 
 Mouse genotyping 
Genomic DNA was extracted from mouse earsnips using the Qiagen DNeasy 
Blood and Tissue Kit according to manufacturer’s protocol. DNA extracted 
was amplified by PCR in a 25ul reaction volume using Qiagen Taq 
polymerase kit, run on a 2% agarose gel and band size determined using a 
reference 100 bp Ladder from NEB.  
Primers used: 
Y317: 5'-TTT CAG TTT CTG CGC TGC C -3' 
Y318: 5'-CGA CCA CCA AGC GAA ACA -3' 
Y319: 5'-TTG GAC TTG CGC GTA CTG TC -3' 
 
Table 3.1 Primers used for genotyping Pml-/- mice. 
Primer combination Band Size Genotype 
Y317/Y319 450 bp WT 




Table 3.2 PCR reagents and thermocycler conditions used for genotyping 
Pml-/- mice. 
PCR reaction (25ul) 
Reagents Volume (ul) 
Qiagen 10x Buffer 2.5 
dNTPs (10mM) 2 
Qiagen Q-Solution (5X) 5 
Y317 Primer (10uM) 1 
Y318 Primer (10uM) 1 
Y319 Primer (10uM) 1 
Distilled Water 7.3 
Qiagen Taq Polymerase (U/ul) 0.2 
DNA (10ng/ul) 5 
3.4 Cell culture
All tissue culture work was carried out in designated areas, under a laminar 
flow hood or a class II biological safety cabinet and was performed under 
sterile conditions with pre-sterilised or autoclaved reagents and consumables. 
All cultures were maintained in an incubator with standard conditions of 37°C, 
5% CO2 in a humidified atmosphere. Cell counting was done using a 
haemocytometer and cultures visualised using an inverted light microscope.  
Alamar blue viability assay 
This assay was used to quantitatively measure cell viability in culture. Healthy 
viable cells maintain a reducing environment within the cytoplasm. Alamar 
blue reagent resazurin, the active ingredient of alamarBlue reagent, is a cell 
Thermocycler conditions 
Step Temperature(°C) Duration 
 Initial 
Denaturation 94 4min 
Denature 
Template 94 30sec 
Annealing 60 1min 
Extension 72 1min 
Number of cycles 35 
Final Extension 72 10min 
Hold 4 Forever 
76 
permeable, non-toxic compound that is blue in colour and non-fluorescent. 
Once it enters the cell, resazurin is reduced to resorufin which is red in colour 
and fluorescent. The colour change is directly proportional to the number of 
viable, metabolically active cells. Alamar blue was added as 10% of total 
volume in each well and left for 2.5 hours at 370C. The resulting fluorescence 
was measured by the plate reader (BIO-Tek Synergy HT) using excitation 
wavelength of 540nm and an emission wavelength of 590nm. Control wells 
containing only media were used to correct the data for background 
fluorescence. 
Osteoclast culture 
This was done using primary mouse bone marrow cells as well as RAW 264.7 
cell line. It is a mouse monocyte-macrophage-like cell line established from 
the ascites of a tumour which was induced in a male mouse by intraperitoneal 
injection of Abselon leukaemia virus (A-MuLV) and forms osteoclasts in 
response to RANKL treatment (Raschke et al. 1978; Vincent et al. 2009). 
Bone marrow cells were isolated from the long bones (tibia and femur) of 3-4 
month old mice.  The mice were culled by cervical dislocation, lower limbs 
carefully dissected to remove any soft tissue and bones collected in sterile 
PBS. This was followed by isolation of bone marrow under a flow hood. The 
epiphyses of long bones were cut, bone marrow flushed with αMEM using a 
plastic 5ml syringe and 25 gauge needle into a 10cm petri dish and 
homogenized with a broader 21 gauge needle. This was centrifuged at 300g 
for 3 mins, supernatant discarded, cell pellet resuspended in αMEM and 
cultured in 10 cm petri dish in the presence of M-CSF (100ng/ml) for 48 hrs to 
generate bone marrow derived macrophages (BMDMs). Adherent cells were 
gently scraped with a rubber scraper after removal of the medium and 
incubation with 5ml cell dissociation buffer for 5 mins at 37°C to lift the cells. 
Fresh medium was added to dissociated cells, all contents of petri dish 
collected in 15 ml falcon tube, centrifuged, supernatant discarded and the cell 
pellet resuspended in 1ml supplemented medium for counting. The cells were 
then plated (seeding density: 10,000 BMDMs per 96 well and 100,000 
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BMDMs per 12 well) and stimulated with M-CSF (at a concentration of 
25ng/ml) and RANKL (100ng/ml), medium replaced on 3rd day and culture 
continued until osteoclasts were formed (usually 4-5 days post RANKL 
stimulation). Multinucleated osteoclasts (≥ 3 nuclei and ≥ 10 nuclei) were 
visualised using TRAcP staining (as described later in section 3.4.7). The 
medium used was αMEM supplemented with 10% foetal calf serum (FCS), 
2mM L-glutamine, 100µg/ml streptomycin and 100 U/ml penicillin.  
For IFN-γ experiments, BMDMs were treated with IFN-γ (5ng/ml) for 24 hrs 
followed by treatment with MCSF and RANKL as above to generate 
osteoclasts. 
RAW 264.7 cell line with early passage number was grown in T75 flask. When 
70-80% confluent, the cells were scraped, centrifuged, pellet resuspended, 
counted and cultured (Seeding density: 10,000 per 96 well and 100,000 per 
12 well) in DMEM (supplemented as above with 10% foetal calf serum (FCS), 
2mM L-glutamine, 100µg/ml streptomycin and 100U/ml penicillin) for 4 days 
with RANKL (100ng/ml) until osteoclasts were formed. 
Protein and RNA were isolated (described in section 3.7.1 and 3.8 
respectively) and collected on the following days during osteoclast 
development: Day 0 (no RANKL), Day 2/3 (intermediate stage) and Day 4/5 
(Final stage of osteoclast). 
 Bone resorption assay (Osteoassay)  
The bone resorption activity of osteoclasts was determined using osteoassay 
surface multi well plate. BMDMs were plated (50,000 cells/well in 500ul/well 
supplemented αMEM) and osteoclasts obtained (as described above in 
osteoclast culture) on Osteo Assay Surface 24 well plates. Following this, cells 
were removed from wells using a 2% sodium hypochlorite solution for 5 
minutes, washed with distilled water and air-dried. For modified Von-Kossa 
staining, plates were treated away from light, with 250 µl/well of a 5% (w/v) 
silver nitrate solution for 30 minutes at room temperature. Supernatants were 
aspirated and rinsed for 5 minutes with distilled water. Supernatants were 
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aspirated again, and incubated in 250 µl/well of a 5% (w/v) sodium carbonate 
in formalin solution for 5 minutes at room temperature. Plates were then 
washed twice with distilled water followed by drying them in a 50°C incubator 
for an hour. Plates were then imaged with a Zeiss inverted microscope and 
resorption areas analysed using ImageJ software (NIH). 
The wells in these plates have a thin film of calcium-phosphate 
(hydroxyapatite) coated at the bottom which acts as a substrate for 
osteoclasts. Osteoclasts grow over the surface and resorb the hydroxyapatite 
layer via their activity and this in turn can be measured by looking at areas of 
clearance under a light microscope. The technique is simple, easy to perform, 
widely reported in literature (Jeganathan et al. 2014; Wong et al. 2019) and 
gives a good direct quantitative measurement of bone resorbing activity of 
osteoclasts in an in vitro setting compared to osteoclast culture on dentine 
slices which are not easy to source, require processing/optimization as well 
as pH adjustments and resorption quantification on dentine is challenging. 
However, the osteoassay method is limited due to the fact that it is less 
physiologically similar to bone compared to dentine and needs support from 
additional biochemical markers of osteoclast activity to validate the findings.  
Osteoclast survival 
Osteoclasts were generated from BMDMs (as described in section 3.4.2) in 
96 well plates. RANKL was then withdrawn from culture medium while 
retaining all other reagents. Plates were fixed at the following time points post 
RANKL withdrawal (0 hrs, 16 hrs, 24 hrs and 48 hrs), stained with TRAcP and 
osteoclasts counted. 
Overexpression of Pml in vitro 
This was done using RAW 264.7 cell line. A GFP expressing plasmid 
(PEGFP, Clontech) was initially used to evaluate the jetPEI-Macrophage 
reagent for transfection efficiency in RAW cells. RAW cells (50-60% confluent) 
were seeded at relevant densities 4 hours before transfection. Various 
combinations were tested as described in Table 3.3. 
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96 well 15,000 0.2 10 0.7 10 20 
96 well 15,000 0.5 10 1.6 10 20 
24 well 100,000 2 50 6.4 50 100 
T25 1.5 
million 
6 100 19.2 100 200 
 
Post-transfection, half the medium was replaced at 3 hrs and in full after 24 
hours. jetPEI alone was used as a negative control to test its toxicity on RAW 
cells. GFP reporter activity was analysed 4 hrs and 24 hrs after transfection. 
Based on the best combination and downstream cell requirement, RAW cells 
were seeded and transfected with GenEZ Mouse Pml ORF expression 
plasmid DNA (OMu22116-Genscript) or empty vector DNA (pcDNA3.1) using 
jetPEI according to the table above and manufacturer protocol (details on next 
page). The vector map is as shown in Figure 3.1. Cells were transiently 
selected for 3-4 days using 500ug/ml neomycin. Overexpression was 
confirmed by qRT-PCR.  Cells overexpressing Pml or control cells were 
seeded in 96 well plate (10,000/well) in supplemented DMEM (150ul/well) and 
stimulated with RANKL (100ng/ml) for 4 days. Cells were then fixed, TRAcP 
stained and TRAcP positive multinucleated cells were counted. 
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Figure 3.1 pcDNA3.1+-DYK vector map. 
The figure above shows different components of the plasmid vector (GenEZ) 
with the inserted ORF (mouse Pml) for expression in mammalian cells (RAW 
264.7). 
JetPEI-Macrophage protocol 
The protocol below describes the transfection procedure in a T25 flask with 
1.5 million RAW cells:  
6 µg of DNA was diluted into 100 µl of 150 mM NaCl, vortexed gently and 
spun down briefly. In a separate tube, 19.2 µl of jetPEI®-Macrophage was 
diluted in 100 µl of 150 mM NaCl, vortexed gently and spun down briefly. 100 
µl jetPEI®-Macrophage solution was added to the 100 µl DNA solution at once 
(avoiding the reverse order). The solution was vortex-mixed immediately and 
spun down briefly followed by incubation for 15 to 30 minutes at room 
temperature. 200 µl of jetPEI®-Macrophage/DNA complexes was added to 
each T25 culture flask and homogenized by gently swirling the flask and the 
flask returned to the cell culture incubator. 
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Pml knockdown in vitro 
This was achieved using arsenic trioxide, an inorganic compound that 
degrades PML and is used in the treatment of acute promyelocytic leukaemia. 
RAW 264.7 were cultured in 12 well plates (as mentioned in 3.4.2) and treated 
with arsenic trioxide for 24 hrs at various concentrations prior to stimulation 
for 4 days with RANKL (100ng/ml) until osteoclasts were formed and effect on 
osteoclast development was assessed. 
Arsenic trioxide was tried at a concentration of 1um, 5um and 25um. Pml 
knockdown was achieved at 25um. 
TRAcP staining 
Tartrate resistant acid phosphatase (TRAcP) is a bone marker secreted by 
osteoclasts and helps in their visualization post-staining. After osteoclasts 
formed, media was removed, washed with PBS and cells fixed in 4% 
formaldehyde (v/v) for 10min followed by a PBS wash. TRAcP stain (65ul per 
well of a 96 well) whose preparation is described in Appendix 1 was then 
applied for 35-45 minutes at 37°C until osteoclasts develop a red colour 
corresponding to expression of TRAcP. The wells were washed with PBS and 
stored in 70% EtOH at 4°C. Osteoclast count was performed using a Zeiss 
inverted light microscope at 10x resolution.  
 Osteoblast culture 
3.4.8.1 Osteoblast culture and bone nodule assay 
Osteoblasts were isolated from the calvariae of 2-4 day old mice (pups) by 
sequential collagenase/EDTA digestion (Details below in section 3.4.8.2) and 
cultured in T75 flask containing αMEM supplemented with 10% fetal calf 
serum, 5% glutamine, 100 μg/ml streptomycin and 100 U/ml penicillin. 
The medium was refreshed 24 hrs later to remove non-adherent cells and on 
reaching confluence (1-2 days later), cells were detached with trypsin, 
counted and re-plated in 12-well plates at a density of 1 × 105 cells/well. Cells 
were cultured in osteogenic medium (αMEM supplemented as above with 3 
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mM β-glycerol phosphate (βGP) and 50 μg/ml Vitamin C (Vit.C). Medium was 
replaced carefully three times per week and cultures continued for up to 18 
days until mineralisation.  RNA and protein were collected at various 
timepoints during osteoblast development. 
3.4.8.2 Collagenase/EDTA digestion of Mouse calvariae for osteoblast 
isolation 
Mouse calvariae were dissected from pup heads using a pair of forceps and 
scissors. They were washed thoroughly in Hank’s balanced salt solution 
(HBSS) and transferred individually to a sterile 15 ml falcon tube containing 
2ml of collagenase type 1 (1mg/ml) in HBSS and incubated in a shaking water 
bath for 10 minutes at 37oC. Supernatant was discarded and each calvaria in 
15ml falcon tube was incubated for 30 minutes in 4ml of collagenase type 1 
(1mg/ml) in HBSS. Cell suspension was removed, collected in a fresh 50ml 
falcon (labelled “Tube Osteoblast”) and mixed with 6ml of standard αMEM. 
The remaining tissue in 15ml falcon tube was washed in 2ml PBS, PBS wash 
transferred to original 50ml falcon tube labelled “Tube Osteoblast” and 
remaining tissue in 15ml falcon tube treated for 10 minutes with 4ml of 
ethylenediaminetetraacetic acid (EDTA 5mM) 1:100 in PBS. Cell suspension 
was removed, transferred to original tube labelled “Tube Osteoblast” and 
mixed with further 6ml of standard αMEM. The remaining tissues in 15ml 
falcon tube were incubated for 20 minutes in 4ml of collagenase type 1 
(1mg/ml) in HBSS. Cell suspension was removed, transferred to original tube 
labelled “Tube Osteoblast” and mixed with final 6ml of standard αMEM. Cell 
suspensions thus pooled (in 50ml falcon tube labelled “Tube Osteoblast”) 
were centrifuged at 300g for 3 minutes. Supernatant was discarded and cell 
pellets were resuspended in supplemented αMEM. 
Mineralized nodules formed after 21 days of calvarial osteoblasts in culture 
were detected for calcium using Alizarin Red staining (details below in section 
3.4.8.3), and bone nodule formation was quantified by destaining the cultures 
overnight in 10% (w/v) cetylpyridinium chloride and dissolving the stain in 10 
mM sodium phosphate (pH 7.0). The absorbance of the extracted stain was 
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then measured at 562 nm in a BIO-Tek Synergy HT plate reader and 
compared to an Alizarin Red standard curve (Standards at 0, 0.05, 0.1, 0.25, 
0.5, 1, 1.5, 2.5, 5, 7.5, 10mM). Alizarin red values were corrected for viable 
cell count as determined by the Alamar Blue viability assay (section 3.4.1). 
3.4.8.3 Alizarin red staining of osteoblast derived mineralised nodules 
Osteoblasts in 12 well plates were washed with pre warmed PBS and fixed in 
70% ethanol. The plates were stored at 4°C overnight. The following day, fixed 
cells were washed with distilled water and stained with 1ml/well of 40mM 
Alizarin red (adjust pH to 4.1-4.3 with ammonium hydroxide (10% v/v)) for 
20mins on a rocker, washed four times with distilled water (dH2O) for 5 mins 
each time and then left to air-dry followed by imaging the plate on an Epson 
scanner. This was followed by destaining of Alizarin red and quantification as 
described in section 3.4.8.2 above. 
Alizarin red staining is the traditional gold standard method for detection and 
quantification of osteoblast mineralisation and used as a readout of osteoblast 
differentiation efficiency. The method is simple, inexpensive and widely 
accepted but time-consuming, cumbersome and requires fixing and 
termination of cultures thereby preventing further examination or manipulation 
of cultures. Alternative methods exist with advantages but also have their 
limitations. Von Kossa is an alternative staining method but also needs cell 
fixation prior to staining and exhibits non-specificity for calcium. Alkaline 
phosphatase detection is more suited to detect matrix maturation as opposed 
to mineralisation. Calcein dye is a fluorescent, non-cell permeable agent 
which can be used to monitor mineralisation without affecting cell physiology 
and background intracellular fluorescence. It provides a suitable alternative to 
alizarin red allowing real-time monitoring of mineral deposition in live cells 
when combined with advanced automatic time-lapse imaging such as 
IncuCyte ZOOM, thereby providing convenience and increased accuracy, but 
at an additional cost. Electron microscopy and infrared spectroscopy are good 




Micro CT (µCT) was performed using an ex vivo Skyscan 1172 system 
(Bruker, Belgium). Mice were originally sacrificed by CO2 inhalation. Lower 
limbs, lumbar spine, skull, liver, spleen and kidney were dissected, isolated 
and fixed in 4% formaldehyde in PBS for a day. They were then removed and 
placed for long term storage in 70% ethanol. The lower limb (usually left femur 
and tibia) of 4-month and 14-month old animals was dissected free of most 
soft tissue, and scanned ex vivo at a resolution of 5µm. Briefly, the leg was 
wrapped in parafilm, placed in the sample holder and mounted upright on the 
stage of µCT. The scanner was warmed initially for 15 mins before starting 
the scanning process. Radiation was set to 60KV and 167μA. Medium camera 
was used with pixel size set to 4.9um with Aluminium filter at 0.5mm and 
rotation step 0.6°. Set oversize and multiple scan was used to get a scout 
scan of the sample and to select the boundaries of the scan (usually 3 
segments spanning from top to bottom: the distal femoral diaphysis, femoral 
metaphysis, knee joint, proximal tibial metaphysis and diaphysis). Each 
segment took around 50 minutes to scan and once finished, the leg was 
returned to 70% ethanol and remaining scans performed. Raw images were 
generated as TIF files. Image reconstruction was performed using the 
Skyscan NRecon package (parameters in Appendix 2) and reconstructed 
images obtained as bmp files.  
µCT analysis 
Skyscan dataviewer software was used to load the reconstructed image stack 
in 3D (transverse, sagittal and coronal axes of the femur and tibia), and to 
rotate and fix the orientation of the bone. 
Trabecular and cortical bone measurements were done using Skyscan CTAn 
software Trabecular and cortical bone analysis was done on the proximal tibial 
metaphysis and diaphysis respectively of all mice (Fig. 3.2 left). The reference 
level used was the end of growth plate (Fig. 3.2 right). The region of interest 
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(ROI) for trabecular analysis was a selection of 200 slices distal to the 
reference level and for cortical analysis, a selection of 100 slices located 500 
slices distal to reference level (Fig. 3.2 left).  
 
Figure 3.2 Images from Skyscan dataviewer software.  
On the left, top yellow box i.e proximal tibial metaphysis represents region of 
interest (ROI) selected for trabecular analysis and the yellow box at the bottom 
in the tibial diaphysis region is the ROI for cortical analysis. The image on right 
represents the reference level used for trabecular and cortical analysis (end 
of growth plate). 
CTAn allows manual tracing of the ROI in a transaxial view of the 3D 
reconstructed slices. Trabecular bone was chosen by selecting the trabeculae 
and excluding the endosteal surface whereas cortical bone includes all the 
cortex (Fig. 3.3left). The software then calculates the following bone 
parameters (Table 3.4) using a series of task lists relevant for trabecular and 
cortical bone which separates soft tissue from bone as well as amelioration of 
ROI such as reduction of background noise, removal of speckles and closing 






Table 3.4 Parameters analysed and output given by CTAn software. 
Parameter Abbreviation (Unit) 
Trabecular bone volume BV/TV (%) 
Trabecular number Tr. N. (1/mm) 
Trabecular thickness Tr. Th. (um) 
Trabecular separation Tr. Sp. (um) 
Cortical thickness Ct. Th. (um) 
 
The output is in the form of an excel sheet. Additionally, CTAn generates a 
3D model of the trabecular and cortical bone that allows visualisation of the 
bone morphology in detail using Skyscan CT Vol software (Fig. 3.3right). 
 
Figure 3.3 Images from CTAn and CTVol software. 
On the left are representative images from CTAn software showing manual 
tracing of ROI for trabecular bone and cortex. On the right are 3D model 









PML expression was detected in human osteoclasts by 
Immunohistochemistry (IHC) of Formalin-fixed paraffin embedded (FFPE) 
sections from healthy controls with unaffected bone as well as bone sections 
from patients with PDB and giant cell tumour of bone (positive control). 
Sections from normal and pathological human bone tissue were subjected to 
Immunohistochemistry using Envision Immuno protocol (described in 
Appendix 4). 
3.7 Immunoblotting
Isolation of protein 
Plated cells had their medium removed, washed with cold PBS followed by 
lysis using RIPA buffer (described in Appendix 5). The plates were placed on 
ice for 10-15 mins followed by storage at -20°C. After thawing, the culture 
wells were scraped with a pipette tip or a syringe plunger, collected in an 
eppendorf tube and centrifuged at 12000g for 10 mins at 4°C and the protein 
(cell extract supernatant) stored for downstream experiments at -20°C. 
Measurement of protein concentration 
The concentration was measured using Pierce protein assay. The working 
solution was prepared by mixing bicinchoninic acid solution with copper II 
sulfate pentahydrate 4% solution with in a ratio of 50:1. Ready-made bovine 
serum albumin protein standards were added along with protein samples 
(diluted 1:5 with sterile water) in duplicate in a 96 well plate (10ul of standard 
or diluted query sample + 200ul of working solution per well), plate sealed and 
incubated at 37°C for 15-20 mins. The colorimetric detection of intense purple 
colour developed was then measured at 562 nm in a BIO-Tek Synergy HT 
plate reader and compared to linear BSA standard curve. 
Gel electrophoresis and Transfer 
Protein samples (20-30ug in total) were mixed with sample loading buffer 
(Appendix 5) in a ratio of 1:5, denatured for 5 mins at 95°C, cooled, 
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centrifuged and subjected to Mini Protean TGX Precast gel (4-20%) 
electrophoresis in a BioRad Tetra cell tank filled with running buffer (Appendix 
5). A ladder (mix of 6ul each of Kaleidoscope and Magic mark) is run in parallel 
to determine molecular weight of the protein. The gel was run for 45 mins at 
200V. Once the dye front disappears at the bottom of the gel, current was 
stopped, the gel was removed from the cassette and electroblotted onto 
Biorad Mini PVDF membranes using Transblot Turbo transfer system. The 
transfer was accomplished in 10 minutes at a constant current of 2.5A and 
25V. Gel transfer assembly is as shown in Fig. 3.4 
Figure 3.4 Gel transfer setup (Image obtained from www.licor.com) 
Antibody treatment and Immunostaining 
Membranes were blocked with 5%(w/v) non-fat milk in Tris buffered saline 
with TBS-tween (TBST) (150 mM NaCl, 50 mM Tris, 0.1% [v/v] Tween-20) for 
1 hr at room temperature and probed with relevant primary antibody (Ab). The 
primary Ab was prepared at the recommended dilutions (1:500 or 1:1000) 
using 3% BSA in TBST. The membrane was incubated with the primary Ab 
(raised in rabbit) overnight with shaking at 4°C. After washing with TBST (3 
washes at 15 minutes each), membranes were incubated with anti-rabbit 
horseradish peroxidise conjugated secondary antibody (1:5000, Cell 
Signalling), washed 3 times for 15 mins each with a final wash in TBS for 
10mins and visualized using Clarity Western ECL kit (BioRad) on a Licor 
Odyssey imager. Intensities of bands were quantified using Image Studio Lite 
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Ver 3.1 software. The target protein was corrected for loading as well as target 
protein normalised by probing the membranes with housekeeping stably 
expressed genes such as Beta Actin and Alpha Tubulin. 
For re-probing with a new antibody, when necessary, the membrane was 
treated with Stripping buffer (Appendix 5) in 50ul DTT and placed in a water 
bath for 10 min at 55°C with constant gentle shaking. The membrane was 
visualised as mentioned above to ensure complete stripping followed by 
blocking and other steps of antibody detection and Immunostaining. 
3.8 Quantitative Real-Time PCR (qRT-PCR)
Cells in culture had their medium removed and lysis buffer added for 3 
minutes. The lysis buffer was prepared by adding 10ul of β-mercaptoethanol 
to 1ml of lysis buffer from RNA isolation kit (Sigma). After removing the 
medium from the wells, 250ul of this mix was added to each well of a 12 well 
plate, plate tapped from side to side, and left at room temperature for 3 
minutes and lysate collected.  The resulting lysate was stored at -70°C until 
RNA isolation. Total RNA was isolated using GenElute Mammalian Total RNA 
Kit (Spin column protocol involving filtering, washing and elution) and/or 
Qiagen RNeasy Mini Isolation kit and RNA was quantified using the Nanodrop 
ND-8000 Spectrophotometer.  
Blood samples from Pagetic cases were stored in RNAlater solution at -20°C 
prior to isolating total RNA using Ambion Ribopure Blood RNA isolation kit, 
RNA quantified using Nanodrop ND-8000 (Thermoscientific) and subjected to 
reverse transcriptase-PCR to generate cDNA.  
The Complementary DNA (cDNA) was generated by reverse transcriptase-
PCR using the Quanta qScript cDNA SuperMix kit following the 
manufacturer’s instructions (details on next page).  
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Quanta reverse transcriptase PCR 
All RNA samples to be reverse transcribed were equated to similar starting 
concentration (100ng-1ug) using DEPC treated water. This was used as the 
template for reverse transcriptase-PCR. All reagents were kept on ice 
including PCR 8 well strip or 96 well plate preparation. PCR reaction and 
conditions were as follows:  
Table 3.5 PCR reaction and cycling conditions for reverse transcriptase-
PCR 
PCR reaction 
Reagents Volume (ul) 
qScript super mix (5X) 4 
DEPC water Variable 
RNA (100ng-1ug) Variable 
Total 20 
cDNA synthesized by reverse transcriptase-PCR was diluted 1:5 or 1:10 with 
DEPC water for qRT-PCR. 
Primers and labelled probes were designed using Primer 3 and the Universal 
ProbeLibrary System Assay Design Center application on Roche Diagnostics 
website: (https://lifescience.roche.com/en_gb/brands/universal-probe-
library.html#assay-design-center). The probe label was FAM for all the targets 
(genes) of interest. Table 3.6 describes primer sequences and other details 
for target genes analysed by qPCR. 
Thermocycler conditions 
Step Temperature Duration 
1 cycle 22°C 5min 
1 cycle 42°C 30min 
1 cycle 85°C 5min 
Hold 4°C Forever 
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Table 3.6 qPCR primers and other details. 
Target 
Gene 































31 74 Mouse 
Real-time PCR was performed using SensiFAST Probe No-ROX kit on a 
Chromo 4TM Detector or Bio RAD CFX Connect system and analysed using 
the Opticon MonitorTM software version 3.1 or Bio RAD CFX Manager V1.0. 
Reagents and cycling conditions are shown in Table 3.6. Amplification curves 
were generated (fluorescence plotted against number of cycles) and Ct values 
determined by the software. Ct value represents the cycle number at which 
the fluorescence of PCR product exceeds the background signal and reaction 
enters exponential phase. 
Samples were normalized to 18s rRNA expression. 18s cDNA was amplified 
with the predesigned VIC-labelled probe-primer combination from Applied 
Biosystems (4319413E) allowing two channel detection of one cDNA. 
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Figure 3.5 Example of quantification curves from Opticon Monitor 3.1 
software.  
Cycle threshold (Ct) is shown as dotted line in both curves. The left image 
shows FAM labelled target gene (PML) expression in an overexpressed 
sample run in triplicate (blue arrow with lower Ct values) compared to negative 
empty vector control (green arrow with higher Ct values). The image on right 
shows VIC labelled normalising control gene expression (18s in this case) for 
PCR reaction (20ul) 
Reagents Volume (ul) 
Sensifast 2x Mix 10 
10uM Forward Primer 0.8 
10uM Reverse Primer 0.8 
10uM Universal Probe 0.2 
DEPC treated Water 4.2 
Total 16 
cDNA template 4 
Thermocycler conditions 
Step Temperature(°C) Duration 
 Initial Denaturation 95 10min 
Denature Template 95 15sec 
Annealing 60 30 sec 
Extension 72 15sec 
Number of cycles  39 
Hold 4 Forever 
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both overexpressed and negative control samples with similar Ct values. The 
red arrows indicate no cDNA control blanks (Ct below threshold). 
3.9 Cloning and digestion of plasmid DNA
Transformation of plasmids into DH5-α cells 
10ml liquid broth (Luria broth LB) without antibiotic was put in a universal and 
heated to 37ºC in a waterbath. Competent cells (DH5-α) from the -80ºC 
freezer were distributed into 50ul aliquots (in 2ml Eppendorf tubes). DH5-α 
cells were thawed on ice. 2µl of appropriate pre-prepared plasmid (at a 
concentration of 50ng/µl) was added to appropriately labelled DH5-α cell 50µl 
aliquot, mixed gently by tapping and incubated on ice for 30 minutes. Cells 
were given a heat shock at 42ºC for 20 seconds and then placed on ice for 2 
minutes. 950µl of pre-warmed LB broth without antibiotic was added to each 
tube and tubes incubated at 37º for 1 hour in shaking incubator at 225rpm. In 
a clean environment with the Bunsen flame on, 50µl of transformation reaction 
was spread onto appropriately labelled agar plate using a sterile spreader and 
covering all the plate. Two plates were done for each transformation and the 
plates placed at 37ºC in the incubator overnight. 
A starter culture was made by adding a colony selected from a streaked plate 
to an appropriately labelled universal containing 5ml of liquid broth with 
antibiotic carbenicllin (100ug/ml final concentration). This procedure was done 
near a Bunsen flame and using a sterile loop. The universal(s) were placed in 
shaking incubator at 37ºC overnight. Next morning, 2ml of the culture medium 
was centrifuged in a 2ml eppendorf tube at 13000g for 1 minute, supernatant 
discarded and a further 2ml of culture medium added to the pellet and spun 
at 13000g for 1 minute (remainder of culture mix was kept in fridge). 
Supernatant was discarded. Qiagen Miniprep kit protocol was performed on 
the pelleted cells as per the manufacturer protocol. The extracted plasmid 
DNA was subjected to restriction enzyme digest (described in next section) 
and sequence verified by PCR-Sanger DNA sequencing as detailed in 
chapter 5. 
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Restriction digest (double digestion) of plasmid DNA 
Pml ORF expression plasmid DNA was double digested with HindIII and 
EcoRV, the product run on a 1.2% agarose gel (Figure 8.1) 
Table 3.8 Restriction digest of Pml overexpression plasmid. 
Similarly empty vector pcDNA3.1 was double digested with XhoI and MluI with 
similar thermocycler conditions and the product run on a 1.2% agarose gel 
(Figure 8.1) 
Table 3.8 Restriction digest of pcDNA3.1 empty vector plasmid. 
Restriction digest reaction (20ul) 
Reagents Volume (ul) 
NEB buffer 2 2 
10U/ul Hind III 1 
10U/ul EcoRV 1 
BSA 0.2 
Distilled Water 10.8 
Total 15 
Miniprep product 5 
Thermocycler conditions 
Step Temperature Duration 
1 37°C 3 hours 
Hold 4°C Forever 
Restriction digest reaction (20ul) 
Reagents Volume (ul) 
NEB buffer 3 2 
10U/ul XhoI 1 
10U/ul MluI 1 
BSA 0.2 
Distilled Water 10.8 
Total 15 
Miniprep product 5 
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3.10 Disease severity score 
A composite disease severity score was computed and tested to see if PML 
expression levels correlated with disease severity scores. The score was 
computed by taking into account various clinical features and complications 
of PDB. Briefly, one point was assigned for each bone affected and additional 
points were assigned as follows: previous orthopaedic surgery for PDB (0=no; 
1=yes); previous fractures through Pagetic bone (0=no; 1=yes); history of 
osteosarcoma (0=no; 1=yes); bisphosphonate treatment in the previous 12 
months (0=no; 1=yes); bisphosphonate treatment >12 months ago (0=no; 
1=yes); bone deformity (0=no deformity; 1=mild or moderate deformity; 
2=severe deformity, for each bone affected by PDB); age at diagnosis (1= ≥70 
years; 2=60–69 years; 3=40–59 years; 4=<40 years) and use of a hearing aid 
in patient with PDB of the skull (excluding mandible and maxilla) (0=no; 
1=yes) (Albagha et al. 2013). Regression model-ANOVA in SPSS 22 was 
used to determine the correlation between PML expression and PDB severity. 
3.11 Statistical analyses 
Analysis was performed using IBM SPSS 22 and Microsoft Excel software. 
Values in the graphs indicate group means ± standard deviation (SD) or 
standard error of mean (SEM), as indicated in the figure legends. Two-tailed 
t-test was performed for comparisons between groups. P value ≤ 0.05 was 
considered to indicate statistical significance. Experiments were performed as 















4 Targeted DNA sequencing of chr15 locus 
 
4.1 Summary 
One of the seven PDB susceptibility loci identified using GWAS on chr 15 was 
subjected to targeted DNA sequencing. The targeted region spanning 200kb 
surrounding the most significant GWAS SNP rs5742915 from this locus was 
investigated in a cohort of 138 PDB cases and 50 unaffected controls and 
included six genes (LOXL1, PML, STOML1, GOLGA6A, ISLR, ISLR2). A total 
of 39 protein coding and 33 regulatory variants were found. However, only 3 
missense variants (including top SNP rs5742915) and a couple of regulatory 
variants were associated with PDB; all located within PML at the 15q24 locus. 
Thus, PML seems to be the most likely susceptibility gene for PDB from this 
locus warranting further investigation by its expression and functional 
analysis.   
4.2 Introduction 
PDB has a strong genetic component. However, mutations in only one gene 
SQSTM1 have been found in approximately 10% of sporadic cases and 40% 
of familial cases but additional causal genes remain unidentified (Laurin et al. 
2002; Hocking 2002). Genome wide association studies have identified seven 
genome wide significant loci that predispose to PDB (Albagha et al. 2010; 
Albagha et al. 2011). 
One of these loci was located on 15q24.1 and it contains likely candidate 
genes PML and GOLGA6A both of which have unknown role(s) in bone 
metabolism. The association at this locus was replicated in several 
independent populations from UK, Australia, Spain, Italy, Belgium and the 
Netherlands (Albagha et al. 2011). The strongest association was with SNP 
rs5742915, which results in an amino acid change (phenylalanine to leucine: 
p.Phe645Leu) at codon 645 within PML (Albagha et al. 2011). 
Therefore, 15q24 locus was investigated by target capture and sequencing of 
a 200 kb region surrounding the top GWAS SNP rs5742915 in 138 PDB cases 
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(negative for SQSTM1 mutations and earlier age at diagnosis of PDB <65 
years) and 50 controls (unaffected individuals). This region included six genes 
(LOXL1, PML, STOML1, GOLGA6A, ISLR, ISLR2).  
 
4.3 Results 
Targeted DNA sequencing of the chr15q24 locus was performed on DNA 
extracted from PDB cases and unaffected controls as described in section 
3.1. My supervisor Dr. Albagha did the initial QC, variant calling and 
annotation and provided me with this data for further analysis. The mean 
coverage of target was 47X, and 98.45% of aligned bases had quality scores 
>20.  
A total of 39 protein-coding variants (summarised in Appendix 7) and 33 
potential regulatory variants (summarised in Appendix 8) were found at this 
locus. These included three novel protein coding variants (two in LOXL1 and 
one in PML) and seven novel potential regulatory variants. 22 missense 
variants were found (5 in LOXL1, 13 in PML, 3 in ISLR and 1 in ISLR2). 
Association testing of common variants was done by chi-square allelic test 
and rare variants were subjected to Fisher’s exact test.  
The top SNP rs5742915 showed highest association (P=0.004) with PDB as 
expected. Three other protein coding SNPs (rs34353835 in STOML1, 
rs743580 and rs743581 in PML) also showed significant association 
(P<0.05). SNPs rs5742915, rs743580 and rs743581 are missense SNPs and 
code for a different amino acid and therefore likely to be of functional 
significance. However, rs34353835 in STOML1 is a synonymous change 





Low scores in phyloP, phastCons and GERP++ (information from SNIPA 
browser: https://snipa.helmholtz-muenchen.de/snipa3/) indicated that all four 
SNPs were lowly conserved and not evolving rapidly. 
Table 4.1 Three missense variants in PML found on Targeted sequencing with 
allele frequencies (AF) and predicted function.  















rs5742915 PML Exonic 
Missense 
(F→L) 
59 43 0.004 Tolerated/Benign 
rs743581 PML Exonic 
Missense 
(G→V) 
26 40 0.01 Benign 
rs743580 PML Exonic 
Missense 
(S→G) 
36 48 0.04 Benign 
F(Phenylalanine), L(Leucine), G(Glycine), S(Serine) and V(Valine). 
In silico analysis of the three significantly associated coding variants 
All 3 missense variants were classed as tolerated and benign by SIFT and 
polyphen respectively. Mutation taster determined them to be probably 
harmless polymorphisms. All 3 SNPs were also not found to be deleterious 
substitutions based on information from SNIPA browser. 
I-mutant (v2.0) which predicts protein stability changes based on protein 
sequence changes resulting from mutations, found that rs5742915 decreases 
protein stability with a Reliability index (RI) of 5. rs743580 too, decreases 
protein stability with a Reliability index (RI) of 5 whereas rs743581 increases 
stability but with a Reliability index (RI) of 0. Higher the RI, higher is the 






Two SNPs in the PML promoter (rs79233608 and rs5742914) also showed 
significant association with PDB.  
Table 4.2 Two regulatory variants in PML found on Targeted sequencing 
with allele frequencies (AF) and predicted function 



























These are in the regulatory region and are predicted to result in promoter loss 
and/or alter transcription factor (TF) binding site. rs79233608 is associated 
with binding of TF GATA2 which plays an important role in haematopoietic 
cell differentiation whereas SNP rs5742914 is associated with binding of TF 
IRF1 and STAT1 both of which play an important role in bone metabolism as 
negative regulators of osteoclastogenesis and osteoblastogenesis (Salem et 
al. 2014).  
Regulation spotter software classed rs5742914 as a harmless polymorphism 
whereas rs79233608 was determined to be functional (with much evidence) 
by the same software.  
However, none of the SNPs was an eQTL for PML gene expression using 
publicly available expression quantitative trait loci (eQTL) data. 
https://genenetwork.nl/bloodeqtlbrowser (Zeller et al. 2010 and Westra et al. 




Figure 4.1 Updated Linkage Disequilibrium (LD) plot of the 15q24.1 locus with 
extent of LD between the SNP rs5742915 and other SNPs in this region which 
were genotyped as part of 1000 Genomes Project (SNAP, Broad Institute). 
 
The SNP rs5742915 is in moderate LD with one of the protein coding 
(missense) SNP rs743580 as well as four other intronic SNPs (rs876383, 
rs7183908, rs752004 and rs9479) found on Targeted Sequencing. The 
presence of a strong recombination hotspot around 100 kb upstream of 
rs5742915 means the association with PDB is unlikely to extend upstream of 
LOXL1. 
Thus, Targeted Sequencing analysis identified 3 missense variants (including 
top SNP rs5742915) and a couple of regulatory variants associated with PDB; 








Figure 4.2 Schematic representation of coding variants found within PML on 
Targeted DNA sequencing in relation to various domains of PML protein. 
R: RING finger; S: SUMOylation site; B1B2: B-boxes; CC: Coiled coil; NLS: 
Nuclear localisation signal; SIM: SUMO interacting motif; NES: Nuclear export 
signal.  
The variants are clustered mainly in the variable C-terminal region of PML 
protein. The three missense variants associated with PDB are shown in blue 
with the most significant GWAS SNP rs5742915 (p.F645L) (which also shows 
highest association on targeted sequencing) is highlighted in yellow. The 
novel SNP (p.P772Q) is only present in controls at a very low frequency, is 
neither associated with PDB nor in LD with top SNP rs5742915. 
The two regulatory variants rs5742914 and rs79233608 (and their possible 
functional role as described in this section before) are located around 120 bp 
and 2kb respectively upstream of exon 1 of PML within the PML promoter. 
DNA sequence of the promoter region surrounding the two SNPs are shown 








Figure 4.3 Schematic representation of two most significant PDB associated 
regulatory variants found within PML on Targeted DNA sequencing in relation 
to PML promoter. 
4.4 Discussion 
In genetic studies of complex disease, GWAS have resulted in identification 
of a number of loci associated with many diseases, however, the most 
significant variants that come up are common in the populations tested with 
mild or moderate effect size and tend to miss rare variants with larger effect 
size (Dickson et al. 2010; Auer & Lettre 2015). With the exception of SNP 
rs1561570 (OPTN locus) and SNP rs2458415 (TM7SF4 locus) which were 
found to be strong eQTL’s in peripheral blood monocytes (Zeller et al. 2010), 
the seven top PDB associated SNPs showed no evidence of functional 
significance based on bioinformatics analysis and were likely marking for 
other unknown true functional genetic variants (information from SNIPA 
browser: https://snipa.helmholtz-muenchen.de/snipa3/).  
With the aim of identifying these functional genetic variants, fine mapping of 
one of the loci on the chr15 PDB susceptibility region resulted in identification 
of three nonsynonymous protein coding SNPs in the PML gene and two 
regulatory SNPs in the PML promoter that were associated with the disease. 




PML has never been implicated directly in bone metabolism and may have a 
role in bone biology by regulating myeloid cell differentiation, proliferation and 
osteogenic differentiation of human mesenchymal stem cells, p62/autophagy 
and/or through its involvement in bone related pathways such as IFN-γ, NF-
kB, TGF-β, and Wnt- β-catenin signalling (Wu et al. 2003; Shtutman et al. 
2002; Lin et al. 2004; El Bougrini et al. 2011; Ahmed et al. 2017). 
PML may indirectly influence bone metabolism since it regulates IFN-
γ signalling which in turn is involved in regulating osteoclastogenesis (Choi et 
al. 2006; El Bougrini et al. 2011). PML gene itself is an Interferon responsive 
gene (ISG) with IFN-γ activated site (GAS) and Interferon stimulated response 
element (ISRE) in its promoter that mediate induction by type I and II IFNs 
(Chen et al. 2015). IFNs induce transcription of PML through activation of 
Janus kinase / signal transducer and activator of transcription (JAK/STAT) 
pathway (Guan & Kao 2015). 
PML induces apoptosis through repression of the NF-kB survival pathway (Fig 
4.2a), an essential pathway in osteoclast biology (Wu et al. 2003). PML 
sequesters NF-kB subunit RelA/p65 and suppresses NF-kB -mediated A20 
transcription by preventing it from binding to the promoter of A20, a NF-kB 
target gene (Wu et al. 2002).  Depletion or lack of PML may result in abnormal 
activation of NF-kB signalling resulting in its nuclear translocation and 
activation of osteoclast specific genes. This in turn shall lead to increased 
osteoclast differentiation and activity thereby predisposing to PDB.  Apoptosis 
is known to be defective in osteoclasts associated with PDB, another 
mechanism by which PML could potentially contribute to PDB (Chamoux et 
al. 2009; Ralston & Layfield 2012). A more recent study found that PML 
promotes NF-kB activity by increased phosphorylation of NF-kB p-65 and 
increased NF-kB DNA binding (Ahmed et al. 2017). So it will be interesting to 
see how PML interacts with NF-kB in the context of bone.  
Cytoplasmic PML (Isoform PML VIIb) is essential for TGF-β function; PML 
positively regulates TGF-β–signalling leading to induction of TGF-β target 
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genes (Lin et al. 2004) via phosphorylation and nuclear translocation of the 
TGF-β signalling proteins Smad2 and Smad3 (Fig 4.2b).  
Figure 4.4 a) Schematic illustration of PML induced apoptosis by inhibition of 
NF-kB (Wu et al. 2003) and b) Role of PML in TGF-β Signalling (Lin et al. 
2004) 
Since TGF-β is known to play a role in the regulating bone remodelling (Wu 
et al. 2016), it is possible that TGF-β signalling might be mediating the 
association between PML and PDB. 
PML knockout mice (Pml-/-) showed a significant reduction of monocytes in 
peripheral blood as well as bone marrow suggesting an impairment in terminal 
maturation of these cells (Wang et al. 1998) possibly leading to increase in 
progenitor cells. Osteoclasts and their precursors are derived from cells of 
monocyte-macrophage lineage including precursors and alterations in PML 
may affect their development.
PML was also found to be stably expressed in human mesenchymal stem 
cells (hMSCs) which are the precursors of osteoblasts and its expression 
increased as cell osteogenic differentiation progressed. PML was found to 
regulate hMSCs by inhibiting their proliferation but promoting their osteogenic 




production, ALP activity and upregulation of bone matrix gene integrin-binding 
sialoprotein (IBSP) (Huang 2013). 
PML gene can also function as a target of WNT–β-catenin signalling pathway 
which in turn regulates osteogenesis of hMSCs in a complex manner 
(Shtutman et al. 2002). Activation of WNT–β-catenin signalling results in 
increased bone due to excess bone formation whereas its impairment leads 
to reduced bone mass as a result of bone resorption exceeding bone 
formation (Baron & Kneissel 2013). β-catenin induces PML expression and 
both proteins have been shown to colocalise in the nucleus (Shtutman et al. 
2002). 
IRF-8 is essential for PML induction in myeloid cells and an obligatory 
regulator of the PML gene in activated macrophages (Dror, Rave-Harel, et al. 
2007). IRF8 regulates bone metabolism by suppressing osteoclastogenesis 
via inhibition of function and expression of nuclear factor of activated cells 1 
(NFATc1), the master transcription factor for osteoclastogenesis (Zhao et al. 
2009). Thus, PML may mediate the effects of IRF8 in bone metabolism. 
PML is also involved in the regulation of autophagy, a novel pathway which 
has recently being found to be dysregulated or defective in PDB. (Pankiv et 
al. 2010). Pagetic osteoclasts are characterised by nuclear inclusions and 
these have recently been proposed to be abnormal protein aggregates in 
autophagy-defective osteoclasts. These osteoclasts also show abnormalities 
in bone resorption as a result of defect in ruffled border formation (De Selm et 
al. 2011). PDB is associated with genetic variants in genes such as SQSTM1, 
OPTN and VCP, all of which are involved in autophagic process. Mice with 
P394L SQSTM1 mutation which develop PDB-like lesions show features 
associated with impaired autophagy in osteoclast precursors (Daroszewska 
et al. 2011). Mutations in ubiquitin binding domain of SQSTM1/p62, the same 
domain which is also involved in autophagy regulation, are associated with 
PDB. PML represses autophagy by inhibiting autophagosome formation. 
MEFs from Pml knockout mice showed increased LC3-II levels as well as liver 
and skeletal muscle of adult Pml-/- mice showed similar increase of LC3-II and 
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autophagosome biogenesis (Missiroli et al. 2017). PML is a known repressor 
of autophagy whereas p62 is degraded by autophagy (Pankiv et al. 2010; 
Missiroli et al. 2017). p62 also localises to PML nuclear bodies. p62 is 
responsible for the accumulation of polyubiquitinated nuclear proteins in PML 
nuclear bodies upon inhibition of nuclear protein export. Hein et al. 2015 have 
also found evidence of physical interaction between PML and p62 using 
Affinity-capture MS/quantitative BAC-GFP interactomics (source BIOGRID). 
Studies have also found p62 expression to be upregulated in Pagetic 
osteoclasts (Chamoux et al. 2009). As mentioned before in Chapter 1, p62 
plays an important role in NF-kB signalling. 
Thus, alteration in PML levels and its interaction with p62 may affect bone 
function by not only altering autophagy but also indirectly by influencing NF-
kB signalling and osteoclast activity thereby contributing to PDB. Thus, PML 
may influence bone metabolism in multiple ways.  
The variants identified to be significantly associated with PDB were clustered 
in and around PML but were not predicted to be deleterious or pathogenic by 
in silico methods. Nonetheless, they could still be functional since the SNP in 
the SQSTM1 gene encoding p62 (leading to P392L change which is the most 
common change associated with classical PDB), though predicted to be 
benign by in silico tools, has been shown to be important for p62 function and 
equivalent mutation (P394L+/+) in mice results in PDB-like lesions 
(Daroszewska et al. 2011).  In the broader context, these genetic variants may 
serve as useful additional markers thereby improving the disease risk 
prediction and facilitate early diagnosis and intervention in susceptible 
individuals.  Since the sample size for the initial study is relatively small, it will 
be replicated in a larger cohort of 2500 cases and results awaited to reveal 
the true association.  
In the meantime, PML will be subjected to further investigation by expression 
analysis in bone cells as well as functional analysis of top GWAS SNP from 
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5 PML expression during development and 
differentiation of bone cells 
5.1 Summary 
Targeted DNA sequencing identified PML as the most likely susceptibility 
gene from chr 15 locus. Expression analysis of PML in two most important 
bone cell lineages: osteoclast and osteoblast was done from mouse as well 
as human tissue. PML was found to be expressed in primary bone cells 
(osteoblasts and osteoclasts) as well as RAW 264.7 cell line and its 
expression varies during the development and differentiation of these cells 
suggesting a possible role in bone biology. PML expression was mainly 
confined to nuclei in bone sections from human tissue. PML was 
downregulated in patients with PDB but the levels did not correlate with 
disease severity. Though the sample size was small, it does raise the 
possibility that reduction in PML expression due to genetic variation could be 
associated with susceptibility to PDB and lack of correlation with disease 
severity indicates that additional factors (both genetic and environmental) 
need to be present for the disease to become fully penetrant and to manifest 












PML is known to be expressed ubiquitously within the human body (Alcalay 
et al. 1998). Genetic variations could influence bone metabolism by altering 
PML expression levels. Therefore, PML expression was evaluated in bone 
cells such as osteoclasts and osteoblasts in mouse as well as human tissue. 
In this chapter, the expression profile of PML was investigated in Formalin-
fixed paraffin embedded (FFPE) sections from human bone tissue affected by 
PDB and compared them with unaffected non-pagetic bone tissue. Finally, 
PML expression was studied in peripheral blood samples from PDB cases 
and compared to healthy controls. The cases were randomly selected and 
recruited from a cohort of PDB patients attending local clinic at Western 
general hospital, Edinburgh under Prof. Stuart Ralston’s care. Controls were 
healthy individuals (either spouse or relative) of Paget’s patients. Blood was 
taken from consented individuals, PBMCs isolated, RNA extracted, converted 
to cDNA and PML expression analysed using qPCR. 
5.3 Results 
 PML is expressed in bone cells from mouse as well as 
human tissue 
5.3.1.1  PML is expressed during osteoclast development in mouse tissue 
Bone marrow cells isolated from wild type C57Bl6 mice were cultured in 
presence of M-CSF and RANKL until osteoclasts were formed as described 
in section 3. RAW 264.7 cells were treated with RANKL until osteoclasts were 
formed. PML expression was determined using western blot analysis.  
PML was expressed in mouse monocyte-macrophage cell line RAW 264.7 as 
well as primary bone marrow derived macrophages (BMDM) and at all stages 
during their differentiation to osteoclasts following stimulation with RANKL. 
PML expression was found to increase during osteoclast formation (Fig. 5.1 








Figure 5.1 PML protein expression during osteoclast differentiation in mouse 
BMDMs.  
a: Immunoblot showing Pml and β-actin protein expression from BMDMs 
before and after treatment with RANKL (Day1-5), b: PML levels expressed as 
a ratio of PML/β-actin. Values are means ± SEM (combined data) from three 








Figure 5.2 PML protein expression during osteoclast differentiation in RAW 
cell line.  
a: Immunoblot showing Pml and β-actin protein expression from RAW cells 
before and after treatment with RANKL (Day 2 and 4), b: PML levels 
expressed as a ratio of PML/β-actin. Values are means ± SEM (combined 






5.3.1.2 PML protein is expressed during osteoblast development in mouse 
tissue 
Osteoblasts grown from calvaria of 2-4 day old wild type C57Bl6 mice were 
cultured for up to 18 days in osteogenic medium until mineralisation. PML 
expression increased during the first week of osteoblast differentiation in 
calvarial osteoblasts and stabilises to basal levels soon after until bone nodule 





Figure 5.3 PML protein expression during osteoblast development.  
a: Immunoblot showing PML and β-actin protein expression from murine 
osteoblasts b: PML levels expressed as a ratio of PML/β-actin. Values are 



















expression increased during the first week of osteoblast differentiation in 
calvarial osteoblasts. 
5.3.1.3 PML is expressed in bone cells of human origin 
Formalin-fixed paraffin embedded (FFPE) sections from unaffected and 
pathological human bone tissue were subjected to Immunohistochemistry 
(IHC) using standard protocol (as described in Appendix 4).  
Initial optimisation of PML immunostaining was done on Tissue microarray 
(TMA) using different concentrations of the sc-5621 (H-238) PML antibody.  
Since PML is ubiquitously expressed, negative controls were performed by 
omitting addition of PML primary antibody during IHC. The optimised antibody 
concentration of 1:200 was then used for staining human bone tissue 
sections. Positive control used for osteoclast staining was Giant cell tumour 
of bone or osteoclastoma and negative control comprised bone sections with 
non-addition of primary antibody. PML was detected in human osteoclasts as 
well as osteoblasts.  
Panel A in Fig. 5.4 shows negative and positive PML immunostaining at low 
and high power magnification (10X and 20X respectively) and includes 
negative (no primary antibody) and positive PML immunostaining (from TMA 
as well as benign bone tumour osteoclastoma). Panel B in Fig. 5.4 shows 40X 
magnification images (negative and positive PML immunostaining) in 







        
Figure 5.4 Detection of Pml in tissue sections using Immunohistochemistry. 
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A. Low and high magnification images of negative (no antibody added) and
positive PML antibody (brown colour) immunostaining in TMA and FFPE
sections of osteoclastoma.
B. Negative control (No antibody added) and positive nuclear immunostaining
(brown colour) for PML in human osteoclasts from FFPE bone sections.
It can be seen in the figure 5.4 that the PML expression (brown staining) is 
mainly nuclear with variability in intensity of staining. In panel B, some 
osteoclasts (nuclei) are positive whereas others are negative for staining. It is 
also clear that osteoclast size is smaller and number fewer in unaffected bone 
compared to those in PDB and GCT.  
These analyses show that PML is expressed in bone cells and its expression 
varies during the development and differentiation of these cells.  
5.3.1.4 PML expression is downregulated in PDB patients 
Next, we investigated PML expression in mRNA derived from peripheral blood 
samples of PDB patients (n=18) compared to healthy controls (n=7).  
Figure 5.5 PML expression in PDB patients is significantly lower compared to 
























P < 0.005 
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Data are shown as mean ± SEM. RNA from blood (PBMC’s) stored in RNA 
later was extracted and converted to cDNA. mRNA levels were assayed by 
qRT-PCR and normalised for 18S rRNA.  
qPCR analysis found that the PML expression in PDB cases was 48% lower 
compared to unaffected controls (P = 0.003)  (Fig. 5.5).  
Next, a composite disease severity score was computed and tested to see if 
PML expression levels correlated with disease severity scores. Clinical data 
was incomplete or not available for a couple of cases. However, no correlation 
was found (P = 0.229) as shown in Figure 5.6. The score was computed by 
taking into account various clinical features and complications of the disease 
such as previous fractures through Pagetic bone, previous orthopaedic 
surgery for PDB, history of osteosarcoma, use of a hearing aid in patient with 
PDB of the skull, bone deformity, bisphosphonate treatment in the previous 
12 months, bisphosphonate treatment >12 months ago, and age at PDB 
diagnosis. 
Figure 5.6 Scatter plot showing correlation between PML expression and 




PML was found to be expressed in mouse primary bone cells (osteoblasts 
and osteoclasts) as well as RAW 264.7 cell line. PML expression increased 
during osteoclast differentiation in both RAW cell line and primary BMDMs 
and was highest in the intermediate stages of development (Day 2-3). Though 
the increase is not so evident in BMDMs due to high error bars when data was 
combined from three biological replicates, individual replicates did show the 
trend for increased expression as osteoclast differentiation progressed. 
Indeed, RNA-sequencing analysis of primary BMDMs also shows the same 
pattern of Pml expression when differentiated into osteoclasts in response to 
RANKL in three independent biological mouse replicates (data not shown). 
PML is subjected to alternative splicing in its C-terminal region leading to a 
number of isoforms. Expression analysis in cells of the monocyte-
macrophage lineage (i.e. RAW 264.7 which is a mouse monocyte-
macrophage like cell line and primary osteoclasts derived from macrophage-
monocyte precursors), however, revealed only a single 97 KDa protein 
corresponding to PML-I isoform. This is consistent with findings from 
Condemine et al. 2006 who showed that PML-I is the most abundant isoform 
in macrophages and isoform specific sequences of PML-I and PML-V are 
highly conserved between human and mouse. Dror et al. 2007 subsequently 
confirmed these findings and found PML-I to be the major splice variant in 
activated macrophages and their study pointed to an interaction of PML-I (in 
response to IRF-8) with AML-1 resulting in differentiation of myeloid 
progenitor cells to monocytes. 
In calvarial osteoblasts, PML expression increased during the first week of 
differentiation and then decreased to basal levels when bone nodules formed. 
Thus, PML expression varies during the development and differentiation of 
these bone cells pointing to a possible role in bone metabolism. 
This is consistent with the previous findings that PML is expressed during 
osteogenic differentiation of hMSCs into osteoblasts and subsequent 
mineralisation (Huang 2013). Moreover, changes in PML expression alter the 
120 
differentiation potential of osteoblasts and in the case of monocytes, a 
reduction in their number (Wang et al. 1998).  
In FFPE samples, PML expression was mainly restricted to nuclei in 
osteoclasts. The intensity of nuclear staining showed variability within the 
osteoclast. This could be attributed to the different stages in the life cycle of 
the osteoclast. It could also result from differences in age and level of activity 
of osteoclasts as well as their proximity to the eroding bone surface. However, 
it is difficult to verify or confirm this unless we analyse a lot of samples and 
also possibly due to the heterogeneity of the tissue within a pagetic bone as 
well as artefacts resulting from processing of bone tissue. 
PML expression was found to be downregulated in patients with PDB. This 
raises the possibility that genetically determined reduction in PML expression 
could be associated with susceptibility to PDB. It is possible that the reduced 
expression of PML in PDB patients results in increased osteoclast formation 
and size which is one of the pathological characteristics of PDB. However, 
there was no correlation between PML expression levels and PDB severity. 
This indicates that additional factors (genetic as well as environmental) need 
to be present for the disease to become fully penetrant and to manifest 
clinically. However, the lack of correlation could also result from the fact that 
our sample size was small and increasing the size of the cohort may make 
the correlation stronger. It will also be interesting to test individual features 
(both clinical as well as disease complications) for correlation with PML 
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6 Effect of PML on osteoclast function in 
vitro 
6.1 Summary 
PML was found to be expressed in osteoclasts, the main bone cell type 
affected in PDB and its expression varies during the development and 
differentiation of these cells. The effect of altered Pml expression on 
osteoclast function in vitro was tested using overexpression and knockdown 
experiments in RAW 264.7 cell line. Also, functional analysis of top GWAS 
SNP rs5742915 which was also found to be the most significant PDB 
associated protein coding variant by targeted DNA sequencing analysis, was 
performed by overexpressing it and assessing osteoclast development in 
RAW 264.7 cell line.  
Pml overexpression inhibited osteoclast formation and fusion whereas 
downregulation by arsenic trioxide promoted osteoclast formation and fusion 
pointing to a negative regulatory role of PML in osteoclast differentiation. 
Arsenic is used in chemotherapy of APL and though it has some degree of 
toxicity against other cell proteins, its action on PML leading to degradation 
confirmed the suppressive role of PML in osteoclast differentiation.  
Overexpression of SNP rs5742915 in RAW 264.7 cell line resulted in a more 
marked reduction in osteoclast formation and fusion compared with WT and 
empty vector control. Thus, contrary to expectation, it appears to suppress 
osteoclast differentiation and inhibit bone resorption rather than facilitate the 
disease progression. This phenotype could be due to various factors and may 
not necessarily mimic the physiological conditions possibly due to testing of 
SNP in isolation, high level of artificial overexpression achieved in vitro as well 
as influence of polygenic/environmental factors in an in vivo setting. 




Fine mapping revealed a few protein coding and regulatory variants within 
PML to be associated with PDB at the chr15 locus. This led to PML being the 
most likely gene predisposing to PDB at this locus. Next, PML was found to 
be expressed in primary bone cells (osteoblasts and osteoclasts) as well as 
RAW 264.7 cell line and its expression varied during the development and 
differentiation of these cells. Notably, PML was found to be downregulated in 
patients with PDB leading to the hypothesis that genetically determined 
reduction in PML expression could result in alteration to bone metabolism or 
turnover leading to increased susceptibility for PDB. Osteoclast is known to 
be the main cell type involved in PDB pathogenesis. This chapter therefore 
focusses on studies to assess the effect of altered PML expression on 
osteoclast function in vitro using overexpression and knockdown experiments 
in RAW 264.7 cell line.  
In addition, the effect of p.Phe645Leu resulting from rs5742915 was assessed 
in murine tissue during osteoclast development by functional assay. 
rs5742915 lies at the start of Exon 9 in the C terminal region of PML and 
therefore exists only in PML isoform 1. It was the only protein coding SNP 
among the seven top GWAS PDB associated hits and was also the most 
highly associated SNP from chr 15 locus in the Targeted sequencing cohort 
resulting in a missense amino acid change from phenylalanine to leucine at 




 Plasmid preparation, verification and transfection 
optimisation of Pml overexpression plasmids 
RAW cells (a mouse monocyte-macrophage-like cell line that differentiates 
into osteoclasts on RANKL treatment) were transfected with GenEZ PML 
ORF expression plasmid or empty vector.  
Transfection optimisation was done as described in section 3.4.5.  
In all combinations tested, GFP was not expressed at 4hrs post transfection 







Figure 6.1 EGFP fluorescence 4 hr and 24 hr post transfection with jetPEI 
reagent in RAW cells. 
GenEZ PML Open reading frame (ORF) expression plasmid DNA from 
Mouse: OMu22116 (WT as well as carrying the GWAS single base change T 
to C) and empty vector DNA (pcDNA3.1) were obtained from Genscript, 
transformed into DH5 alpha E. coli cells (details in Methods section 3.9.1) and 
colony minipreps done to obtain plasmid DNA followed by restriction digest 
(details in Methods section 3.9.2). Sanger sequencing was also performed to 
confirm presence of PML ORF WT as well as the missense change 
associated with SNP rs5742915 (T to C). 
 
GFP 4 hr post transfection GFP 24 hr post transfection 
 100 um 
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Sanger sequencing revealed the WT sequence as well as expected 
nucleotide change (T>C) in the ORF plasmid corresponding to rs5742915. 
Part of PML ORF sequence from Genscript clone WT OMu22116 with 
nucleotide change highlighted in red and primers for PCR-sanger sequencing 




Figure 6.2 Schematic representation of PML ORF verification by restriction 
enzyme digest and Sanger sequencing. 
PML ORF plasmid double digest gave band sizes of 2.7kb and 5.2Kb whereas 
empty vector double digest gave band sizes of 4.7kb and 0.7kb. 
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 Effect of Pml WT overexpression on osteoclast development 
in RAW 264.7 cell line 
The last combination from Table 3.3 in Methods section was chosen since it 
gave good GFP expression post transfection during optimisation and also 
satisfied the downstream cell requirements. Accordingly, RAW cells were 
seeded at a density of 1.5 million cells per T25 flask and transfected with 6ug 
of GenEZ PML ORF expression plasmid DNA (OMu22116-Genscript) or 
empty vector DNA (pcDNA3.1) using jetPEI. Cells were transiently selected 
with neomycin (500ug/ml) for 4 days and stimulated with RANKL (100 ng/ml) 
for 4 days to generate osteoclasts. Cells were TRAcP stained and TRAcP 
positive multinucleated cells (TRAcP + MNC) were counted and numbers 
were compared to the WT control after correction for cell viability.  
Pml WT overexpression was verified by qPCR as well as western blot (Fig. 
6.3 b,a).  
                  a b
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WT Pml overexpression in RAW cells resulted in a significant reduction in 
number and size of osteoclasts compared to empty vector control (Fig. 6.3 
c,d) 
Figure 6.3 Overexpression of WT Pml in RAW cells reduces their ability to 
form TRAcP+ multinucleated (MNC) cells upon stimulation with RANKL. 
a. Immunoblot showing expression of Pml and β-actin in cell lysates from
RAW cells transfected with PML ORF expression plasmid compared with
Empty vector.
b. PML mRNA expression in cells overexpressing Pml (orange bar) compared
to control cells (blue bar). mRNA levels were assayed by qRT-PCR and




means ± SEM (data presented from one biological replicate) representative 
of three independent experiments. 
c. Decreased number of TRAcP+ MNC - osteoclasts (≥3 nuclei) or
hypernucleated MNC (≥10 nuclei) generated from RAW cells overexpressing
Pml compared to control cells. Values are means ± SEM (data presented from
one biological replicate) representative of three independent experiments.
Minimum 6 wells were counted for each biological replicate.
d. TRAcP staining showing reduction in size and number of osteoclasts in Pml
overexpressing cells compared to control cells.
 Effect of Pml knockdown on osteoclast development in RAW 
264.7 cell line 
Arsenic trioxide is an inorganic compound that degrades PML and is used in 
the treatment of acute promyelocytic leukaemia (APL), a disorder caused by 
disruption of tumour suppressor PML. Arsenic is known to downregulate Pml 
(Zhu et al. 1997; Lallemand-Breitenbach et al. 2008). Accordingly, RAW cells 
were treated with arsenic trioxide for 24 hrs at various concentrations prior to 
starting RANKL and effect on osteoclast development was assessed. 
Pml downregulation was achieved at 25um arsenic concentration as verified 
by Western blot (Fig. 6.4) and resulted in a significant increase in number and 
size of osteoclasts compared to vehicle PBS (Fig. 6.5 a,b). 
Figure 6.4 PML protein degradation was achieved with arsenic trioxide 
(As2O3) at 25um concentration as shown using Western blot.  
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Figure 6.5 Pml downregulation in arsenic treated RAW cells enhances 
osteoclast formation and fusion. 
a. Increased number of TRAcP+ MNC - osteoclasts (≥3 nuclei) or
hypernucleated MNC (≥10 nuclei) generated from arsenic treated RAW cells
compared to control cells. Values are means ± SEM (data presented from one
biological replicate) representative of three independent experiments.
Minimum 6 wells were counted for each biological replicate.
b. TRAcP staining showing increase in size and number of osteoclasts in




Cellular fusion is essential for osteoclasts to effectively resorb bone. DC-
STAMP plays a key role in this fusion. Expression analysis of Dcstamp in 
arsenic treated RAW cells revealed a significant increase especially on Day 4 
following RANKL treatment compared to WT RAW control (Fig. 6.6). 
Figure 6.6 Expression analysis of Dcstamp mRNA by qPCR during osteoclast 
development in Arsenic treated RAW cells. 
Reveals a significant increase especially on Day 4 following RANKL treatment 
compared to WT control. Values are means ± SEM (data presented from one 
biological replicate) representative of two independent replicates presented 
as % of WT. 
 Effect of SNP rs5742915 overexpression on osteoclast 
development in RAW 264.7 cell line 
Similar to WT PML ORF, RAW 264.7 cells were transfected with GenEZ PML 
ORF expression plasmid (carrying the GWAS single base change T to C) or 
empty vector (pcDNA3.1) and transiently selected for 3-4 days with 500ug/ml 
neomycin and stimulated with RANKL (100 ng/ml) for 4 days. Cells were 
TRAcP stained and TRAcP positive multinucleated cells (TRAcP + MNC) 
were counted.  
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Pml overexpression was determined using qPCR (Fig. 6.7). 
Figure 6.7 PML mRNA expression in cells overexpressing PML GWAS SNP 
(orange bar) compared to control cells (blue bar).  
mRNA levels were assayed by qRT-PCR and normalised for 18S rRNA and 
presented as % of control cells. Values are means ± SEM (data presented 
from one biological replicate) representative of three independent 
experiments. 
Overexpression of GWAS SNP resulted in a more marked reduction in 
osteoclast formation and fusion compared to WT PML ORF (Fig 6.8 a,b).  
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Figure 6.8 Overexpression of SNP rs5742915 in RAW cells reduces their 
ability to form TRAcP+ multinucleated (MNC) cells upon stimulation with 
RANKL. 
a. Decreased number of TRAcP+ MNC - osteoclasts (≥3 nuclei) or
hypernucleated MNC (≥10 nuclei) generated from RAW cells overexpressing
SNP rs5742915 (green bar) compared to WT Pml (Orange bar) and empty
vector control (blue bar) cells. Values are means ± SEM (data presented from
one biological replicate) representative of three independent experiments.
**p<0.0001. Minimum 6 wells were counted for each biological replicate.
b. TRAcP staining showing reduction in size and number of osteoclasts in Pml






PML expression was evident in bone cells and downregulation of this gene 
was found in PDB patients compared to controls. This led to examining the 
effect of altered PML expression on the development and function of 
osteoclast, the main bone cell type involved in PDB. The experiments were 
performed by modifying Pml expression levels in RAW 264.7 cell line in vitro 
and noting its effect on osteoclast differentiation and development.  
Pml overexpression in vitro in RAW 264.7 cell line inhibited osteoclast 
formation and fusion whereas downregulation by arsenic trioxide promoted 
osteoclast formation and fusion. These findings indicate that PML plays a role 
in bone metabolism as a negative regulator of osteoclast differentiation.  
It is known that arsenic is a toxic compound and has non-specific effects on 
other proteins. This was evident from the degradation of tubulin in the western 
blot (Figure 6.4). It is known to alter the function of steroid receptors e.g. 
estrogen receptor as well as affects several interleukins and cytokines either 
turning them off or on leading to alterations in osteoclast differentiation and 
activity. Its effects are, however, known to be more pronounced in human cells 
compared to animal cells of non-bone origin (Lever 2002).  The dose of 
arsenic trioxide that was needed to achieve knockdown of PML in vitro was 
much higher than that used in a clinical setting for APL treatment and was 
probably because RAW cells (monocyte-macrophage-like cell line) were 
resistant to lower doses of arsenic. Interestingly, arsenic as a pesticide in 
imported cotton has been suggested to be an environmental risk factor for 
PDB development in high prevalence area of cotton mill towns in Lancashire 
in 1970’s (Lever 2002).  More importantly, however, arsenic is also known to 
degrade PML (Zhu et al. 1997; Lallemand-Breitenbach et al. 2008) and is 
therefore also used in chemotherapy of APL. The degradation of PML was 
verified in my downregulation experiment and arsenic was found to promote 
osteoclast differentiation.  
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This downregulation was achieved by chemical means via proteasomal 
degradation of PML. Also, arsenic at higher doses is known to affect cell 
viability and induce apoptosis in various cell types. Other methods of 
downregulation such as lentiviral shRNA mediated gene knockdown or 
CRISPR mediated gene editing would be less toxic and more specific but 
need more optimisation and are costly as well as more labour-intensive and 
would have been counterintuitive since arsenic mediated downregulation 
along with wt Pml overexpression data had given adequate information 
needed to justify getting a full PML knockout mouse model for in vivo 
assessment of PML depletion on bone metabolism. 
p.Phe645Leu change associated with the SNP rs5742915 is predicted to be 
tolerated by SIFT and benign by Polyphen and is not highly conserved through 
evolution (Fig 6.9).  
This means there could be other variants driving the association with PDB risk 
and the SNP rs5742915 is simply tagging for these or in LD with the causal 
SNP(s). Nonetheless, it could still be a risk associated variant since 
bioinformatics tools do not always provide correct functional prediction. As 
mentioned before, the SQSTM1 P392L mutation, which is known to cause 
PDB in humans, is predicted by bioinformatics tools to be benign but 
functional studies have showed this variant to be pathogenic and cause PDB-
like disorder in mice (P394L+/+) (Daroszewska et al. 2011). 
Though the PML SNP rs5742915 is not highly conserved, this may not be so 
relevant in context of PDB which is a late onset disorder and does not affect 
reproduction. Thus, rs5742915 may still affect osteoclast though not highly 
conserved. Moreover, rs5742915 was one of the 697 variants which achieved 
genome-wide significance in relation to polygenic trait of adult human height 
in large scale GWAS studies. (Lango et al. 2011; Wood et al. 2014), indicating 




Figure 6.9 Conservation of rs5742915 across various species using Ensembl 
phylogenetic information. 
Overexpression of Pml carrying the GWAS SNP rs5742915 risk allele (C) 
resulted in a more marked reduction in osteoclast formation and fusion 
compared with cells overexpressing the WT PML (reference allele T) and 
control empty vector cells. Thus, rs5742915 is a functional variant in context 
of PDB. The C allele is present at a higher frequency in cases compared to 
controls in the initial targeted sequencing cohort. Interestingly, however, it 
appears to protect against PDB rather than facilitate the disease progression 
by inhibiting osteoclast development.  
This could be due to various factors. The SNP on its own may be functional 
in murine cell line with a protective phenotype but the function in a 
physiological setting may be influenced/altered by presence of surrounding 
SNPs (haplotype). Moreover, the overexpression levels achieved in such 
experiments may not accurately reflect the levels in a physiological setting 
and the control of gene expression and its effects could be more subtle than 
achieved in these in vitro studies.  
Also, the net effect on PDB development or susceptibility may be modified by 
presence of other risk alleles involving multiple genes in an individual as well 
 rs5742915 (T      C) 
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as influenced by environmental factors highlighting once again the incomplete 
penetrance and the complex interplay between genetic and environmental 
triggers in complex disease evolution such as PDB.  
The in vitro studies have therefore acted as a proof of concept or pilot 
experiment to confirm the osteoclast phenotype in relation to PML prior to 
investing more time and effort in sourcing Pml knockout mice to confirm and 
explore the initial findings in RAW cells. Studies in Pml knockout mice will 
throw further insights into the role of PML in bone metabolism and is 



















Explore role of PML in bone 
metabolism using knockout mouse 
model of PML 
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7 Explore role of PML in bone metabolism 
using knockout mouse model of PML 
7.1 Summary 
The role of PML in bone remodelling in vivo was investigated by using a 
mouse knockout model of PML. Pml -/- mice not only exhibited increased 
osteoclast formation and fusion similar to in vitro findings, but also showed 
increased activity and survival compared to WT ex vivo. Osteoclast related 
genes such as Ctsk encoding cathepsin K and Dcstamp were found to be 
upregulated during the differentiation of osteoclasts in these mice. Calvarial 
osteoblasts from Pml-/- mice showed increased mineralized calcium 
deposition compared to WT ex vivo. The above findings further confirm the 
role of PML in bone metabolism. 
Assessment of bone micro-architecture by µCT in 4 month and 14 month old 
mice revealed no significant differences in bone structure between Pml -/- mice 
and WT controls. There was also no evidence of bone lesions associated with 
PDB. Thus, increase in osteoblast mineralization seems to counteract 
increased bone resorption by osteoclasts thereby leading to a normal skeletal 
phenotype even with advancing age. Pml -/- mice are being aged to 22 months 
of age and will be assessed for bone structure and evidence of lesions to see 
if they exhibit late onset penetrance and adverse bone phenotype. 
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7.2 Introduction 
Pml overexpression in RAW 264.7 cell line led to a decrease in osteoclast 
number and size whereas chemical downregulation by arsenic trioxide 
reversed this phenotype pointing to a negative regulatory role of PML in 
osteoclast development and differentiation.  
As a result, a mouse knockout of PML was obtained to confirm the in vitro 
findings as well as use ex vivo osteoclast and osteoblast cultures from these 
mice to further explore the role of PML in bone biology. This chapter focusses 
on studies to assess the effect of altered Pml expression on osteoclast and 
osteoblast function and in addition, phenotyping analysis of these mice using 
micro-CT scanning at different ages. 
7.3 Results 
 Osteoclast development, survival and activity in Pml 
knockout mice 
The role of PML in bone remodelling in vivo was investigated by using a 
mouse knockout model of PML. C57Bl6 PML knockout mice (Pml -/-) were 
obtained from National Cancer Institute, USA. PML was disrupted in the 
mouse germ line and knockout generated by deleting part of exon 2 which 
encodes the RING finger domain.  
PML mice were genotyped to verify the identity of homozygous (-/-), WT (+/+) 
and heterozygous (+/-) mice as described in section 3.3.1.  
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Figure 7.1 Schematic representation of genomic DNA from WT and Pml -/- 
mice. 
It shows the partially deleted region from exon 2 which was replaced by a 
neomycin selection marker cassette as well as details of primers used for 
genotyping. Gel electrophoresis results are as shown in Figure 7.2. 
Figure 7.2 Mouse genotyping using PCR and agarose gel electrophoresis. 
WT-Wild Type; HET- Heterozygote, HOM-Homozygote, NTC-No DNA 
template control for PCR. 
Bone marrow cells from WT and Pml -/- mice were isolated and cultured in 
presence of M-CSF and RANKL until osteoclasts were formed. TRAcP 
positive multinucleated osteoclasts (≥3 nuclei) were counted and numbers 
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were compared to the WT control. The cells were also cultured on Osteoassay 
plates to assess osteoclast activity and bone resorption. 
Osteoclasts formed from Pml -/- mice were significantly higher in number and 










Figure 7.3 Loss of PML in BMDMs enhances osteoclast formation, fusion and 
activity 
a. Increased number of TRAcP+ MNC - osteoclasts (≥3 nuclei) or 
hypernucleated MNC (≥10 nuclei) generated from Pml -/- mice compared to 
WT. Values are means ± SEM (data presented from one biological replicate) 
representative of three independent experiments. Minimum 6 wells were 
counted for each biological replicate. 
b. TRAcP staining showing increase in size and number of osteoclasts in Pml 
-/- mice compared to WT. 
c. Modified Von-Kossa staining on osteoassay plate shows higher activity and 
resorption in Pml -/- mice compared to WT. 
d. Image J analysis of resorbed areas on osteoassay plate. Area resorbed 
expressed as % as well as area resorbed per osteoclast was much higher in 
Pml -/- mice compared to WT. Values are means ± SEM (combined data) 








Effect of PML loss on osteoclast marker genes in Pml -/- mice: 
Osteoclast marker gene such as Ctsk (Cathepsin K) was upregulated in Pml
-/- mice as well as WT in response to RANKL but showed enhanced expression 
in Pml-/- mice compared to WT until the intermediate-late (Day3) stage of 
osteoclast development (Fig. 7.4). 
Figure 7.4 Expression analysis of Cathepsin K mRNA by qPCR in Pml-/- and 
WT mice during osteoclast development. 
Cathepsin K mRNA expression was significantly higher in Pml-/- mice 
compared to WT in the intermediate stage (Day3) of osteoclast development. 
Values are means ± SEM (combined data) from two independent replicates 
presented as % of WT.  
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Expression analysis of osteoclast fusion gene Dcstamp in Pml -/- mice (where 
fusion was higher) revealed a significant increase following RANKL treatment 
compared to WT (Fig. 7.5) 
Figure 7.5 Expression analysis of Dcstamp mRNA by qPCR in Pml -/- mice 
Reveals a significant increase following RANKL treatment compared to WT 
control. Values are means ± SEM (combined data) from three independent 
replicates presented as % of WT. ns = not significant 
Thus, PML loss results in a substantial increase in osteoclast formation, fusion 
and activity.  
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Osteoclasts from Pml -/- mice showed significantly higher survival compared 
to WT at 16 hours (hrs) and 24 hrs post RANKL withdrawal.  Osteoclast 
numbers were also higher at 48 hrs but not significant (Fig. 7.6). 
 
Fig. 7.6 Osteoclast survival post RANKL withdrawal.  
Osteoclast survival was significantly higher in Pml -/- mice compared to WT at 
16hrs (73%) and 24hrs (64%) post RANKL withdrawal. Osteoclast numbers 
were also higher at 48hrs but not significant. Values are means ± SEM 
representative of one biological replicate from four independent replicates. 








 Effect of PML deficiency on calvarial osteoblast 
mineralisation 
Mouse neonatal calvarial osteoblasts were differentiated from Pml -/- mice and 
compared with those from WT. Calvarial osteoblasts were cultured for 18 days 
in osteogenic medium until mineralized bone nodules were formed. The 
mineralized calcium deposits were visualized using Alizarin red staining and 
the content quantified by destaining followed by measuring the absorbance of 
the extracted stain. Osteoblast mineralization was found to be significantly 
higher in knockout mice compared to WT. (Fig.7.7). 
Figure 7.7 Alizarin red staining in calvarial osteoblasts from Pml-/- and WT 
mice to assess bone nodule formation.  
Photograph of mineralized nodules stained with Alizarin red dye. Alizarin red 
(left) and Quantification of the stain (right). Values were corrected for viable 
cell number as determined by the Alamar Blue assay and presented as means 
± SEM representative of one biological replicate from three independent 
experiments.  
Mineralisation determined using Alizarin red was significantly higher in 
knockout mice compared to WT.  
Next, the levels of alkaline phosphatase (ALP), an enzyme involved in bone 
mineralisation were assessed during osteoblast development. ALP mRNA 
was significantly higher at basal levels in calvarial osteoblasts from Pml -/- mice 
and upregulated during the initial week of osteoblast development (Day7). 
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The levels then fell significantly below WT in the second week (Day11) but 
recovered to higher levels compared to WT during final stages of 
mineralization (Day20). (Fig. 7.8). 
 
Figure 7.8 Expression analysis of Alkaline phosphatase (ALP) mRNA by 
qPCR in Pml-/- and wt mice during osteoblast development.  
ALP mRNA level was significantly higher at basal levels in calvarial 
osteoblasts from Pml -/- mice compared to WT. Values are means ± SEM 
(combined data) from three independent replicates presented as % of WT. ns 










 Effect of PML deficiency on skeletal phenotype in young (4 
month old) mice  
Micro-CT (µCT) analysis of lower limbs was used to assess bone mass and 
structure as well as presence of osteolytic lesions in younger WT as well as 
Pml-/- mice. The following were measured (Bone Volume/Total Volume, 
Trabecular number, separation and thickness as well as Cortical thickness). 
µCT analysis revealed no significant differences in trabecular and cortical 
bone parameters between the two genotypes (Fig.7.9 a,b).  There was no 





Figure 7.9 Analysis of Bone Structure in Pml -/- and WT mice by MicroCT 
(a) Comparison of bone volume/total volume (BV/TV); trabecular thickness 
(Tb.Th) and trabecular number (Tb.N) between WT and Pml-/- female mice 




(b) Comparison of cortical thickness (Cort. Th.) using uCT of cortical bone
from the tibial diaphysis between WT and Pml-/- female mice.
Values are means ± SEM from nine Pml -/- and eight WT mice aged 4 months. 
ns=not significant. None of the parameters analysed showed significant 
differences between the two genotypes. uCT resolution was 4.9um. 
Figure 7.10 Representative CTVol generated 3D model images of (a) 
trabecular bone from tibial metaphysis and (b) cortical bone from tibial 





 Effect of PML deficiency on skeletal phenotype in older (14 
month old) mice  
Pml-/- mice were aged and assessed for bone structure and evidence of 
lesions at 14 months of age to determine how lack of PML affects the bone 
remodeling process with age. MicroCT analysis (done similar to that 
described in younger 4 month old mice), however, revealed no significant 
differences in cortical bone structure between Pml -/- and WT mice (Fig 7.11). 
 
Figure 7.11 Analysis of cortical thickness in 14 month old Pml -/- and WT mice 
by MicroCT. Difference between two genotypes was not significant in Pml -/- 
and WT female mice (n=8 each). Values are means ± SEM. ns=not significant. 
uCT resolution was 4.9um. None of the mice analysed had any focal osteolytic 
lesions characteristic of PDB at the age of 14 months.  
Table 7.1 Female mice (WT and Pml-/-) screened for presence of focal PDB-
like lesions by MicroCT. 
Mouse Model PML knockout 
Age group 4 months 14 months 
Genotype WT Pml-/- WT Pml-/- 
Total (n) 8 9 8 8 





PML was found to be expressed in bone cells and lower levels of this gene 
were found in PDB patients compared to controls. In vitro studies in RAW 
264.7 cell line found that Pml overexpression inhibited osteoclast formation 
and fusion whereas downregulation by arsenic trioxide promoted osteoclast 
formation and fusion pointing to a negative regulatory role in osteoclast 
differentiation.  
Further studies in PML knockout mice using ex vivo primary mouse derived 
cultures corroborated these findings and osteoclasts from these mice not only 
exhibited increased osteoclast formation and fusion but also showed 
increased activity and survival compared to WT. Osteoclast related genes 
such as Ctsk encoding Cathepsin K and Dcstamp were found to be 
upregulated during the differentiation of osteoclast precursors into mature 
osteoclasts in primary BMDMs from these mice.  
Osteoclast is the primary cell type affected in PDB. Osteoclasts from pagetic 
patients show increased number, size and nuclei as well as increased activity 
and prolonged survival compared to normal subjects (Roodman et al. 2005, 
Seitz et al. 2009, Chamoux et al. 2009). Findings from this chapter showed 
that PML loss resulted in a substantial increase in osteoclast formation, fusion, 
survival and activity. The findings therefore clearly point to a potential role of 
PML in PDB pathogenesis. 
Osteoblast was also investigated using PML knockout mice. Calvarial 
osteoblasts from Pml-/- mice showed increased mineralized calcium 
deposition compared to WT ex vivo. This is likely due to a direct primary effect 
of PML deficiency on osteoblast. 
Assessment of bone micro-architecture by µCT in young mice at age of 4 
months revealed no significant differences in bone structure between Pml-/- 
mice and WT controls. Thus, increase in osteoblast mineralization seems to 
counteract increased bone resorption by osteoclasts thereby leading to a 
normal skeletal phenotype.  Moreover, the levels of Alkaline phosphatase 
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(ALP) mRNA were also found to be significantly higher at basal levels (early 
stages of osteoblast differentiation) in osteoblasts from Pml -/- mice compared 
to WT and do not show a sustained increase like they do in WT as osteoblast 
differentiation proceeds. This could mean that osteoblasts, in absence of 
PML, are already exposed to high levels of ALP at basal levels and during 
initial stages of their differentiation leading to their higher activity and 
subsequent mineralization to neutralize the effects of increased bone 
resorption by osteoclasts.  
It is also worth noting that PDB is a late-onset disease characterized by focal 
osteolytic lesions generally affecting older people. So the bone remodeling 
changes in Pml -/- mice may actually manifest at a later age than the younger 
age of 4 months when we assessed these mice. Hence, Pml -/- mice were 
aged and assessed for bone structure and evidence of lesions at 14 months 
of age. MicroCT analysis, however, revealed no significant differences in 
cortical bone structure between Pml -/- mice and WT controls. There was also 
no evidence of bone lesions. Thus, bone remodeling changes mediated by 
osteoclast and osteoblast seem to balance each other out even with 
advancing age.  
Interestingly, however, a recent study (Wong et al. 2019) found evidence of 
PDB associated bone lesions with 100% penetrance only once the mice 
reached 22 months of age. The mice in question were deficient in another 
PDB susceptibility gene OPTN, which is also known to be a negative regulator 
of osteoclastogenesis. Therefore, Pml -/- mice are being aged to 22 months of 
age and will be assessed for bone structure and evidence of lesions to see if 
they develop late onset phenotype similar to that observed in Optn deficient 
mice. 
In addition to µCT, additional assessment of phenotype in Pml -/- mice and WT 
controls which would strengthen the current findings include measurement of 
bone turnover markers in serum and quantitative assessment of bone 
structure and remodelling by bone histology as well as bone 
histomorphometry analysis using bone sections from these mice.  
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Bone turnover markers commonly used for assessing bone resorptive activity 
as well as bone formation include C-terminal telopeptide of Type 1 collagen 
(CTX) and N-terminal propeptide of Type 1 procollagen (PINP) respectively. 
Abnormalities in bone remodelling including PDB shall be reflected in 
abnormal levels of these markers. The CTX ELISA assay quantitatively 
determines CTX, a collagen breakdown product which is released in 
circulation post bone resorption and in turn determines the level of osteoclast 
/ bone resorptive activity. Similarly, PINP assay measures PINP, a marker of 
bone formation which is released in circulation during collagen biosynthesis. 
It is important to take into consideration that though these markers provide 
good indication of aberrant bone turnover or remodelling, they are subject to 
random individual as well as biological variation (less so with PINP) such as 
age, gender, body mass index, fasting/food intake status and circadian 
variations. Also, they provide only a snapshot of the bone turnover status at a 
single time point when the serum is collected. In addition, levels of matrix 
protein osteocalcin and osteoblast derived bone specific ALP (BSAP) in 
serum can be used as markers of bone formation and serum or urinary N-
terminal telopeptide of Type I collagen (NTX) as a bone resorption marker 
along with osteoclastic enzymes Cathepsin K and TracP.  
Though µCT is much more sensitive technique due to its high resolution and 
broader coverage in 3D compared to bone histomorphometry, performing the 
latter would reveal further information on bone microarchitecture (structure as 
well as remodelling) in these mice. For example. TracP staining of bone tissue 
sections with aniline blue counterstain followed by histomorphometric analysis 
would not only allow visualisation of osteoclasts in situ but also give 
quantitative output of bone resorption indices (like osteoclast number and 
surface). Similarly, Von Kossa staining with Van Gieson counterstain would 
enable osteoid analysis and provide quantitative output of bone formation 
indices (such as osteoid surface and volume). Calcein double labelling on the 
other hand will enable dynamic assessment of bone formation and 
remodelling by measuring parameters such as mineral apposition rate and 









































8 Effect of PML on signalling in osteoclast 
8.1 Summary 
Studies in RAW cells and Pml -/- mice pointed to a negative regulatory role of 
PML on osteoclast differentiation. PML is associated with various pathways 
which play an important role in osteoclastogenesis. PML positively regulates 
Interferon gamma (IFN-γ) signalling and Interferon regulatory factor 8 (IRF-8) 
is a known regulator of PML gene in response to IFN-γ activation. IRF-8 is 
known to suppress osteoclast development by inhibiting NFATc1 whereas 
IFN-γ inhibits osteoclastogenesis by interfering with RANK-RANKL signalling 
and Cathepsin K expression.  
Hence, effect of IFN-γ stimulation on Pml -/- mice was explored during RANKL 
mediated osteoclastogenesis. It was found that IFN-γ stimulation inhibited 
osteoclastogenesis in WT mice but the effect was not so pronounced on 
osteoclasts in Pml -/- mice. Also, osteoclast related gene’s (Nfatc1) expression 
was much higher in Pml-/- mice compared to WT in the initial stages of 
osteoclast development. PML deficiency may therefore result in IFN-γ and/or 
IRF-8 ineffective in suppressing osteoclastogenesis. In other words, actions 
of IRF-8 and/or IFN-γ in regulating osteoclastogenesis may be mediated via 
PML.  
8.2 Introduction 
PML is associated with various pathways which play an important role in bone 
metabolism. 
IFN-γ inhibits both osteoclast formation at an early stage by interfering with 
RANK-RANKL signalling pathway (Takayanagi et al. 2000) and osteoclast 
gene expression (Cathepsin K) in preosteoclastic cells (Pang et al. 2005) as 
well as mature osteoclasts (Kamolmatyakul et al. 2001). IFN-γ is also known 
to induce IRF-8 and PML in mouse peritoneal macrophages (Dror et al. 2007). 
PML gene is a target gene regulated by IRF-8 in response to IFN-γ activation 
(Khalfin-Rabinovich et al. 2011). IRF-8 and IFN-γ both have binding sites in 
the PML promoter (Stadler et al. 1995; Dror et al. 2007). 
157 
 
IRF-8 is a transcription factor expressed in haematopoietic cells particularly 
monocytes, macrophages and dendritic cells and plays an integral role in their 
development (Tamura et al. 2015). IRF-8 is known to be downregulated in 
RANKL mediated osteoclastogenesis whereas Irf8-/- mice show enhanced 
osteoclastogenesis and subsequently develop osteoporosis (Zhao et al. 
2009).   
IRF-8 is essential for PML induction in myeloid cells and an obligatory 
regulator of the PML gene in activated macrophages (Dror et al. 2007). 
Moreover, IRF-8 has also been found to inhibit the expression and function of 
nuclear factor of activated cells 1 (NFATc1) (Zhao et al. 2009), the master 
transcription factor for osteoclastogenesis.  
Thus, effects of IRF-8 and IFN-γ in osteoclast may be mediated via PML. 
Hence, we investigated the effect of IFN-γ stimulation on Pml -/- mice during 














IFN-γ stimulation inhibited osteoclastogenesis in WT mice but the effect was 
not so substantial on osteoclasts in Pml -/- mice (Fig. 8.1 a).  
Figure 8.1 Effect of IFN-γ on osteoclast formation and fusion in Pml -/- and WT 
mice. 
BMDMs from both genotypes were treated with 5ng/ml IFN-γ for 24 hrs 
followed by treatment with MCSF and RANKL to generate osteoclasts. a) IFN-
γ treatment resulted in increased reduction of TRAcP+ MNC - osteoclasts (≥3 
nuclei) or hypernucleated MNC (≥10 nuclei) in WT (blue bars) compared to 
Pml -/- (orange bars) mice. Values are means ± SEM (data from one biological 
replicate) representative of two independent experiments. *p <0.5; **p<0.01 




numbers from (from one biological replicate) representative of two 
independent experiments. Osteoclast formation and fusion was significantly 
reduced in WT compared to Pml -/- mice. 
Effect of Pml gene knockout on the expression of Nfatc1, the master regulator 
of osteoclast was also assessed. Nfatc1 gene as expected was upregulated 
in WT as well as Pml-/- mice during RANKL mediated osteoclast 
differentiation. However, Nfatc1 expression was much higher in Pml -/- mice 
compared to WT in the initial stages of osteoclast development (Fig. 8.2). 
Figure 8.2 Expression analysis of Nfatc1 by qPCR in Pml-/- and WT mice 
during osteoclast development.  
Nfatc1 expression was much higher in Pml-/- mice compared to WT in the 
initial stages of osteoclast development. Values are means ± SEM (cpmbined 
data) from three independent replicates presented as % of WT. ns =not 
significant 
As mentioned in previous chapter, Cathepsin K was found to be more 
upregulated in Pml-/- mice compared to WT in response to RANKL until later 
stage of osteoclast differentiation. Dcstamp, the master osteoclast fusion 
regulator, was also found to be highly expressed in Pml-/- mice compared to 
WT in response to RANKL treatment. 
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8.4 Discussion 
PML gene contains binding sites for IFN-γ and IRF-8 in its promoter (Stadler 
et al. 1995; Dror et al. 2007) and is regulated by IRF-8 in response to IFN-γ 
activation (Khalfin-Rabinovich et al. 2011). Thus, lack of PML may be 
rendering IFN-γ and/or IRF-8 ineffective in suppressing osteoclastogenesis.
We found that IFN-γ treatment inhibited osteoclastogenesis in WT mice but 
the effect was not so pronounced on osteoclasts in Pml -/- mice. IFN-γ is known 
to activate STAT1 (Stark et al. 1998) and failed to  inhibit RANKL-induced 
osteoclastogenesis in Stat1-/- mice (Takayanagi et al. 2000) whereas PML 
positively regulates IFN-γ responses by inducing STAT-1 DNA 
phosphorylation and DNA binding leading to higher induction of IFN-γ target 
genes (El Bougrini et al. 2011). IRF-8 is one of the IFN-γ induced target genes 
regulated by JAK-STAT1 pathway (Kanno et al. 1993; Dror, Alter-Koltunoff, et 
al. 2007). Cathepsin K whose levels are enhanced during osteoclast 
development, is inhibited by IFN-γ in response to RANKL (Kamolmatyakul et 
al. 2001; Pang et al. 2005).  
We found Cathepsin K to be more upregulated in Pml -/- mice compared to WT 
in response to RANKL until the later stages of osteoclastogenesis. This may 
be a direct effect of PML deficiency on Cathepsin K and/or failure of 
endogenous IFN-γ to suppress Cathepsin K in absence of PML. 
Under basal conditions, Nfatc1 is expressed at low levels in unstimulated 
BMDMs whereas osteoclast differentiation in response to RANKL results in 
marked upregulation of Nfatc1 (Takayanagi et al. 2002). We saw similar trend 
for Nfatc1 in WT as well as Pml -/- mice but the expression was much higher 
in Pml -/- mice compared to WT in the pre-osteoclasts. This might contribute 
to the osteoclast phenotype we see in Pml-/- mouse model and could be 
explained by a direct effect of PML deficiency on NFATc1.  
IRF-8 inhibits osteoclastogenesis by interfering with function and expression 
of NFATc1. (Zhao et al. 2009). This means that osteoclast phenotype we see 
in Pml-/- mouse model could also result from a lack of PML which hinders IRF8 
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from inhibiting NFATc1 during initial stages of osteoclastogenesis. Thus, IRF-
8 effect on osteoclastogenesis in Pml-/- mice could also be blunted by absence 
of its downstream target gene PML. 
Therefore, PML may mediate IFN-γ responses in osteoclast by altering 
STAT1/IRF-8 and Cathepsin K activity. 
Multinucleation and cellular fusion is essential for osteoclasts to effectively 
resorb bone. DC-STAMP plays a key role in this fusion process (Miyamoto 
2006) and we found it to be highly expressed in Pml -/- mice compared to WT 
in response to RANKL treatment. This explains the increased fusion and 
therefore size of osteoclasts we observe in Pml-/- mice compared to WT. 
Thus, my study points to a negative role of PML in osteoclast development 
probably achieved by modulating response of IFN-γ and IRF-8 in association 
with direct or indirect regulation of osteoclast related genes such as Ctsk 
(Cathepsin K), Dcstamp and Nfatc1 (Fig. 9.3). Osteoclasts are already primed 
for increased formation, differentiation, fusion and activity due to upregulation 
of these factors in absence of PML rendering negative regulators ineffective 
in suppressing osteoclastogenesis. 
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Figure 8.3 Potential role of Pml during osteoclast differentiation. 
PML seems to achieve this by controlling IRF-8 and IFN-γ activity as well as regulation of osteoclast related genes 
such as Nfatc1, Ctsk and Dcstamp as depicted in figure above. 
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9 Discussion, conclusions and future 
studies 
PDB was first identified in late 19th century (Paget 1877). It is the one of the 
most common metabolic bone disorder, second only to osteoporosis. PDB is 
characterised by focal abnormalities of increased bone turnover and abnormal 
bone remodelling (Ralston et al. 2008). 
The disease has a late-onset affecting 1-2% of Caucasians aged 55 years 
and above and UK has the highest PDB prevalence in the world (Detheridge 
et al. 1982, Van Staa et al. 2002). Many patients are asymptomatic but others 
may suffer from bone pain, bone fracture, bone deformity, deafness and 
secondary osteoarthritis. These complications can be extremely disabling due 
to loss of mobility and can result in a substantial reduction in quality of life. Its 
late-onset and asymptomatic presentation means long term permanent 
skeletal damage may have already occurred by the time it is diagnosed and 
the current therapeutic modalities only offer symptomatic relief and short term 
metabolic control but not a cure for the disease. Thus, morbidity and not 
mortality, is the main concern in relation to this chronic, late-onset bone 
disease. There have been significant developments in last few decades in 
understanding pathophysiology of PDB, but its aetiology is still incompletely 
understood. It is regarded as a complex disease resulting from an interplay 
between genetic and environmental factors. 
PDB has a strong genetic basis. Mutations in SQSTM1 (which is the only 
known causal gene for classical PDB), have been found in approximately 10% 
of sporadic cases and 40% of familial cases which means additional causal 
genes remain unidentified (Ralston et al. 2008, Ralston and Albagha, 2011). 
GWAS studies have identified seven other risk loci predisposing to PDB 
(Ralston et al. 2008; Albagha et al. 2010; Albagha et al. 2011). Identification 
of causal genetic variants and how they regulate bone metabolism by acting 
alone or interacting with each other as well as environmental triggers of PDB 
is crucial to develop a full understanding of this disease. Research in our lab 
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has focussed on investigating the seven new risk loci and genes within to fully 
elucidate their role in bone metabolism. 
One of these loci (15q24) is a strong genetic susceptibility locus for PDB. 
Though this locus contains several genes (LOXL1, PML, STOML1, 
GOLGA6A, ISLR, ISLR2), targeted DNA sequencing identified PDB 
associated variants only within PML that suggested it to be the likely candidate 
gene from this locus.  
PML was found to be expressed in primary bone cells osteoblasts and 
osteoclasts as well as RAW 264.7 cell line and its expression varies during 
the development and differentiation of these cells.  
PML expression was downregulated in patients with PDB. This raises the 
possibility that genetically determined reduction in PML expression is 
associated with susceptibility to PDB. However, there was no correlation 
between PML expression levels and PDB severity. This could be due to the 
small sample size of the cohort but also indicates that additional factors 
(genetic as well as environmental) need to be present for the disease to 
become fully penetrant and to manifest clinically.  
Pml overexpression inhibited osteoclast formation and fusion whereas 
downregulation by arsenic trioxide promoted osteoclast formation and fusion 
pointing to a negative regulatory role in osteoclast differentiation. Studies in 
Pml knockout mice validated these findings and osteoclasts from these mice 
also showed increased activity and survival compared to WT. Thus, PML 
deficiency resulted in a substantial increase in osteoclast formation, fusion, 
survival and activity.  
IFN-γ treatment failed to suppress osteoclast formation during RANKL 
mediated osteoclast differentiation. Cathepsin K was found to be more 
upregulated in Pml -/- mice compared to WT in response to RANKL until the 
later stages of osteoclastogenesis whereas Nfatc1 expression was much 
higher in Pml -/- mice compared to WT in BMDMs during the initial stages of 
osteoclast development both of which appear to promote development of the 
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precursors down the route of osteoclast lineage as well as enhance osteoclast 
formation and differentiation. Dcstamp was found to be highly expressed in 
Pml -/- mice compared to WT thereby leading to increased fusion and therefore 
size of osteoclasts observed in these mice. 
IFN-γ interferes with RANKL-induced osteoclastogenesis by suppressing 
Cathepsin K expression whereas IRF-8 achieves this by inhibiting NFATc1. 
In light of above findings, PML might be implicated in osteoclast signalling by 
controlling IFN-γ and IRF-8 pathways in association with direct or indirect 
regulation of osteoclast related genes such as Ctsk, Dcstamp and Nfatc1. 
Calvarial osteoblasts cultured ex vivo from Pml-/- mice showed increased 
mineralized calcium deposition compared to WT. This probably results from a 
direct effect of PML deficiency on osteoblast differentiation. This data is 
consistent with the observation that arsenic Trioxide which degrades PML, 
also stimulates collagen synthesis and osteoblast differentiation (Xu et al. 
2015). Levels of alkaline phosphatase (ALP) mRNA which promotes bone 
mineralisation were also found to be significantly higher at basal levels (early 
stages of osteoblast differentiation) in osteoblasts from Pml-/- mice compared 
to WT. 
Assessment of bone micro-architecture by µCT in mice revealed no significant 
differences in bone structure between Pml-/- mice and WT controls even after 
ageing them to 14 months. Thus, bone resorption by osteoclasts is balanced 
by increase in osteoblast mineralization thereby leading to a normal skeletal 
phenotype.   
In addition to optineurin (OPTN) which has recently been shown to be 
important for type I interferon (IFN-β) signalling in maintaining bone 
homeostasis via negative regulation of osteoclastogenesis (Obaid et al. 2015, 
Wong et al. 2019), PML seems to achieve this by controlling type II interferon 
signalling (via IFN-γ/IRF-8 axis).  
Nagy et al (2008) found significant upregulation of Interferon signalling 
pathways in monocytes from a small cohort of pagetic patients compared to 
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controls.  At the same time, however, interferons are known to inhibit 
osteoclast differentiation (Takayanagi et al. 2000, 2002) Thus, mediators of 
interferon pathways such as OPTN, PML and/or IRF-8 could hold the key to 
provide an explanation for such observations.  
Also, measles virus which induces both Type I (Helin et al. 2001) and IFN-γ 
(Type II interferon) response (Griffin 2016), has been shown to be strongly 
correlated with PDB development (Kurihara et al. 2011). Thus, changes in 
PML may potentially impair antiviral immunity by altering IFN-γ activity thereby 
increasing susceptibility to PDB. 
The above findings further strengthen the case of assigning PDB to an 
osteoimmunological disorder and at the same time, also open up new 
therapeutic targets for its treatment and control. 
In conclusion, this project has identified Pml as a novel regulator of bone 
metabolism. PDB patients have reduced levels of PML expression. 
Decreased expression of Pml leads to increased osteoclast differentiation and 
activity. Lack of PML impairs type II interferon signalling as well as 
upregulates osteoclast related genes leading to increased bone resorption 
with a subsequent increase in bone mineralisation by osteoblasts. Thus, 
genetic variants associated with PDB found within PML at the chr15 locus 
possibly contribute to PDB susceptibility by reducing its expression thereby 
enhancing osteoclast differentiation and activity. 
Future work 
It is worth noting that PDB is a late-onset disease characterized by focal 
osteolytic lesions generally affecting older people and the penetrance 
increases with age (Ralston et al. 2008) as was evident in Optn deficient mice 
(Wong et al. 2019). So the bone remodeling changes in Pml -/- mice may 
actually manifest at a later age than 14 months when we assessed these 
mice. Pml-/- mice will be assessed for bone turnover, structure and evidence 
of lesions at 22 months of age to determine how lack of PML affects the bone 
remodeling process and disease penetrance with more advancing age. 
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PML is a direct inhibitor of the p38 MAPK which plays an important role in 
skeletogenesis and bone metabolism by regulating various transcription 
factors involved in osteoclast and osteoblast development (Shin et al. 2004; 
Thouverey & Caverzasio 2015). p38 alpha subunit functions downstream of 
RANK-RANKL interaction to  stimulate osteoclast formation, maturation and 
bone resorption by phosphorylating and transcriptional activation of the p65 
NF-kB subunit, MITF, STAT1 and NFATc1 (Thouverey & Caverzasio 2015). 
At the same time, p38 MAPK signalling positively regulates early osteoblast 
differentiation, late osteoblast maturation as well as extracellular matrix 
deposition and mineralisation (Thouverey & Caverzasio 2015). The 
phenotype of osteoclast and osteoblast we see in our knockout mice could 
also be arising from lack of interaction between PML and p38 in relation to 
bone. PML deficiency may result in failure to inhibit p38 which in turn leads to 
NFATc1 and cathepsin K (IFN γ-STAT1 mediated) upregulation accompanied 
by increased osteoblast mineralisation. Further studies will be needed to 
confirm the link between PML and p38-MAPK pathway in relation to bone cell 
development. 
Mutations in SQSTM1/p62 are associated with PDB. p62 also localises to 
PML nuclear bodies (Pankiv et al. 2010). PML is a known repressor of 
autophagy whereas p62 is degraded by autophagy (Ravikumar et al. 2010; 
Missiroli et al. 2017). Mice with P394L SQSTM1 mutation which develop PDB-
like lesions show features associated with enhanced autophagosome 
formation such as increased expression of genes Atg5, Lc3 and Lc3II protein 
in osteoclast precursors (Daroszewska et al. 2011). Studies have also found 
p62 expression to be upregulated in Pagetic osteoclasts (Chamoux et al. 
2009). 
Interestingly, it was found that autophagy markers Atg5 and Lc3 though 
upregulated in BMDMs, were downregulated post-RANKL stimulation in PML 
knockout mice (data not shown) which supports the hypothesis that 
autophagy inhibition may predispose to PDB (Usategui-Martín et al. 2015) 
leading to protein aggregates and characteristic cytoplasmic/nuclear 
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inclusions seen in Pagetic osteoclasts (Malkani 1974; Mills et al. 1988; 
Sieradzan et al. 1999). But our autophagy marker data are conflicting with the 
P394L Sqstm1 mice data (Daroszewska et al. 2011) as well as the fact that 
PML represses autophagy (Missiroli et al. 2017). It appears that PML 
represses autophagy in macrophages but regulation in osteoclasts is more 
complex. Further detailed studies in relation to p62 as well as exploring LC3II 
protein levels and other methods of assessing autophagy may help in 
dissecting these pathways or interactions further. However, initial findings 
indicate other factors/pathways to be more important for PDB pathogenesis 
in these mice compared to autophagy. 
NFATc1 is a major downstream target of NF-kB, an essential pathway in 
osteoclast biology which is repressed by PML (Wu et al. 2003; Kim & Kim 
2014; Boyce et al. 2015). RANKL induces NFATc1 gene via NF-kB and c-Fos 
signalling pathway in osteoclasts (Kim & Kim 2014). PML transcriptionally 
represses NF-kB by binding to its target A20 via the C-terminus (Wu et al. 
2002; Wu et al. 2003). Therefore, lack of PML may result in upregulation of 
NF-kB and its target gene NFATc1 thereby promoting osteoclast 
differentiation. 
Upregulation of Nfatc1 in Pml-/- mice in response to RANKL when compared 
to WT was evident only in early stages of osteoclastogenesis. This indicates 
that activation of NF- kB leading to early induction of NFATc1 may contribute 
but makes upregulation of NF-kB alone unlikely to result in osteoclast 
phenotype in these knockout mice since the upregulation with reference to 
WT was not sustained in later stages. Further studies are needed to confirm 
this and establish the exact role of PML in NF-kB signalling in bone, if any. 
Thus, in addition to interferon gamma signalling, precise mechanisms 
underlying osteoclastic gene upregulation (especially role of PML in relation 
to NF-kB and p38MAPK signalling) and involvement in osteoblast biology 
needs to be explored further. Studying osteoclast-osteoblast interaction in a 
co-culture system will be of interest.  
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PML is important for the PML nuclear body formation which host multiple 
interactions with a huge array of proteins and thereby play an important 
regulatory role in multiple cellular processes (Salomoni et al. 2008; Guan & 
Kao 2015). This could be assessed by studying the presence and 
characteristics of PDB nuclear inclusions by electron microscopy of 
osteoclasts generated from Pml-/- mice as well as human PBMC derived 
osteoclasts from PDB cases (if they resemble PML nuclear bodies) and 
compare them with unaffected controls. 
Methylation status at the PML locus could be evaluated to determine if control 
of gene expression at this level is via epigenetic mechanisms and the 
interaction, if any, between genetic and epigenetic factors. 
In recent years, diet as an environmental factor, has gained significant 
importance in our lives since it affects our gut microbiota (GM) or microbiome. 
Studies in mice have implicated GM as a regulator of bone mass mainly via 
its effect on immune system (Ohlsson and Sjögren 2015) which we know in 
turn, affects osteoclastogenesis. Thus, exploring effects of altered diet/GM in 
Pml-/- mice and other PDB mouse models may improve our understanding of 
PDB pathogenesis and bone metabolism in general.  
Above studies as well as ageing analysis in PML knockout mice will throw 
further insights into the role of PML in relation to bone metabolism and 
substantiate its role in accelerated bone remodelling disorders such as PDB.  
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Appendix 1. TRAcP Staining of osteoclasts 
Solutions for TRAcP staining were prepared as follows: 
Naphthol-AS-BI-phosphate  
10 mg/ml Naphthol-AS-BI-phosphate in N.N-Dimethylformamide  
Veronal buffer  
1.17 g sodium acetate (anhydrous) and 2.94g sodium barbiturate, both 
dissolved in 100 ml of dH2O 
Acetate buffer  
0.82 g sodium acetate anhydrous dissolved in 100 ml of dH2O and pH 
adjusted to 5.2 with 0.6 ml glacial acetic acid which is made up to 100 ml with 
dH2O 
Pararosanilin 
1g Pararosanilin added to 20ml dH2O followed by 5ml concentrated HCl. 
Solution heated carefully in a waterbath while stirring until fully dissolved and 
filtered after cooling to room temperature. 
Sodium Nitrite 
4g of sodium nitrite in 100mls dH2O 
TRAcP staining solution was prepared fresh by mixing solution A and B as 
mentioned below. Solution B was prepared prior to fixing the cells since it 
needs time to bind before being added to Solution A and the mix filtered 
through 0.2um filter. 
Solution A  
150 ml of Napthol-AS-BI-phosphate  
750 ml of Veronal buffer  
900 ml Acetate buffer  
900 ml Acetate buffer with 100 mM Sodium Tartrate  
Solution B  
120 ml of Pararosanilin  
120 ml of Sodium Nitrite (4%) 
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Appendix 2. Nrecon software reconstruction parameters 
Parameter Description Setting 
Smoothing 
Smoothens images and 
removes noise 
Width, 1 pixel 
Beam hardening factor 
Corrects for absorption 
of lower-energy X-ray 
on the outside of 
specimen 
10% 
Ring artefact reduction 
Corrects for the non-
linear behaviour of 




Appendix 3. CTAn software analysing parameters 
Parameter Description Setting 
Smoothing/Filtering Smoothes images and 
removes noise 






background to binary 
images 
Global, Low level 80-
100, High level 255 
Despeckle Remove speckles from 




3D Model Creates 3D surface 
from binary images 
Adaptive rendering, 
file saved as .p3g 
3D Analysis 
Calculates 3D 
parameters of binary 
images 
Output of Trabecular 
thickness, number 
and separation as 







Appendix 4. Immunohistochemistry Envision protocol 
FFPE tissue blocks were obtained with help of Prof. Donald Salter from NHS 
Lothian tissue archive and included samples from patients with PDB, Giant 
cell tumour as well as tissue microarrays for initial optimisation of primary 
antibody (PML) concentration for IHC. Samples were processed for FFPE by 
fixing them in neutral buffered formalin for 24 hours at RT. Post-fixation, bone 
tissue was decalcified and samples passed through a series of graded ethanol 
and xylene washes and then infiltrated with molten paraffin wax and 
embedded into blocks. The FFPE samples were then processed for IHC at 
Division of Pathology Histology services by Helen Caldwell. Briefly, FFPE 
blocks were cut into thin sections of 4um thickness using a Leica microtome, 
placed in a floatation bath to flatten them and transferred to positively charged 
Superfrost slides and baked overnight in a low temperature oven. Envision 
Immuno protocol was then performed using heat induced epitope retrieval 
technique with the following steps: 
1. Dewax sections in xylene under hood through graded alcohols and finally
to water, the sequence being two successive Xylene washes for 5 mins each
followed by EtOH 100% (2min), then EtOH 100%(2min), then EtOH
80%(2min), then EtOH 50%(2min) with final wash in tap water.
2. Perform antigen retrieval on slides by treating them with antigen retrieval
solution (0.1Msodium citrate and 0.1M citric acid; pH 6) in pressure cooker,
heated in a microwave for 5 minutes, leave to cool for at least 20 minutes on
a paper.
3. Wash slides in PBS-Tween (0.1%) twice for 5 minutes.
4. Treat sections in 3% hydrogen peroxide in water for 10 minutes which
blocks endogenous peroxidases in tissue.
5. Wash slides with PBS-Tween (0.1%) for 5 minutes.
6. Add slides to Sequenza rack.
7. Block with Dako Total Protein blocking solution from Agilent for 30 minutes.
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8. Incubate sections in PML H-238 sc-5621 primary antibody diluted 1:200
with Dako antibody diluent for 1 hour at room temperature.
9. Wash with PBS-Tween (0.1%) twice.
10. Incubate section with Dako envision labelled polymer (secondary
antibody) from Agilent for 30 minutes.
11. Wash slides with PBS-Tween (0.1%) twice.
12. Add DAB substrate diluted in DAB buffer until colour develops to visualise.
13. Wash sections in tap water.
14. Counterstain with Hematoxylin for 10 minutes and wash successively with
water, then ethanol 50%, 80% & 100% twice followed by three consecutive
Xylene washes (5 mins each).
15. Sections were mounted using DPX mounting medium (Sigma) using cover
slip and analysed using Olympus BX51 or Zeiss inverted microscope.
Appendix 5. Protein isolation and Western blot reagents 
RIPA lysis buffer  
1% Triton 100X, 0.5% (w/v) Sodium Deoxycholate, 50 mM Tris-HCl (pH 7.4), 
0.1% (w/v) Sodium Dodecyl Sulphate (SDS) and 150 mM Sodium Chloride 
were dissolved in dH2O. Stored at 4°C. 
This was reconstituted with Protease inhibitor, Phosphatase inhibitor, 0.5M 
EDTA and 1M Sodium Fluoride (NaF) prior to extracting protein from cultured 
cells/tissue.  
Electrophoresis running buffer  
100 ml of 10X TGS Buffer (Biorad) in 900 ml of dH2O. Stored at room 
temperature. 
Samples loading protein buffer (5X stock)  
5.2 ml of 1M Tris-HCl pH adjusted to 6.8, 3 g SDS, 1 g of DL-Dithiothreitol 
(DTT), 6.5 ml glycerol and 130 ul of 10% (w/v) Bromophenol Blue. Stored at -
20°C. 
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1X TBS  
50ml of 20X TBS Buffer (Thermoscientific Pierce) in 950 ml dH2O. Stored at 
room temperature. 
TBST 
0.1% (v/v) Tween-20 in TBS prepared as above. Stored at room temperature. 
Stripping buffer  
2% (w/v) SDS and 62.5 mM Tris-HCl (pH 6.7). Make up with dH2O. Stored at 
4°C. Then, finally add 1mM DTT prior to use. 
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Appendix 6. Apparatus, Software, Consumables and 
reagents 
Apparatus Supplier 
Axiovert 200 inverted microscope Carl Zeiss, UK 
Axiovert 40 CFL inverted 
microscope 
Carl Zeiss, UK 
Balance Fisherbrand and Ohaus, 
Switzerland 
Bench top centrifuge Sigma, Germany 
Bench top Eppendorf centrifuge Sigma, Germany 
Bio2 safety cabinet Envair, UK 
Bio-Tek Synergy HT plate reader Fisherscientific, UK 
BX51 microscope Olympus, UK 
Captair Bio flow RNA workstation Erlab, US 
CFX Connect real time PCR 
machine 
Biorad, UK 
Class II biological safety cabinet Nuaire, UK 
CO2 Incubators Cell 240 Heraeus, Germany 
Fridge / Freezer Lec, UK 
Fume hood Envair, UK 
Gel tanks, Criterion Biorad, UK 
Heat block Grant, UK 
Horizontal electrophoresis tanks Fisherscientific, UK 
Hot plate / stirrer Thistlescientific, UK 
Icemaker Scotsman AF103 
MJ Research thermocycler GRI, UK 
Nanodrop ND-8000 Thermoscientific, UK 
Odysssey Fc Imaging system Li-cor, UK 
Pipettes (2,20,100,200,1000ul) Nichipet, Gilson, Eppendorf, UK 
Powerpack basic Biorad, UK 
QImaging Retiga CCD camera Media cybernetics, UK 
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Rocking table / Shaker Biometra, Germany 
Skyscan 1172 uCT system Skyscan, Belgium 
Syngene GelDoc Imaging system Fisherscientific, UK 
Tetrad 2 thermocycler Biorad, UK 
Transblot Turbo blotting system Biorad, UK 
Vortex Fisherscientific, UK 
Waterbath Grant OLS Thistlescientific, UK 
  
Software Supplier 
BioTek Gen5 plate reader software Biotek, UK 
Burrows-Wheeler Alignment tool Wellcome Trust Sanger Institute, 
UK 
CFX manager software Biorad, UK 
Chromas Pro Technelysium Pty Ltd, UK 
GATK  Broad Institute, US 
Genesys software, Syngene Synoptics, UK 
Genetools software, Syngene Synoptics, UK 
Image studio lite ver 3.1 Li-cor, UK 
ImageJ NIH, US 
Microsoft Word, Powerpoint, Excel, 
Windows 
Microsoft, US 
Mutation surveyor V3.30 Softgenetics, US 
Opticon monitor 3.1 software GRI, UK 
PLINKSeq Harvard, NIH, US 
Polyphen 2 Harvard, NIH, US 
QCapture Pro software Media cybernetics, UK 
SIFT Genome Institute, Singapore 
Skyscan 1172 MicroCT software Skyscan, Belgium 
Skyscan CTAn software Skyscan, Belgium 
Skyscan CTVol software Skyscan, Belgium 
Skyscan Dataviewer software Skyscan, Belgium 
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Skyscan NRecon software Skyscan, Belgium 
SPSS 22 IBM, US 
Other reagent / consummable Supplier 
0.5ml, 1ml and 2ml eppendorf tubes Greiner, UK 
1ml Pasteur pipette Fisher scientific, UK 
96 well PCR plates Thermo scientific, UK 
96 well, 12 well, 24 well tissue 
culture plate 
Corning, UK 
Adhesive PCR plate seals Thermo Fisher scientific, UK 
Agarose Bioline, UK 
Alamar Blue reagent Invitrogen, UK 
Alizarin Red S Sigma Aldrich, UK 
Ammonium hydroxide Sigma Aldrich, UK 
Arsenic Trioxide Sigma Aldrich, UK 
Axygen microcentrifuge tubes Axygen Corning, UK 
BCA protein assay Sigma Aldrich, UK 
BSA (Bovine serum albumin) Sigma Aldrich, UK 
Calcein Sigma Aldrich, UK 
Cell dissociation buffer Gibco, UK 
Cell scrapers Sarstedt, UK 
Cetylpyridinium chloride Sigma Aldrich, UK 
Clarity western ECL substrate Biorad, UK 
Collagenase IA Sigma Aldrich, UK 
Copper II sulfate Sigma Aldrich, UK 
Cover slips SLS, UK 
DEPC treated water Thermo Fisher scientific, UK 
DMSO Sigma Aldrich, UK 
DNA ladders (100bp, LMW and 1kb) New England Biolabs, UK 
dNTPs Thermo Fisher scientific, UK 
DPX mounting medium Sigma Aldrich, UK 
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DTT (Dithiothreitol) Sigma Aldrich, UK 
EDTA (Ethylenediamine tetraacetic 
acid) 
Sigma Aldrich, UK 
Ethanol Absolute for molecular 
biology 
Fisher scientific, UK 
Falcon (15ml and 50ml) Greiner, UK 
FCS (Fetal calf serum) Hyclone, UK 
Filter sterile (0.45um) Merck Millipore, UK 
Forceps World precision instruments, UK 
Genticin Lifetech, UK 
Glacial acetic acid AnalR Sigma Aldrich, UK 
Glycerol VWR, UK 
Hanks’s solution HBSS Sigma Aldrich, UK 
HCl (Hydrochloric acid) AnalR BDH, UK 
Interferon gamma Lifetech, UK 
Jet-PEI macrophage Polyplus, UK 
Kaleidoscope ladder Biorad, UK 
Kisol foil Taab Lab, UK 
L-Glutamine Invitrogen, UK 
Magic Mark Invitrogen, UK 
Methanol Thermo Fisher scientific, UK 
MicroAmp 8-cap flat PCR strip Thermo Fisher scientific, UK 
Mini Protean TGX gels Biorad, UK 
M-CSF Prospec Tany, US 
N,N-Dimethylformamide Fisher scientific, UK 
Naphthol-AS-BI-phosphate Sigma Aldrich, UK 
Needles (19,21,25G) BD, US 
Neubauer’s chamber Hawksley, UK 
Nitrile gloves Fisher scientific, UK 
Optical flat 8 cap strips Bioplastics, UK 
Orange G Sigma Aldrich, UK 
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Paraformaldehyde Taab Lab, UK 
Pararosanilin Sigma Aldrich, UK 
Penicillin Invitrogen, UK 
PBS tablets Invitrogen, UK 
PCR primers Invitrogen, UK 
Petri dishes BD, UK 
Phosphatase inhibitor cocktail Sigma Aldrich, UK 
Pipette tips (all sizes) Starlab, UK 
Protease inhibitor cocktail Sigma Aldrich, UK 
Protein BSA standards prediluted Thermo Fisher scientific, UK 
qPCR nonskirted 96 well white plates Bioplastics, UK 
qScript cDNA supermix Quanta bioscience, US 
RANKL R&D systems 
RNA later solution Sigma, Thermoscientic, UK 
Scalpel VWR, UK 
Scissors S. Murray & Co. Ltd, UK
SensiFAST No-ROX qPCR mix Bioline, UK 
Silver nitrate Sigma Aldrich, UK 
Silver nitrite Sigma Aldrich, UK 
Sodium acetate anhydrous Sigma Aldrich, UK 
Sodium barbiturate BDH, UK 
Sodium carbonate Sigma Aldrich, UK 
Sodium chloride Sigma Aldrich, UK 
Sodium deoxycholate Sigma Aldrich, UK 
Sodium dodecyl sulphate (SDS) Biorad, UK 
Sodium fluoride Sigma Aldrich, UK 
Sodium hypochlorite Sigma Aldrich, UK 
Sodium phosphate Sigma Aldrich, UK 
Sodium tartrate dibasic dihydrate Sigma Aldrich, UK 
Stripettes (2ml, 5ml, 10ml, 25ml and 
50ml) 
Costar, UK 
Streptomycin Invitrogen, UK 
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SYBR Safe DNA gel stain Thermo Fisher scientific, UK 
Syringes (all sizes) BD, UK 
Taq polymerase and accessory kit 
reagent 
Qiagen, UK 
Taqman 18s Gene expression rRNA 
mix 
Applied biosystems, UK 
Tissue culture flasks (25 and 75 cm2) Greiner, UK 
Tris Biorad, UK 
Tris-EDTA buffer Sigma Aldrich, UK 
Triton X-100 Sigma Aldrich, UK 
Trypsin/EDTA Sigma Aldrich, UK 
Tween 20 Biorad, UK 
Universal probe library Roche, UK 
Vitamin C BDH Lab, UK 
Xylene AnalR Sigma Aldrich, UK 
β Glycerol -2- phosphate Sigma Aldrich, UK 
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Appendix 7. Summary of protein coding variants found at 15q24 locus by Targeted Sequencing 
























LOXL1 N/A 74219158 G A Exonic p.A12T missense 0.0 1.0 0.26 Benign 
N/A 74219308 G A Exonic p.V62M missense 0.0 1.0 0.26 Tolerated Benign 
rs1048661 74219546 G T Exonic p.R141L missense 23.6 24.0 0.79 Tolerated Benign 
rs3825942 74219582 G A Exonic p.G153D missense 13.4 17.0 0.34 Damaging Benign 
rs138183635 74219602 G C Exonic p.A160P missense 0.7 0.0 0.53 Tolerated Possibly 
Damaging 
rs41429348 74220000 C T Exonic p.D292D synonymous 2.9 3.0 0.26 
rs13329473 74239525 C T Exonic p.F489F synonymous 0.4 0.0 0.73 
STOML1 rs34353835 74277666 C T Exonic p.P261P; p.P174P; p.P211P;
p.P219P
synonymous 6.5 1.0 0.03 
rs10851866 74277795 T C Exonic p.A176A; p.A131A; p.A218A;
p.A168A
synonymous 35.1 42.0 0.19 
rs370609840 74281464 G A Exonic p.N125N; p.N38N; p.N83N synonymous 0.4 0.0 0.73 
PML rs17849259 74315358 C T Exonic p.A264A synonymous 0.4 1.0 0.46 
rs140050477 74315485 C T Exonic p.R307C missense 0.0 1.0 0.26 Damaging Possibly 
Damaging 
rs148158604 74325040 G C Exonic p.G461A missense 0.4 0.0 0.73 Tolerated Benign 
rs386449354 74327684 G A Exonic p.A628T; p.A580T missense 0.4 0.0 0.73 Benign 
rs75056290 74327819 C T Exonic p.R673C; p.R625C missense 0.4 0.0 0.73 Benign 
rs140648301 74327949 A G Exonic p.Q716R; p.Q668R missense 0.4 0.0 0.73 Benign 
rs144170102 74327973 G A Exonic p.R724Q; p.R676Q missense 0.7 0.0 0.53 Benign 
rs743580 74328116 A G Exonic p.S724G; p.S772G missense 31.5 39.0 0.05 Benign 
rs146867846 74328125 C A Exonic p.Q775K; p.Q727K missense 0.4 0.0 0.73 Benign 
rs743581 74328141 G T Exonic p.G780V; p.G732V missense 23.9 33.0 0.01 Benign 
rs743582 74328206 G C Exonic p.A802P; p.A754P missense 6.5 7.0 0.17 Benign 
N/A 74328261 C A Exonic p.P820Q; p.P772Q missense 0.0 1.0 0.26 Possibly 
Damaging 
rs5742915 74336633 T C Exonic p.F645L missense 43.1 36.0 0.005 Tolerated Benign 
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rs61751122 74336656 C T Exonic p.A652A synonymou
s 
2.2 2.0 0.31 
rs61751123 74336725 C T Exonic p.A675A synonymous 1.4 0.0 0.57 
rs111398700 74336874 A G Exonic p.K725R missense 1.1 1.0 0.28 Tolerated Benign 
rs61751124 74337073 C G Exonic p.P791P synonymous 0.4 1.0 0.46 
ISLR2 rs3743207 74425410 T C Exonic p.D105D synonymous 0.7 2.0 0.28 
rs3889598 74425505 C T Exonic p.S137F missense 0.7 2.0 0.28 Damaging Benign 
rs141520519 74426925 C T Exonic p.G610G synonymous 0.7 1.0 0.43 
rs140851809 74427231 G A Exonic p.E712E synonymous 0.4 0.0 0.73 
ISLR rs76808097 74467585 T C Exonic p.M129T missense 0.0 1.0 0.26 Damaging Possibly 
Damaging 
rs11854957 74467796 C T Exonic p.A199A synonymous 15.6 19.0 0.30 
rs1052622 74467856 G A Exonic p.T219T synonymous 43.8 44.0 0.70 
rs150108021 74467878 C T Exonic p.L227L synonymous 0.0 1.0 0.26 
rs150921456 74468105 G A Exonic p.P302P synonymous 1.1 2.0 0.61 
rs140374543 74468266 G C Exonic p.G356A missense 1.1 0.0 0.56 Tolerated Benign 
rs149028569 74468321 C T Exonic p.N374N synonymous 0.0 1.0 0.26 
rs140714071 74468355 G A Exonic p.V386I missense 0.4 0.0 0.73 Tolerated Possibly 
Damaging 
aAllele Frequency (AF) calculated by (number of alleles observed/total number of alleles) and shown as percentage. 
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Appendix 8. Summary of potential regulatory variants found at 15q24 locus by Targeted Sequencing 

















LOXL1 rs12708513 74218178 G C Promoter 50.0 50.0 1 Promoter Loss Hltf; ZEB1 
rs16958477 74218466 A C Promoter 33.3 39.0 0.72 Promoter Loss; ENCODE 
TFBS 
ZNF263; Tcfcp2l1 
N/A 74218479 T A Promoter 0.4 0.0 0.73 ENCODE TFBS ZNF263 
rs139557020 74218509 C G Promoter 1.4 2.0 0.65 Promoter Loss; ENCODE 
TFBS 
ZNF263; Pax2 
STOML1 rs2304715 74284406 C G Intronic 35.9 35.0 0.64 ENCODE TFBS POLR2A 
rs28454082 74284780 C G Promoter; Intronic 0.4 0.0 0.73 Promoter Loss; ENCODE 
TFBS 
 NFKB1;  ZNF263;  
ZNF143; STAT1; STAT2; 
SP2 
N/A 74284784 G C Promoter; Intronic 0.0 1.0 0.26 Promoter Loss; ENCODE 
TFBS 
 NFKB1;  ZNF263;  
ZNF143; STAT1; STAT2 
SP2 
rs28575231 74284801 C G Promoter; Intronic 0.4 0.0 0.73 Promoter Loss; ENCODE 
TFBS 
 NFKB1;  ZNF263;  
ZNF143; STAT1; STAT2 ; 
SP2 
rs11633520 74284805 C G Promoter; Intronic 38.8 39.0 0.64 ENCODE TFBS ZNF263;NFKB1; ZNF143; 
STAT1 STAT2; SP2 
rs79233608 74285177 G A Promoter; Intronic 8.3 1.0 0.004 Promoter Loss GATA2; Esrrb; ETS1 
rs111819443 74285446 G A Promoter; Intronic 0.0 1.0 0.26 Promoter Loss MZF1_1-4 
rs185313180 74285530 C A Promoter; Intronic 0.4 0.0 0.73 Promoter Loss TFAP2A 
STOML1; PML rs2301272 74286482 C T Promoter; Intronic 2.2 3.0 0.70 Promoter Loss Mafb; ETS1 
STOML1; PML rs2301273 74286882 C T Promoter; Intronic 1.8 3.0 0.44 Promoter Loss; ENCODE 
TFBS 
 ZNF263; ZNF143; SP1; 
SP2; IRF1 
STOML1; PML rs5742914 74286929 C T Promoter; 5'UTR 7.6 17.0 0.02 Promoter Loss; ENCODE 
TFBS 
 ZNF263; STAT1;  SP1; 
SP2; IRF1 
STOML1; PML rs371460626 74287381 C T Promoter; Intronic 0.4 0.0 0.73 Promoter Loss; ENCODE 
TFBS 
REST; EBF1; FOXC1 
LOC283731; 
ISLR2 
rs79925446 74420796 C T Promoter; ncRNA 0.4 1.0 0.46 ENCODE TFBS SUZ12 
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ISLR2 rs2279379 74421010 C G Promoter 17.8 25.0 0.08 Promoter Loss ETS1; TFAP2A 
rs183039083 74421025 C T Promoter 0.7 0.0 0.53 Promoter Loss TFAP2A; MZF1_1-4 
N/A 74421254 C T Promoter 0.4 0.0 0.73 Promoter Loss Mafb; TFAP2A; Klf4 
LOC283731; 
ISLR2 










rs75640427 74421442 G A Promoter; ncRNA 0.7 0.0 0.53 ENCODE TFBS; Promoter 
Loss 
SUZ12; SP1 
ISLR2 rs28665184 74422047 C G Promoter; 5'UTR 0.4 0.0 0.73 ENCODE TFBS SUZ12; GATA2 
rs142361296 74422822 Insertion C Intronic; 5'UTR 1.8 1.0 0.34 ENCODE TFBS SUZ12 
N/A 74422822 Insertion N Intronic; 5'UTR 1.1 0.0 0.56 ENCODE TFBS SUZ12 
ISLR N/A 74465485 G A Promoter 0.0 1.0 0.26 Promoter Loss; ENCODE 
TFBS 
E2F1; CTCF 
 ISLR rs71434225 74465522 A Deletion A Promoter 10.5 12.0 0.13 Promoter Loss; ENCODE 
TFBS 
CTCF; FOXA1 
N/A 74465522 AA Deletion 
AA 
Promoter 4.0 3.0 0.76 Promoter Loss; ENCODE 
TFBS 
CTCF; FOXA1 
rs111365628 74466130 G A Promoter; 5'UTR 0.0 1.0 0.26 ENCODE TFBS; Promoter 
Loss 
TFAP2A; POLR2A 
rs923118 74466271 G T Promoter; 5'UTR 15.6 19.0 0.30 ENCODE TFBS; Promoter 
Loss 
TFAP2A; Myc; Mycn; 
POLR2A 
rs1385650 74466466 G A Promoter; Intronic 44.9 44.0 0.37 Promoter Loss Arnt::Ahr; HIF1A::ARNT 
rs73431458 74466703 G A Promoter; Intronic 9.1 5.0 0.40 Promoter Loss TFAP2A 
aAllele Frequency (AF) calculated by (number of alleles observed/total number of alleles) and shown as percentage. 
